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Abstract 
Histidine-rich glycoprotein (HRG) is a plasma protein that regulates key cardiovascular 
processes such as coagulation, angiogenesis and immune response. The protein consists 
of six distinct functional domains: two N-terminal domains (N1 and N2), two proline-
rich regions (PRR1 and PRR2), a central histidine-rich region (HRR) and a C-terminal 
domain. The HRR binds Zn
2+
, which alters the affinity of HRG towards various ligands 
including the anticoagulant, heparin.  
A key aim of this study was to structurally characterise HRG. The 1.93 Å crystal 
structure of the HRG N2 domain presented here represents the first crystallographic 
snapshot of the molecule. The N2 domain is cystatin-like and N-glycosylated at 
Asn184. An S-glutathionyl adduct was observed at Cys185, providing in vivo evidence 
that release of an anti-angiogenic HRR/PRR fragment is controlled in part by a redox 
mechanism, representing a novel further role for GSH in regulation of angiogenesis. 
Since Zn
2+
 regulates some of the functions of HRG, the dynamics of Zn
2+
 in plasma 
were investigated using a combination of ITC, ELISA and thrombin assay systems. Zn
2+
 
is normally associated with albumin in circulation, but its ability to bind Zn
2+
 is 
allosterically inhibited upon fatty acids binding to albumin. Elevated plasma fatty acid 
levels are associated with some disease states. It is proposed that this may alter the 
proportion of Zn
2+
 bound to HRG, which could in turn activate thrombin to promote 
coagulation. These studies provide evidence to suggest that Zn
2+
-dependent activation 
of HRG (following fatty acid binding to albumin) may play a role in the development of 
haemostatic complications in susceptible individuals. 
Finally, the Zn
2+
 binding ability of albumin was probed in order to locate unidentified 
sites using recombinant albumin mutants. H9A, H67A, E252A, D256A and H288A 
mutants all exhibited diminished Zn
2+
 binding ability, indicating that these residues are 
involved directly or indirectly in Zn
2+
 binding. 
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Chapter 1 
Introduction 
The cardiovascular system of humans, and other vertebrates, can be simplified to its 
basic components: the heart muscle, blood vessels and blood itself. Blood is a fluid 
which had a mystic and poetic role in the history of medicine, until slowly revealing its 
complex composition and extensive function through the modern age. Blood can be 
described as a type of connective tissue consisting of 45% formed elements (cells, 
fragments) and 55% aqueous phase (plasma). The formed element phase gives the blood 
its structural matter, containing platelets, white blood cells and the haem-porphyrin 
carrying red blood cells from where the distinctive red colour is observed. Plasma is a 
pale yellow fluid, acting as the continuous phase of the colloidal suspension and a 
solvent for water soluble proteins, small molecules, nutrients and ions. The major 
proteins in plasma include serum albumin, fibrinogen and globulins (Seeley et al. 2007). 
Albumin  
Albumin dominates the proteins which make up the dynamic and diverse plasma 
proteome, circulating at a concentration of 600 µM (approximately 60% of total plasma 
protein) and is responsible for maintaining the osmotic pressure of blood since it does 
not pass easily into tissues (Peters, 1996). The 585 amino acid sequence of albumin 
leads to a single chain globular protein of 66.5 kDa with a characteristic high solubility 
due to the abundance of ionic residues affording a high total charge to the structure at 
physiological pH. This high aqueous solubility allows albumin to indulge in a range of 
binding and transportation activities involving a broad spectrum of compounds, 
including metals, fatty acids, haematin, bilirubin and steroidal hormones (Richieri et al., 
1993; Adams et al., 1980; Brodersen, 1982) that have an intrinsic hydrophobicity which 
would otherwise preclude their high concentrations in plasma.  
Albumin undergoes discrete phases of allosteric modulation in response to external 
conditions and internal effectors. At acidic pH between 2.7 and 4.3, albumin displays 
increased viscosity and decreased solubility with reduced α-helix content in a 
conformation described as the fast (F) form. The neutral (N) form occurs between pH 
4.3 and 8, in the absence of any binding partners. In the presence of ligands at this pH 
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range (or at basic pH above 8 without ligands) albumin develops the basic (B) form, 
losing some α-helix content (Figure 1.1). 
 
Figure 1.1. (a) Crystal structure of human serum albumin (PDB ID: 1BJ5), showing five fatty acid 
binding sites (FA 1-5). The fats are shown as pink spheres with their respective carboxyl oxygen atoms in 
red. Residues forming the major zinc binding site are also shown as spheres where interacting atoms of 
Asn99 and His67 are coloured yellow, and those of His247 and Asp248 are coloured cyan. The protein 
peptide backbone is coloured to show the individual domain as labelled (Barnett et al., 2013). The N- and 
C-terminal are labelled. Figure drawn using PyMol by Dr. Claudia Blindauer. (b) Amino acid sequence of 
human serum albumin, showing the domains (coloured as before) and the secondary structure elements 
(rectangle: α-helix; arrow: β-sheet). 
C
N
DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAEN 60  
CDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDV 120
MCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLD 180
ELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTE 240
CCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSL 300
AADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADP 360
HECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVS 420
RNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCF 480
SALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMD 540
DFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL 609
(a)
(b)
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This flexibility is the key to the extensive binding ability of the albumin molecule and 
its facility to provide a variety of reversible binding sites. Analysis of the primary 
structure shows three homologous domains (domain I, II and III respectively), each 
made up of two separate subdomains (A and B).  The flexibility is a corollary of the 
high α-helix content, inducing a spring-like effect on the structure resulting in controlled 
contraction and expansion influenced by binding partners. X-ray crystal results show a 
globular heart-shaped structure; selected significant albumin structures are given in 
Table 1.1. 
Table 1.1. Selected albumin structures, giving PDB codes and highlighting importance. 
 
Albumin ligand binding: Fatty acids 
Plasma free fatty acids are generally dominated by C16 and C18 (long-chain) fatty 
acids, and these are predominantly mobilised by tightly regulated enzymatic lipolysis 
from triglyceride stores in adipose tissues (Lafontan and Langin, 2009). Following 
which, they are then released into the circulation and made available for transport by 
albumin (van der Vusse, 2009). Transport of fatty acids has a characteristic rapid 
turnover and a short circulatory half-life of up to 4 minutes (Eaton et al., 1969). 
Although the exact mechanism by which albumin enables the uptake of fatty acids to 
cells is unknown, the presence of albumin specific receptors on cell surfaces may 
partake in this process (Schnitzer et al., 1992; Schnitzer and Oh, 1994). Dole and 
Gordon investigated the importance and function of fatty acids in general metabolism 
(Dole, 1956; Gordon, 1957; Gordon and Cherkes, 1956). Fatty acids are the primary 
PDB Code Year Authors Notes
1AO6 1997 Sugio et. al. (1999) First X-ray crystal structure of HSA
1BJ5 1998 Curry et. Al. (1998) Structure of HSA with myristic acid
2BXG 2005 Ghuman et. Al. (2005) HSA complexed with ibuprofen
2I2Z 2006 Yang et. al. (2007) HSA complexed with asprin
4F5S 2012 Bujacz (2012)
First X-ray crystal structure of bovine 
albumin. First structure of albumin 
complexed with a metal (calcium).
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source of energy for several tissues such as the renal cortex, resting skeletal muscle, 
myocardium and liver (Coppack et al., 1994). Concentration of plasma fatty acids has 
been shown to be in the region of 250–500 μM as a basal level (Rogiers, 1993) of which 
most originates from subcutaneous abdominal fat while only a small proportion 
originates from visceral fatty deposits (Nielsen et al., 2004; Karpe et al., 2011). An 
increase in adipose tissue lipolysis is observed when there is an increased demand for 
energy by the body, hence increasing the bioavailability of fatty acids in the system 
(Coppack et al., 1994). Chronically elevated levels of plasma fatty acid have been 
clinically associated with certain conditions such as cancer, obesity and diabetes 
(Richieri et al., 1993). They have also been observed as a symptom of analbuminemia 
(plasma HSA deficiency) (Bartter et al., 1961). In obesity, the plasma fatty acid 
concentration increase is mainly due to the expansion of adipose tissue and a subsequent 
delay in the clearing process (Boden, 1998). In addition, plasma fatty acid levels in such 
conditions can lead to further subsequent elevations, since high levels of fatty acids in 
circulation can inhibit the effects of insulin on lipolysis (Jensen et al., 1989).  
The fatty acid interaction with albumin has been studied extensively by a variety of 
complementary biophysical techniques including dialysis (Pedersen et al., 1995), 
13
C 
NMR (Choi et al., 2002; Simard et al., 2006) and X-ray crystallography (Curry et al., 
1998; Bhattacharya et al., 2000; Petitpas et al., 2001). It is supposed that up to 6 molar 
equivalents of fatty acid can be bound to albumin under physiological conditions with 
Kd values ranging between 1.5 and 90 nM (Peters, 1996). Greater than 2 molar 
equivalents will only bind during conditions of elevated plasma fatty acid levels 
(Richieri and Kleinfeld, 1995). Figure 1.1 illustrates the heart-shaped form of albumin 
and shows the binding sites for its main endogenous ligands, fatty acids, distributed 
across the protein. Human albumin is able to bind up to ten molecules of fatty acids per 
protein molecule, with the five main sites labelled FA1-5 (Figure 1.1) (Bhattacharya et 
al., 2000). Crystallographic analysis describes precise details of each fatty acid binding 
site, revealing a considerable divergence of topology (Curry et al., 1998; Curry et al., 
1999). The sites are situated either within individual sub-domains, at the interface 
between two domains or at the interface of two sub-domains of the same major domain. 
This assortment of binding sites through otherwise homologous domains leads to varied 
fatty acid affinity due to the primary intermolecular interactions involved in non-
covalent bonding and the heterologous steric interdomain regions. Studies on albumin 
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mutants have shown that the greatest affinity of fatty acid binding occurs at sites FA2, 
FA4 and FA5. These sites form narrow tunnels fitting the hydrophobic tail of the fatty 
acid molecule, with its carboxylate head at the pocket entrance interacting 
electrostatically with polar or basic groups (Simard et al., 2005; Simard et al., 2006). 
Two additional sites of medium affinity, fatty acid sites 1 and 3, share a similar 
interaction but form shorter flattened slots as the binding cavity. These sites all involve 
well defined salt bridges between the positively charged protein side chains and 
negatively charged fatty acid head groups as well hydrogen bonding to stabilise the fatty 
acid to protein interaction (Curry et al., 1998; Bhattacharya et al., 2000). The two 
weakest sites, sites 6 and 7, are located at the protein surface, with relatively poorly 
defined van der Waals interactions with the hydrophobic fatty acid tail. Most of these 
binding sites are an intrinsic construct of the protein tertiary structure, but some 
conformational rearrangement is required for albumin to reach repletion of fatty acids.  
The response to fatty acid binding essentially involves the rearrangement of domains I 
and III relative to domain II via rotations around the interdomain helices (Fasano et al., 
2009). Thus, fatty acid sites 2 and 3 which intersect their respective domains (Figure 1) 
take the greatest allosteric responsibility when occupied.  
Preceding the wealth of crystallographic structural information, binding studies by 
Sudlow et al. showed the presence of two drug binding sites (Sudlow et al., 1975; 
Sudlow et al., 1976) located in sub-domains IIA and IIIA respectively (Carter and Ho, 
1994). These sites present an attractive opportunity to allow the transport and delivery 
of drug compounds otherwise affected by adverse solubility in the blood. However, 
physiology exhibits a complexity prohibiting this simplicity. For example, a drug 
compound would need to have a measured affinity for albumin allowing reversible 
binding and favourable pharmacokinetics to reach a desired target. Also, the allosteric 
spirit of albumin is susceptible to changes in levels of endogenous ligands, which could 
result in an unanticipated release of drug compound with the potential for intoxication.  
Albumin ligand binding: Metals  
Having referred so far to examples of organic compounds involved with albumin, it 
should be noted that this relationship is not exclusive: albumin also binds inorganic 
species such as transition metal ions, providing a vehicle for their circulatory travels and 
moderating plasma levels of free species. Essential and toxic cations including Ca
2+
, 
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Ni
2+
, Cu
2+
, Cd
2+ 
and Zn
2+
 have been observed to bind to one of at least four metal sites. 
These metal sites include the generic “Amino terminal Cu2+ and Ni2+ binding” motif 
(ATCUN) which is present in many proteins, the main Zn
2+ binding site known as “site 
A”, a Cd2+ binding site known as “site B” which is currently unidentified and the only 
free thiol group in the structure, Cys34, which can bind heavy metal compounds of Au, 
Pt and Hg
2+
 (Harford and Sarkar, 1997; Bal et al., 1998; Sadler and Viles, 1996; 
Christodoulou et al., 1994; Esposito and Najjar, 2002). This solitary free thiol is redox 
active, partaking in thiolation and nitrosylation and forming mixed disulphides. Also, 
Cys34 is involved in the dimerisation of albumin observed in vitro (Quinlan et al., 
2005). Additionally, albumin is known to bind Ca
2+ 
and Mg
2+
. However, it is known 
that Ca
2+
 (and thus analogously, Mg
2+
) bind stronger to the B form of albumin but also 
help cause this conformational change in a synergistic approach (Kragh-Hansen and 
Vorum, 1993; Peters, 1996).  Recently, a crystal structure of bovine albumin complexed 
with Ca
2+
 was solved, and was the first instance of a metal bound albumin structure 
(Majorek et al., 2012). Figure 1.2 shows a schematic diagram of the HSA molecules, 
with the features significant in regards to this project highlighted.  
 
Figure 1.2. Schematic diagram of HSA, showing the domains labelled I, II and II. The positions of five 
main fatty acid sites (FA1-FA5) are highlighted. The binding positions for Zn
2+
, Cu
2+
, Ni
2+
 and Ca
2+
 are 
shown. The proximity of the major Zn
2+
 binding site (site A) and FA2 can be observed. 
Zinc is an essential nutrient, involved in a profuse array of structural, catalytic and 
cocatalytic functions in enzymes and proteins amounting to 10% of the human 
proteome (Andreini et al., 2006). Zinc was revealed to be an essential nutrient first in 
the 1930s during an animal study on the effect of dietary zinc intake on the growth and 
survival of rats and mice (Todd et al., 1993). However it took 30 years for the 
realisation that zinc is also important for human health (Prasad, 1991). The full d
10
 
valence shell of Zn
2+ 
permits an isotropic ionic environment with regards to ligand 
I II III
Cu2+
Ni2+
Zn2+
FA1 FA2 FA3 FA4 FA5
Sudlow’s site 1 Sudlow’s site 2
Ca2+ Ca2+
Ca2+
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binding, allowing a distortion from strict tetrahedral or trigonal bipyramidal 
coordination spheres which is commonly observed in Zn
2+ 
protein structures (Thorp, 
1998). The d
10
 electronic configuration also renders the zinc ion inactive towards redox 
reactions, indicating a reason for the bias of nature towards using Zn
2+
 in many 
applications, although this property contributes frustration to the analytical chemist. 
Numerous studies have attempted to define the interactions between Zn
2 +
 and human 
blood plasma proteins (Himmelhoch et al., 1966; Song and Adham, 1979; Dawson et 
al., 1981; Scott and Bradwell, 1983; Chilvers et al., 1984; Foote and Delves, 1984; 
Manley and Gailer, 2009; Malavolta et al., 2012), and have led to the agreement that 
serum albumin is the key Zn
2 +
 transporter in plasma (Chesters and Will, 1981). 
Additionally, albumin is suggested to facilitate the endothelial uptake of zinc (Rowe and 
Bobilya, 2000).The proposed zinc binding site in albumin is unusual, firstly because it 
is assumed to adopt the less common trigonal bipyramidal arrangement but also because 
of the inclusion of asparagine as an oxygen donor. Typical ligands are histidine, 
cysteine, aspartic acid and glutamic acid. However, structures of zinc binding proteins 
with the same framework as site A have been solved (Odintsov et al., 2004). A standard 
value for the zinc concentration in normal adult blood plasma is 16.6 ± 6.2 μM 
(Rukgauer et al., 1997). The zinc pool in plasma is subjective to dietary intake, along 
with a range of other influences. For example, plasma zinc levels decrease during 
inflammation and infection as part of the acute phase response. The complete rate of 
turnover of plasma Zn
2 +
 is substantial, since the total amount of plasma zinc is replaced 
around 150 times each day (King, 2011). 
A usual means of assessing zinc speciation in plasma involves fractionation into low- 
and high-molecular weight components (by ultrafiltration) (Foote and Delves, 1988). 
Recently, several zinc specific fluorescent dyes have been synthesised and used to 
quantify total and free plasma zinc (Kelly et al., 2011). A free Zn
2 +
 concentration in the 
range of 1–3 nM was inferred by studies using the dye ZnAF-2 and confirmed that most 
of the Zn
2 +
 binding capability of plasma is located in the high-molecular weight 
fraction. Between 75-90% of total Zn
2 + 
in plasma is chelated to HSA, and this fraction 
makes up the majority of the plasma Zn
2 + 
pool available for exchange (Chilvers et al., 
1984; Manley and Gailer, 2009). Total plasma zinc associated with the low-molecular 
weight fraction was found to be less than 1% (Foote and Delves, 1988), most likely due 
to the amino acids cysteine and histidine chelating zinc (Giroux and Henkin, 1972). The 
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remaining 10–20% of plasma zinc is bound tightly to α2-macroglobulin (Parisi and 
Vallee, 1970) and retinol-binding protein (Chilvers et al., 1984), and is unavailable for 
exchange.The interaction between Zn
2 +
 and albumin is thus particularly important 
within the blood. Perfused rat intestine studies have shown that albumin is responsible 
for the transport of newly-absorbed Zn
2 +
 to the liver (Smith et al., 1979). 
Nuclear magnetic resonance (NMR) experiments have been used to identify the Zn
2 + 
and Cd
2+
 binding sites, using 
111
Cd
2+
 and 
113
Cd
2 +
 as a probe for Zn
2+ 
in combination 
with site directed mutagenesis studies. NMR resonances equate to three different sites 
of chelation for Cd
2+ 
and Zn
2+ 
with each respective metal having one high affinity 
binding site, not affected by competition from other metals. Site A appears at 110–
150 ppm and site B at 25–30 ppm (Martins and Drakenberg, 1982; Goumakos et. al., 
1991; Sadler and Viles, 1996).  
The characteristic chemical shift of site A pointed to a metal coordination which 
included 2 or 3 nitrogen donors with additional oxygen donors, while site B is 
structured around one nitrogen donor and three oxygen donors. Addition of 1 equivalent 
of Zn
2 +
 during the Cd
2+
 NMR experiments blocked the peak relating to site A, but left 
the site B signal intact, leading to the inference that site A had a stronger affinity for 
zinc (Martins and Drakenberg, 1982; Goumakos et. al., 1991; Sadler and Viles, 1996). 
Corresponding examination of the structural database revealed conserved residues at the 
domain I/II interface composed of His67 and Asn99 (domain I) and His247 and Asp249 
from domain II. The high affinity zinc binding site has recently been situated, modelled 
and characterised using NMR, zinc k-edge extended X-ray absorption fine structure 
(EXAFS) spectroscopy and site-directed mutagenesis (Figure 1.3) (Stewart et al., 2003; 
Blindauer et al., 2009).  
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Figure 1.3. Data from Zn k-edge EXAFS experiments for wild-type and mutant albumin-zinc complexes. 
(a) HSA + 1 molar equivalent Zn
2+
 in purple, HSA + 1 molar equivalent Zn
2+
 + 1 molar equivalent Cd
2+
 
in red. HSA + 1 molar equivalent Zn
2+
 + 1 molar equivalent Cd
2+
 + 1 molar equivalent Cu
2+
 in cyan. 
Under these conditions, Zn
2+
 is thought to occupy site A, Cd
2+
 is thought to occupy site B preferentially, 
and Cu
2+
 the N-terminal ATCUN site. The excellent agreement of intense peak at ca. 2 Å suggests that in 
each sample, Zn
2+
 coordinated to the same site. (b) EXAFS spectra for wild-type HSA (purple) and H67A 
mutant HSA (green), where the H67A mutation is clearly shown to perturb zinc binding to albumin. (c) 
Comparison of experimental (purple) and modelled (red) data (Blindauer et al., 2009). 
Site A is fundamentally a five-coordinate interdomain site involving His67 and Asn99 
residues from domain I and His247 and Asp249 residues from domain II, plus one non-
protein ligand, likely to be a water molecule. The backbone carbonyl oxygen of His247 
offers a weak sixth coordination position (Figure 1.4). The molecular model calculated 
for this proposed site showed a favourable geometry with respect to the apo-albumin 
structure. Furthermore, this site neighbours fatty acid site 2 and shows structural 
disruption upon fatty acid binding, correlating with the absence of the characteristic 
111
Cd
2+
 peak in albumin exposed to high fatty acid concentrations (Stewart et al., 2003; 
Lu et al., 2008). This leads to a possible physiological implication where extracellular 
Zn
2+
 concentrations may be influenced by this relation with plasma fatty acid levels.  
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Figure 1.4. Structural overlay of residues forming the main zinc site on albumin from published X-ray 
structure of unliganded albumin (PDB ID: 1AO6) in black, and EXAFS-refined model in Corey-Pauling-
Koltun colouring (Zn ion shown in purple, oxygen in red, nitrogen in blue) (Blindauer et al., 2009).  
Figure drawn using PyMol by Dr. Claudia Blindauer.  
In addition to its role in Zn
2+
 binding, Asp249 in HSA has been identified as being 
involved in the binding of Ca
2 +
, as observed in the crystal structure of bovine serum 
albumin (Asp248 in domain II of bovine albumin corresponds to Asp249 in human 
albumin), signifying that an interplay between Zn
2+
 and Ca
2+
 might occur in plasma 
(Majorek et al., 2012). Also, albumin binding Mn
2+
 has been shown to be affected by 
binding
 
of Zn
2 +
, leading to the conclusion that the high-affinity Zn
2 +
 site is also a Mn
2 +
 
binding site (Fanali et al., 2012a). Cisplatin, the anticancer drug, can preclude Zn
2 +
 
binding to the high-affinity site by crosslinking between the side chains of His67 and 
His247 (Hu et al., 2011). Mutant recombinant human albumins have helped identify the 
major residues involved in the zinc binding site of HSA and have also been shown to 
augment or impede the HSA affinity for zinc. By replacing the weak binding side-chain 
of Asn99 with His or Asp, HSA was shown to have an increased Zn
2 +
 affinity (by one 
order of magnitude at least). In contrast, a decrease in Zn
2 + 
affinity is acquired upon 
mutation of His67 to a non-chelating Ala residue (Blindauer et al., 2009). Extended X-
ray absorption fine structure studies established that both Asn99His and Asn99Asp 
mutants bind zinc in a similar 5(+ 1) coordinate ligand site, while the His67Ala mutant 
data produced an EXAFS fit with one fewer ligand (Figure 1.2). 2D 
1
H total correlation 
spectroscopy NMR analysis of the mutants identified the cross-peaks relating to His67 
and His247 for wild-type HSA, which enabled monitoring of the effects of different 
binding partners (metals, fatty acids) on this site. 
H247 
backbone
H2O
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Albumin ligand binding: Allosteric effects between fatty acids and metals 
Based on the X-ray crystal structural data available at the time, identification of the first 
Zn
2 +
-binding site of HSA (site A) revealed that the site is pre-formed in crystal 
structures of fatty acid free albumin (i.e. fatty acid binding to albumin disrupts the Zn
2 +
-
binding site structure). Fatty acid site 2 (FA2) is the main fatty acid binding site 
accountable for structural disruption in this location. Being one of the highest affinity 
fatty acid sites, even at 1:1 albumin:fatty acid ratios, it is considerably occupied. 
FA2 is one of the highest affinity sites and becomes significantly occupied at fatty 
acid:albumin ratios as low as 1:1 (Simard et al., 2006). It is a very enclosed site with an 
almost completely linear binding pocket shaped from subdomains IA, and IIA and IIB 
(Curry et al., 1999). However, FA2 requires a substantial change in protein 
conformation upon binding fatty acids, since the subdomain pockets which form the 
sites are observed to be apart by 10 Å in structures of fatty acid free albumin. The 
change required involves the rotation of the domains (domain I with respect to domain 
II) (Curry et al., 1998; Bhattacharya et al., 2000), the procession of which alters the 
arrangement of the residues involved in Zn
2 + 
binding. Essentially, this allosteric 
modulation means that the normally preformed zinc site is disrupted, once fatty acid 
binding has occurred at FA2 (Figure 1.5). This phenomenon is observed in all current 
crystal structures of fatty acid bound albumin, over a fatty acid chain length from C10 
to C22 (Bhattacharya et al., 2000; Choi et al., 2002; Lu et al., 2008; Stewart et al., 
2009). However, the crystal based structural data did not allow for any conclusions to 
be drawn regarding the dynamics of zinc and fatty acid binding; fatty acid binding to 
FA2 and zinc binding to site A may be equally exclusive, or fatty acid binding would 
preclude zinc binding (or vice versa). 
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Figure 1.5. Fatty acid binding site FA2 and the major zinc site (site A) residues. The binding pocket for 
fatty acids in FA2 is formed by residues from both domain I (yellow/orange) and domain II (blue), 
illustrated as a coloured surface. The carbons of the fatty acid molecule are shown as pink space-filling 
spheres, and can be seen under the coloured surface. Metal-binding nitrogen and oxygen atoms are also 
highlighted as spheres. The presence of the fatty acid molecules forces the two His residues apart by > 8 
Å, thereby destroying the zinc site. Under apo-conditions, the His residues are separated by 
approximately 4 Å (Barnett et al., 2013). Figure drawn using PyMol by Dr. Claudia Blindauer.  
113
Cd NMR spectroscopy provided early experimental evidence for the disturbing of 
metal binding by fatty acids, since the spectra showed significant broadening and a 
lower intensity in albumin samples isolated from plasma that were not subjected to a de-
fatting process (Sadler and Viles, 1996). Later, it was established for recombinant 
Cd2HSA that an 8-times excess of octanoate had a significant effect on the 
111
Cd peak 
corresponding to site A (although site B was not affected) (Figure 1.6a) (Stewart et al., 
2003). The Hε1 1H NMR resonances for His67 and His247 were affected by titrating 
octanoate into HSA, signifying that octanoate binds close to these residues (Figure 1.6b) 
(Lu et al., 2012a). These experiments also determined that zinc binding to site A was 
not eliminated by octanoate binding to FA2, since the 
1
H spectra of Zn–HSA were 
identical, regardless of the presence and absence of octanoate.  
From this, it was unclear if HSA is able to bind Zn
2 +
 stronger to site A than octanoate is 
to FA2 (and therefore causing octanoate displacement), or whether binding of zinc and 
octanoate could occur simultaneously. Isothermal titration calorimetry (ITC) was used 
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to address this question by studying the binding of Zn
2 +
 and octanoate to bovine serum 
albumin (BSA) interactively. Both ligands produced identical binding curves regardless 
of the presence or absence of the other. Incidentally, previous reports had stated that the 
presence of octanoate in HSA samples prevented it from crystallising isomorphically to 
all other fatty acid-bound structures (Bhattacharya et al., 2000). Thus it was proposed 
that the short C8 chain of octanoate is not able to provoke the same conformational 
change that is observed when longer chain fatty acids bind, since it is unable to pin the 
two interdomain half-sites together. This was in agreement with a structural model 
describing the simultaneous binding of Zn
2 +
 and octanoate (Lu et al., 2012a). 
Concerning the disappearance of peak A in 
111
Cd NMR spectra of HSA samples with 
two equivalents of Cd
2+
 induced by octanoate, it is possible that the metal is not 
displaced but binding of octanoate to one pocket simply affects the dynamics of Cd
2 +
 at 
site A. 
 
Figure 1.6. NMR experiments on wild-type and mutant albumins. (a) 
111
Cd NMR spectra conducted 
under conditions of 1.5 mM Cd2HSA, 50 mM Tris, 50 mM NaCl at pH 7.4. The centre spectrum shows 
Cd2HSA. Both octanoate and Zn
2 +
 perturb Cd
2 +
 binding to the peak at ca. 130 ppm corresponding to site 
A. Mutations of zinc-binding residues either eliminate the peak (H67A) or shift it (N99H mutant) (b) 
Resolution-enhanced 
1H NMR spectroscopy of metal and fatty acid binding to HSA. His Hε1 protons are 
represented by the sharp peaks. Peaks 1 and 4 have been assigned to residues H67 and H247 respectively, 
and both are affected by octanoate, Zn
2+
, and mutations of H67 or N99 (Blindauer et al., 2009). 
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Contrastingly, the competition between Zn
2 +
 and myristate (C14) studied by ITC 
revealed that these ligands influenced the binding of each other to BSA (Figure 1.7a and 
b).  
 
Figure 1.7.Thermodynamic studies between metal and fatty acid binding to HSA by isothermal titration 
calorimetry. (a) Titration of Zn
2 +
 (333 μM) into bovine serum albumin (25 μM) in 50 mM Tris, 50 mM 
NaCl, pH 7.2 at 298 K, in the presence and absence of myristate. Here, zinc binding to two sites was 
observed, with apparent binding constants of log K′ = 5.67 and 4.15 respectively. Correcting for pH 
influence and the weak Zn
2 +
 chelation by the Tris buffer gave a stoichiometric log K = 7.0 for the 
strongest site. At high myristate concentrations (5 molar equivalents), no zinc binding could be detected. 
(b) Titration of bovine serum albumin (12.5 μM) with myristate in the presence and absence of Zn2 + or 
Co
2 +
 in H2O at 298 K. Although no effect on fatty acid binding stoichiometry was observed, there was a 
reduction in the exothermic strength of the interaction, as it is likely that the binding of a fatty acid 
molecule to FA2 requires the removal of metal ions in site A and/or B. (c) Cobalt binding to bovine 
serum albumin was studied under identical conditions to those used for Zn
2 +
 binding to allow for direct 
comparisons to be made. Evidently, Co
2 +
 binding is significantly weaker than Zn
2 +
 binding, in agreement 
with Sokolowska et al. (2009), but an effect of myristate is still seen. However, in contrast to the effect on 
Zn
2 +
 binding, 5 molar equivalents of myristate did not completely eliminate Co
2 +
 binding. This could 
indicate that either site B is less affected by fatty acids than site A, and/or that Co
2 +
 can compensate for 
the potential loss of sites A and B by binding to the N-terminal ATCUN motif (Blindauer, 2013).  
Increasing the myristate concentration significantly decreased the stoichiometry of 
Zn
2 +
:BSA and the overall affinity of the interaction, while Zn
2 +
 did not alter the 
stoichiometry of myristate binding to BSA, but the binding energetics were observed to 
be less exothermic. Thus the affinity of albumin for myristate was concluded to be 
higher than that for Zn
2 +
 (Lu et al., 2012a), consistent with literature data. The data 
obtained showed the occupation of two Zn
2 +
 sites, which were affected by the myristate 
concentration. The maximum ratios used (5:1 myristate:BSA) showed complete 
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inhibition of Zn
2 +
 binding at the experimental conditions used. 
111
Cd NMR experiments 
using myristate showed an effect on a second metal site. Addition of a 5-fold excess of 
myristate suppressed the peak corresponding to site A in a similar manner as octanoate. 
However, unlike with octanoate, the peak corresponding to site B also disappeared upon 
addition of myristate (Lu et al., 2012a). This suggests that myristate binding could have 
an extra influence on site B, which is propositioned as a candidate for a second Zn
2 +
 
site. Site B currently remains unidentified, but based on the effects of fatty acids 
observed in these experiments it is possible that, like site A, it may also be an 
interdomain site.  
Interestingly, the ITC experiments revealed that the zinc binding properties (affinity and 
capacity) of BSA are affected by levels of myristate as low as 1 molar equivalent. 
Therefore, the phenomenon of fatty acids modulating the affinity of albumin for Zn
2+ 
is 
likely to occur at all physiological levels, and is not exclusive to extreme experimental 
conditions. This is given some context by the fact that FA2 is one of the highest affinity 
fatty acid sites and so its occupation upon binding of the first equivalent of fatty acid is 
reasonable (Simard et al., 2006). The binding of zinc and fatty acids (medium to long 
chain) to albumin are therefore interactive, as advocated by the examination of X-ray 
structures. This mechanism might mean that albumin is a link between the distribution 
and levels of plasma fatty acids, which reflect energy status, and zinc in plasma and 
nearby tissues. 
Physiological implications of modulation of metal binding by fatty acids 
There are many links between Zn
2 +
 homeostasis and signalling in energy metabolism 
(Cunnane, 1982; Costarelli et al., 2010). Zinc affects concentration and activities of the 
hormones, glucagon (Hardy et al., 2011), leptin (Mantzoros et al., 1998; Chen et al., 
2000) and insulin (Rutter, 2010). Insulin is essential for sufficient HSA synthesis. In 
diabetes, patients have a diminished albumin synthesis rate, which may influence fatty 
acid transport by albumin and cell uptake (Fanali et al., 2012b). Leptin, made in 
adipocytes, controls energy intake and expenditure and it is believed that because of 
this, Zn
2 +
 status has a direct impact on appetite and eating behaviour (Shay and 
Mangain, 2000). Hyperleptinemia (high levels of leptin) in obesity is coupled with 
hypozincemia (low levels of plasma zinc) (Oh and Choi, 2004). Similarly, zinc 
influences the activity of adiponectin (a hormone also secreted by adipocytes) which is 
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also implicated in fatty acid oxidation and plays a part in insulin resistance (Briggs et 
al., 2012). The oligimerisation and thus activity of both adiponectin and insulin is due to 
their direct interaction with Zn
2 +
, and so is heavily reliant on available zinc ion levels. 
Fatty acid synthesis and esterification (lipogenesis) in adipocytes has been shown to be 
heightened by Zn
2 +
 in vitro (Oh and Choi, 2004), and Zn
2 +
 is actively taken up into 
adipocytes during fatty tissue formation (Smidt et al., 2011). Increased intracellular 
Zn
2 +
 levels may influence leptin signaling directly via inhibition of protein tyrosine 
phosphatase 1B, which leads to the inhibition of a key enzyme in the leptin and insulin 
signaling pathways, phosphoinositide 3-kinase (Volpe et al., 2007).  
Modulation of the albumin affinity for zinc may lead to substantial consequences. One 
possibility would be that the reduced affinity of fatty acid-bound albumin for zinc alters 
the speciation of zinc in plasma (i.e. the zinc would bind to alternative proteins). 
Another possibility could be a change in plasma zinc speciation would affect its uptake 
by endothelial cells leading to consequent downstream effects.  
Albumin influences Zn
2 +
 uptake into cells, as described by evidence from several 
experiments. Albumin affects uptake of zinc by fibroblasts, since it can act as an 
extracellular ligand for zinc and so buffer the free Zn
2 +
 levels (Ackland and McArdle, 
1990). For endothelial cells, Zn
2 +
 coordinated by albumin can be taken up through 
endocytosis pathways. Also, the cells have a greater affinity for albumin carrying Zn
2 +
 
compared to the apoprotein (Gálvez et al., 2001). Hence, regardless of the mechanism 
by which albumin contributes in cellular Zn
2 +
 uptake, any modulation of its Zn
2 +
 
affinity can be expected to impact cellular Zn
2 +
 homeostasis. However, it should be 
noted that other mechanisms of cellular regulation (including the expression of 
membrane-bound zinc transporters) exist and are significant (Devirgiliis et al., 2007). 
While zinc levels in plasma are reliably constant, there exist certain conditions where 
these levels are reduced (King, 2011). Due to the numerous connections between zinc 
and lipid (and thus energy) metabolism, it is problematic to separate consequences from 
causes. However, in order to ascertain the credibility of a contribution of fatty acid 
induced redistribution of  Zn
2 +
, clinical or physiological conditions in which both raised 
plasma fatty acid levels and reduced plasma zinc levels may be encountered are of 
interest. Conditions where lower plasma zinc levels and increased plasma fatty acid 
levels were observed together have been reported and include vigorous aerobic exercise 
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(Volpe et al., 2007), obesity, diabetes and cardiovascular disease (Ghayour-Mobarhan et 
al., 2005; Soinio et al., 2007; Jansen et al., 2012; Boden, 2011). 
In cardiovascular disease, conditions leading to reduced energy consumption by the 
heart could potentially lead to elevations of free fatty acids (at least a temporary 
increase), since fatty acids provide a large fraction of the energy used by the heart 
(myocardium in particular). Consequently, it could be that the lower levels of plasma 
zinc recorded in chronic heart failure (Foster and Samman, 2010) and acute myocardial 
infarction (Katayama et al., 1990; Tan et al., 1992; Arnaud et al., 1994; Gomez et al., 
2000) are a direct corollary of the high free fatty acids levels. It is known that levels of 
zinc in serum are known to fall suddenly in the few hours following a myocardial 
infarction (MI), with lowest levels detected after 2 or 3 days, subsequently returning 
slowly to baseline values (Katayama et al., 1990). Saliently, the plasma of patients with 
MI was observed to have a reduced capacity to bind metals, resulting in the 
development of a clinical test: the albumin-cobalt-binding (ACB) assay (Bar-Or et al., 
2000).  
MI is defined by the heart muscle experiencing a lack of oxygen supply and is a 
precursory sign for acute myocardial infarction (i.e. heart attack). Bar-Or et al. designed 
the ACB assay (Bar-Or et al., 2000) founded on the premise that MI could provoke 
modifications to albumin molecules in circulation that affect its capability to coordinate 
to metals. It was established that plasma or serum from MI patients exhibits a 
considerably lower capacity for Co
2 +
 binding, which can be measured rapidly in a 
colorimetric assay by the reaction of Co
2 +
 in excess with the reducing agent, 
dithiothreitol. Detection of the brown coloured Co
2+
-dithiothreitol complex is measured 
at 500 nm to provide the result (Bar-Or et al., 2000). The ACB assay has a respectable 
negative prognostic use and is the only clinical test available for the rapid early 
assessment of MI. An abormal reading of the ACB allows MI (and hence imminent 
heart attacks) to be prevented (Collinson and Gaze, 2008; Gaze, 2009; Christenson et 
al., 2001). However, the efficacy of the test has been called into question, since the test 
is not necessarily specific for this condition (Dominguez-Rodriguez and Abreu-
Gonzalez, 2010). Irregular readings relating to low cobalt binding capacity have been 
observed in cases other than that of ischemia. These include diabetes, obesity (Kaefer et 
al., 2010), cancer, metabolic syndrome, fatty liver infections (Amirtharaj et al., 2008), 
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renal disease, stroke, and even continuous aggressive exercise (Apple et al., 2002; Lippi 
et al., 2005). 
The ACB assay is thought to detect the biomarker known as “ischemia-modified 
albumin” (IMA), with the fundamental premise that ischemia causes modifications to 
the amino-terminal copper and nickel binding (ATCUN) motif. For example, truncation 
at the N-terminus, a known modification of albumin that occurs due to oxidation (Chan 
et al., 1995). Peptide models of the N-terminus have been used to study the binding of 
Co
2 +
 (Bar-Or et al., 2001) but critically N-terminus modifications of albumin from 
ischemic patients could not be validated (Bhagavan et al., 2003; Bar-Or et al., 
2008). The molecular mechanism behind the lower Co
2 +
 affinity has remained obscure. 
Some studies have suggested that the major sites for Co
2 +
 binding are sites A and B, 
and not the N-terminus (Mothes and Faller, 2007; Sokolowska et al., 2009).  
Although the N-terminus can in principle bind Zn
2 +
and Co
2 +
 (Lakusta and Sarkar, 
1979), the ATCUN motif generates a square planar geometry which is more suitable to 
low-spin d
8
 and d
9
 metal ions such as Ni
2 +
 and Cu
2 +
. The d
7
 Co
2 +
 ion and the d
10
 Zn
2 +
 
ion are not as attracted to the ATCUN motif site, instead preferring octahedral 
geometries in general. This introduced the possibility that fatty acids could also 
influence Co
2 +
 binding if site A or B are indeed involved in its coordination (Mothes 
and Faller, 2007). This direct effect was demonstrated, where high levels of plasma fatty 
acids affect the cobalt binding capacity of albumin (Amirtharaj et al., 2008) and the 
correlation between plasma fatty acids and IMA was described as “plausible but not 
causative” (Bhagavan et al., 2009). Later, site B was identified as the major Co2 + 
binding site (Sokolowska et al., 2009) which had previously been shown to be 
susceptible to fatty acid binding (Lu et al., 2012a).  
Based on these clinical observations and in vitro studies, it was proposed that IMA was 
simple regular albumin in the presence of higher fatty acid levels. ITC studies involving 
the competitive binding of myristate and Co
2 +
 (analogous to the Zn
2+
 and myristate 
studies) established that the presence of myristate did indeed affect Co
2 +
 binding 
(Figure 1.6b and c) (Lu et al., 2012b). Interestingly, Co
2 + 
binding was less affected by 
the addition of five molar equivalents of myristate compared to Zn
2 +
 binding, where 1.3 
molecular equivalents of Co
2 + 
were still observed to bind. This effect was attributed to 
variances in binding affinities of the three sites (site A, site B and a third unknown site 
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which is possibly the ACTUN motif) for Zn
2 +
 and Co
2 +
, and to the different effects that 
fatty acids induce on each of the three sites. Based on ITC
 
and 
111
Cd NMR data, site A 
is impaired to the greatest extent, followed by site B, but no significant negative change 
is anticipated at the N-terminus, based on structural deliberations. Thus, with site A 
being the primary site for Zn
2 +
 but only a secondary site for Co
2 +
, comprehensive 
abolition of site A has a major influence on Zn
2 +
 binding, but a minor effect on Co
2 +
 
(which can be compensated by alternate binding of Co
2 +
 to the N-terminus). 
Absorbance readings of a mock ACB test involving physiologically applicable 
concentrations of BSA and 0–5 molar equivalents of myristate showed an association 
between the level of fats and the read out from the test (Lu et al., 2012b). This was an in 
vitro demonstration that elevated fatty acids in plasma are able to directly influence the 
results of the ACB assay.  
Additionally, since IMA involves non-covalent binding, it explains the quick return to 
normal IMA levels within hours once the ischemic incident is complete. Since albumin 
has a long half-life in plasma, any covalent modifications that are formed are not likely 
to be processed and cleared in such a short time frame, while plasma fatty acids are 
known to be cleared from the system in a similar frame of time (Eaton et al., 1969). 
Although this is a plausible and likely mechanism, it is important to note that it does not 
exclude the workings of other mechanisms that are able to influence cobalt binding to 
albumin, such as acidosis reducing local pH. 
The abundance of zinc in the body requires tight homeostatic regulation which is 
achieved through many mediators and transporters in both intracellular and extracellular 
environments. As stated earlier, a consequence of fatty acid induced inhibition of zinc 
binding to albumin could be the alteration of the speciation of zinc in circulation. That 
is to say, since albumin is the main transporter of zinc in plasma, if the zinc is unable to 
bind to where it usually would (its binding sites on albumin), the zinc in circulation 
must be bound to alternate proteins. One such protein is histidine rich glycoprotein 
(HRG), which is of particular interest since its action is regulated by its coordination of 
zinc. 
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Histidine Rich Glycoprotein (HRG) 
HRG is a 507 amino acid multidomain protein of an approximate mass of 75 kDa, with 
six predicted N-linked glycosylation sites, present in the plasma at low micromolar 
concentrations (Jones et al., 2005). The plasma proteome is dominated by the presence 
of up to 60% HSA, which equates to around 40 mg/ml. HRG can be said to be 
moderately abundant in plasma since it circulates in the same range as other classic 
plasma proteins such as IgG, IgA, factor H and the complement proteins in the range of 
0.05-0.5 mg/ml (Anderson and Anderson, 2002).  
The amino acid sequence of HRG was derived from the nucleotide sequence of its 
cDNA by Koide et al. (1986). The structure of HRG is composed of two N-terminal 
domains (N1 and N2) evolutionarily related to cystatins, a central eponymous histidine 
rich region (HRR) with two proline rich regions (PRR1 and PRR2) at either side of the 
HRR and a C-terminal domain (C) (Jones et al., 2005). The distinctive domains are held 
together by an arrangement of six disulphide bonds, forming the intact protein molecule 
(Figure 1.8). The domain structure allows for HRG to bind to a multitude of molecules 
including plasminogen (Lijnen et al., 1980), fibrinogen (Leung, 1986), thrombospondin 
(Leung et al., 1984), IgG (Gorgani et al., 1997), heparin (Lijnen et al., 1983a) and haem 
(Katagiri et al., 1987) as well as cell surface receptors such as Fcγ receptors (Poon et 
al., 2010), heparan sulphate (Jones et al., 2004) and platelets (Horne et al., 2001). Some 
of the studies on the binding profile of HRG used recombinant HRG expressed in 
human embryonic kidney cells (Olsson et. al. 2004; Rydengard et. al., 2007) or insect 
cells (Jones et. al., 2004). The variety of ligands that HRG displays an affinity for is 
mirrored in its presence as a regulator of several physiological processes, including 
immune function, angiogenesis and the coagulation of blood.  
HRG binds to heparin, a potent anticoagulant, with a strong affinity thereby regulating 
the cascade of usual mechanisms. Heparin would normally bind to antithrombin III, 
forming a heparin-antithrombin III complex that inhibits activated coagulants such as 
thrombin (Lijnen et al., 1983b). The formation of the HRG–heparin complex is 
enhanced in the presence of Zn
2 +
 (Jones et al., 2004). The most salient feature of HRG 
is promoted by its etymology, it contains an unusual prevalence of histidine (and 
proline) residues each accounting for approximately 13% of the amino acid sequence. 
The histidine rich region bears an extraordinary repeating amino acid sequence of Gly-
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His-His-Pro-His, developing a chain of histidine residues associated with binding metal 
ions (Figure 1.8).  
 
Figure 1.8. (a) The domain structure of the 507 amino acid human HRG represented as blocks, showing 
the N-terminal domains (N1 and N2), the first proline rich region (PRR1), the histidine-rich region 
(HRR), the second proline-rich region (PRR2), and the C-terminal domain (C). The dotted lines show the 
disulphide bridging arrangement through the protein, and the stars represent putative glycosylation sites. 
The unique repeating amino acid sequence of the HRR is also shown. (b) Chemical structure of the 
polysaccharide heparin. X = H or SO3
-
, Y = H, SO3
-
 or Ac. 
Pioneering work by Morgan showed that HRG can bind, Zn
2+
, Cu
2+
, Cd
2+
, Hg
2+
, Co
2+
 
and Ni
2+
 (Morgan, 1981; Morgan and Guthans, 1982). These studies provided 
fundamental insights into the methods of the protein, revealing that the Zn
2+ 
binding is 
pH dependent, with less binding observed at acidic pH, indicating that protonation of 
histidine residues reduces affinity. It was also reported that rabbit HRG is able to 
compete with albumin in respect to Zn
2+ 
binding (Morgan, 1981; Morgan and Guthans, 
1982). This is an intriguing observation since albumin has a greater affinity for Zn
2+
 (Kd 
= 30 nM cf. Kd = 1-4 µM) (Masuoka, 1993) and circulates at a much higher plasma 
concentration than HRG (Masuoka et al., 1993), but has less known binding sites. These 
studies demonstrated that that the affinities of the two proteins are relatively close 
together in relation to Zn
2+ 
chelation.  
The ability of human HRG to bind up to 10 molar equivalents of Zn
2 +
 effectively 
multiplies the zinc binding site concentration of HRG (Morgan and Guthans, 1982). 
Therefore, relatively small perturbations could possibly lead to shifts in Zn
2 +
 
-HPHKHHSHEQHPHGHHPHAHHPHEHDTHRQHPHGHHPHGHHPHGHHPHGHHPHGHHPHCH-
(a)
(b)
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distribution between albumin and HRG. Additionally, the concentration of Zn
2 +
 that is 
essentially free to move in plasma may reach the levels necessary for Zn
2 +
-dependent 
HRG complex formation (i.e. activation) during thrombosis, since platelet-derived α-
granules release Zn
2 +
 at the site of a thrombus (Horne et al., 2001). It is supposed that 
this system may assist in the temporal and spatial regulation of blood clotting (Vu et al., 
2013). 
In individuals suffering from elevated plasma fatty acid levels, it is conceivable that 
fatty acid-binding to albumin could release exchangeable Zn
2 +
 which may consequently 
enhance the formation of HRG–heparin complexes. Indirect evidence for this includes 
blood analbuminemia (no serum albumin), which is associated with hypercoagulability 
(Koot et al., 2004). Dietary studies have also shown that platelet aggregation and 
fibrinolysis can be increased by intake of some fatty acids (Prost-Dvojakovic and 
Samama, 1973; Kerr et al., 1965). Therefore it is possible that this mechanism may 
contribute to thrombotic symptoms that are clinically associated with conditions such as 
diabetes, cancer and obesity (Richieri et al., 1993). The examination of this relationship 
between fatty acid binding to albumin, the consequent Zn
2 +
release and possible 
increased coordination of zinc to HRG forms the premise and hypothesis of this 
research project. 
Albumin, Fatty Acids and Zn
2+
 Dynamics: Activation of HRG and a possible 
implication in blood coagulation  
One reservation regarding the early albumin studies looking at fatty acid and metal 
binding is to do with the preparation of the albumin samples used in experiments. One 
study using sheep albumin gave preliminary results showing no metal binding to the 
protein. It was noted that the albumin preparation did not include a de-fatting step, the 
inclusion of which resulted in the expected metal binding (Sadler and Viles, 1996). 
Following on from here, it was postulated that the presence of fatty acids induces an 
allosteric disruption of the Zn
2+ 
binding site, confirmed by crystal structure comparison.  
This supposed release of exchangeable Zn
2+ 
could switch on a chain of molecular 
events, where its binding to HRG leads to the formation of anticoagulant inhibiting 
complexes. High levels of plasma fatty acids are prevalent in conditions such as cancer, 
diabetes, obesity (Ghayour-Mobarhan et al., 2005; Soinio et al., 2007; Jansen et al., 
2012; Boden, 2011) and these conditions also present an increased risk of thrombosis. 
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With high levels of HRG associated with thrombotic disorders, it is pertinent to propose 
a potential relation between fatty acids binding to albumin, the subsequent release of 
Zn
2+ 
and the increased coordination of zinc to HRG (Figure 1.9). 
 
 
Figure 1.9. Schematic representation of the molecular interactions under investigation. Increasing fatty 
acid levels may shift the equilibrium towards the right.  
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Aims 
The major hypothesis under investigation during this doctoral research project is to 
develop an understanding of the regulation of the Zn
2+
 dependent activities of histidine-
rich glycoprotein as influenced by fatty acid binding to albumin. Another major aim is 
to gain better insight into the metal binding properties of albumin. The project is divided 
into separate chapters with individual aims.  
Chapter 2: Experimental techniques 
Chapter 3: Structural characterisation of HRG.  
Chapter 4: Investigations into Zn
2+
 and heparin binding to HRG and implications for                   
thrombin activation.  
Chapter 5: Identification of novel metal binding sites on albumin.  
Chapter 6: Conclusions 
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Chapter 2 
Experimental techniques 
Protein purification 
One of the simplest and easiest methods for protein purification is immobilised metal 
affinity chromatography, which was developed in the ‘70s (Porath et al. 1975). This 
process utilises either a protein’s native or engineered affinity for metals (usually Ni2+ 
or Cu
2+
) immobilised on a matrix. Histidine exhibits the strongest interaction with 
immobilised metal ions, as electron donor groups on the histidine imidazole ring readily 
form coordination bonds with the metal. Nickel, copper and zinc can coordinate with 
donor atoms such as O and S but have a distinct preference for N. Also, the imidazole 
group of histidine is partially deprotonated at physiological pH (pKa ~ 6.5). Therefore, 
provided that the histidine is accessible, it will provide the protein with the ability to 
bind to these metal ions.  
Consecutive histidine residue containing amino acid sequences are proficiently retained 
during immobilised metal affinity chromatography. The matrix is washed, and the 
polyhistidine sequences can be eluted simply by either adjusting the imidazole content 
or the pH of the buffer. Imidazole, due to structural similarity with histidine, provides 
effective competition for the metal matrix thereby releasing the histidine sequence from 
binding. Reducing the pH alters the charges of the imidazole group of histidine (making 
it more positively charged), hence precluding its binding to the positive metal matrix. 
This understanding and simplicity led to the development of “His-tags” to modify 
desired proteins for ease of purification (Hochuli et al. 1987, 1988), and is now 
common practise in purification protocols.  
The nickel affinity chromatography method was used here to purify HRG either from 
rabbit serum/plasma or human plasma, by exploiting the histidine-rich nature of HRG 
and consequent affinity for metal ions. The procedure used was a modified version of 
established protocols for HRG purifications (Mori et al. 2003), which in one simple step 
affords high yields and high purities. 
While this one step procedure was deemed suitable for most experiments, an extra 
purification step was added prior to protein crystallography experiments. To further 
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purify and ensure homogeneity, HRG was subjected to size exclusion chromatography 
(also known as gel filtration).  Size exclusion chromatography separates molecules 
based on their hydrodynamic volume (their sphere of rotation in solution) and has been 
applied in protein purification for decades. During size exclusion, larger molecules are 
retained on the column for shorter periods of time than for smaller molecules (which 
could include salt and other buffer constituents), thus effective separation of a 
heterogeneous sample can be achieved, once optimal procedures and conditions are 
developed. This method can also be used to “desalt” or exchange the buffer solution in 
protein samples. Separation is made possible by pores within the resin that provide a 
longer pathway through the column for smaller analytes, which can fit through the pore.  
Size exclusion columns generally have a low resolution and come in many stationary 
phase arrangements of different pore sizes and matrix material allowing for the selection 
of the most appropriate column for specific samples. The state of the protein sample can 
also affect the retention time of proteins, since hydrophobic and electrostatic 
interactions occur between the protein and the matrix, which can result in larger peak 
volumes or lower resolution (Regnier, 1983). The ionic strength of the solution can also 
influence retention times, where moderate to high salt concentrations subdue 
electrostatic interactions of proteins with the column matrix (Stulík et al. 2003). As with 
high-performance liquid chromatography, organic solvents like acetonitrile can be used 
in the buffers to reduce interactions (Welling et al. 1985). However, this is a harsh 
method which can potentially denature the target protein.  
Protein Crystallography  
Protein crystallography attempts a molecular choreography of the most dynamic and 
pliable constructs in chemical physiology. Protein molecules display an abstract quality 
of arranging into structures relating to function while paradoxically being composed of 
apparent random sequences of amino acids. Crystallography is the most powerful 
technique available to examine the tertiary and even quaternary structure of proteins. 
Crystals are achieved by exposing a protein sample of high purity to conditions at the 
limit of precipitation. In order to establish these, parameters including protein 
concentration, salt content, precipitant, pH and temperature are varied to establish 
optimal conditions for crystallisation to occur. Another aspect of importance is the 
homogeneity of the protein in the sample. It is imperative that the protein molecules are 
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of the same homogeneity in order to build on one another to form a crystal (Benvenuti 
and Mangani, 2007). 
During the crystallisation process, molecules in solution associate with each other to 
form a uniform solid phase lattice. This process is encouraged by altering the chemical 
and physical environment to make the formation of the lattice conformation 
thermodynamically favourable. The difference between the changes in entropy and 
enthalpy is the energy released during crystallisation. Due to rotational and translational 
disorder, the molecule has favourable entropy in solution, but is enclosed by a 
coordination sphere of water molecules that give the system unfavourable entropy. The 
surface charge of the protein molecule allows it to hydrogen bond with the water 
molecules (enthalpically favourable). However, these interactions are altered during 
crystallisation where hydrogen bonds with some of the water molecules are sacrificed in 
areas where stronger intramolecular ionic and hydrogen bonds are available, and thus 
the regular order of the crystal lattice lowers the entropy of the crystalline system. 
Hydrophobic regions of protein molecules are likely to be hidden by intermolecular 
interactions, preventing the formation of unfavourable bonds with water molecules. The 
solution entropy is increased however, by the expulsion of water molecules (Benvenuti 
and Mangani, 2007). 
Varying the conditions described above can be used to control and exploit these energy 
profiles. For example, the pH determines the charge on the molecule thereby 
manipulating the interactions of the protein with the solution. Polymeric alcohols such 
as polyethylene glycol (PEG) quench water molecules away from a crystal lattice, 
allowing it to pack tighter. Adding counter-ions can protect surface charges and alter the 
solvent chemical potential. Divalent metals can directly interact with the protein and 
attenuate lattice contacts. The inclusion of metal ions can also help solve phasing issues 
further on in the structure resolution process. The physical environment during 
crystallisation can be changed by several methods including dialysis, controlled 
evaporation or vapour diffusion (Dessau and Modis, 2011).   
A popular vapour diffusion method used routinely for crystallisation is the sitting drop 
vapour diffusion technique. A mixed drop (between nanoliter and microliter in volume) 
containing sample, buffer and precipitant reagents is placed on a platform to put it in 
vapour equilibration with a liquid reservoir well. Initially, the precipitant concentration 
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in the drop is lower than that in the reservoir (i.e. the water concentration in the drop is 
higher). Over a period of time water vapour leaves the drop and equilibrates with the 
reservoir well. Since water is leaving the drop solution, the sample is effectively being 
concentrated thereby increasing the relative supersaturation of the sample. This is a key 
step during crystallisation, since the process involves the effort to push the sample 
through different phases to achieve reproducible crystal growth.   
A phase diagram provides an appropriate illustration of the crystallisation process, 
showing the states which occur during attempted crystallisation. It shows the balance of 
pivotal parameters such as protein concentration, additives and precipitants in a constant 
juggle to produce crystals. Phase diagrams are kept in mind during the design and 
optimisation of crystal experiments (Figure 2.1) (Ataka, 1993; McPherson 1999). 
 
Figure 2.1. Phase diagram for a vapour diffusion crystallisation experiment, showing the four possible 
zones. The protein sample begins in an undersaturated state but during the evaporation process becomes 
more concentrated and tends towards the nucleation zone. Once crystals nucleate, the protein 
concentration in solution drops and the sample sits in the metastable zone, most suitable for crystal 
growth. 
Four zones represent the varying points of saturation where the zone of high 
supersaturation is likely to induce protein precipitation and a zone of undersaturation 
where the protein is soluble and stable in solution thus precluding crystal formation. In 
between these conditions exists a zone of moderate supersaturation, where nucleation 
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occurs spontaneously. This zone is encouraging for the growth of crystals. But the 
desired condition rests in the metastable zone of supersaturation, where crystals forming 
after nucleation are stable and may grow well ordered crystals. Crystallisation ensues in 
two phases, nucleation followed by growth. Nucleation is a necessary for crystallisation, 
but requires different conditions than those required for growth. According to the phase 
diagram, once nucleation has been achieved and spontaneous growth follows, the 
protein concentration in solution will decrease and the phase will drop down into the 
metastable zone (Ataka, 1993; McPherson, 1999). Generally, the crystallisation process 
takes two stages where the first aim is to determine lead conditions for crystallisation of 
the molecule and secondly to optimise those conditions to produce quality single 
crystals of at least 10 μm3 in dimension for X-ray diffraction. 
All X-ray diffraction experiments were performed by Dr. Stephen McMahon. 
Isothermal Titration Calorimetry (ITC) 
One of the main calorimetric techniques applied to investigate protein binding 
interactions is isothermal titration calorimetry (ITC). ITC measures the heat energy 
generated during the association of molecules at a constant temperature; once a ligand is 
titrated into a protein solution the exothermic or endothermic heat is detected. ITC 
allows for the association constant (Ka, and thus the dissociation constant, Kd), the 
standard Gibbs free energy change (ΔG), the enthalpy change (ΔH), the entropy change 
(ΔS) and the stoichiometry (n) of the binding reaction to be determined simultaneously. 
Additionally, if experiments are performed over a range of different temperatures the 
heat capacity change (ΔCp) of the binding reaction can be calculated (Chen and Wadso, 
1982; Wiseman et al., 1989; Freire et al., 1990). Since most interacting systems are 
characterised by changes in enthalpy, ITC has vast range of potential applications. 
In modern instruments, the calorimeter is based on a cell feedback system which 
measures the difference in heat effects between the sample cell and a reference cell. A 
constant power is applied to the reference cell which activates the feedback circuit, in 
turn regulating the temperature in the sample cell. The baseline signal is the resting 
power applied to the sample cell. If the reaction between the sample and the titrant is 
exothermic a decrease in the necessary feedback power is required (since the reaction 
provides energy to the system), and endothermic reactions require an increased 
feedback power (since the reaction will take energy out of the system). The reaction 
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enthalpy for each injection is obtained by integrating the area of the peak formed which 
deviates away from the resting baseline. Thus the power applied by the calorimeter to 
keep the system under isothermal conditions is a means of following the interaction. 
Figure 2.2 shows a schematic representation of an ITC calorimeter (Wiseman et al., 
1989; Freire et al., 1990). 
For a typical ITC experiment, the reference cell is filled with water and the sample cell 
with the sample of interest. The ligand is introduced by an electronically controlled 
injection syringe which is continuously stirring during an experiment, to allow complete 
instantaneous mixing in the sample cell after an injection. The mechanical heat provided 
by the stirring is constant and becomes part of the resting baseline. Setting up ITC 
binding experiments is very challenging due to the nature of  non-covalent binding, 
where heats are intrinsically small  (in the range of 5-10 kcalmol
-1
), and are released 
during the binding experiment. Additionally, ligand titration produces further heat 
effects arising from mixing and dilution which are frequently comparable to the binding 
heat of interest, and so corrections must be made to account for these. The setup of an 
ITC experiment depends largely on the thermodynamic characteristics (the expected 
binding affinity and the heat effect) of the system of interest. Thus the appropriate 
concentration of the protein placed in the cell depends on the binding affinity between 
the protein and ligand. The shape of the binding curve is dependent on the product of 
the concentration of macromolecule [M] and the binding constant Ka, which is termed 
as the dimensionless constant, C.  
 
Figure 2.2. Diagram showing the concept behind an isothermal titration calorimeter. The system is kept 
at a constant temperature, and the power required to sustain this temperature relative to the reference cell 
is recorded as the titrant is injected into the sample cell.  
Reference cell Sample cell
Syringe with titrant
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At high C-values (over 500), the shape of the curve approaches a step function and so 
becomes insensitive to changes in Ka and thus unsuitable for determining binding 
constants. At low C-values (less than 10), the binding curve essentially forms a 
horizontal line which reveals very little experimental information regarding affinity 
constants. Conditions should be optimised to have a C-value in the range of 10–100 for 
an accurate and reliable determination of Ka. To measure at these C-values, very strong 
binding interactions (10
7–108 M-1) require low concentrations of the protein. With a 
lower affinity of the interaction or lower concentrations of the protein, the signal will 
becomes smaller and reach the detection limit of ITC. Therefore, it is necessary to use 
high protein concentrations to obtain informative isotherm curves if a low binding 
affinity is expected or observed. There is no limit in principle to the low binding affinity 
interactions that can be determined, however in experimental practice there are 
problems with stability or solubility and often with availability of the precious protein 
sample in order to optimise conditions such that the C-value range is 10–100. Even at 
low ligand concentration, only a small percentage of ligand is bound to the protein, 
making sufficient heat detection difficult and thus problematic to determine ΔH 
accurately (Bhatnagar and Gordon, 1995). 
For high quality isotherms, an appropriate protocol has to be established by optimising 
parameters such as protein concentration, ligand concentration, the injection volume and 
the injection spacing. The ligand concentration is usually much higher than the sample 
concentration since several molar equivalents must be injected to reach saturation. The 
ITC experiment should be designed to reach or at least approach complete saturation of 
the binding sites by the end of the experiment. To generate an appropriate number of 
data points, which will improve data analysis by allowing for better curve fitting, the 
ligand is added in small quotients. However, this volume should not be so small such 
that the heat signal is too small to maintain high precision of each injection data point. 
In the instance of the interaction heat being small, the injection volume can be 
increased. In cases where the ligand has poor solubility, it is possible to place it in the 
sample cell and to inject the protein (Bhatnagar and Gordon, 1995). 
The time interval in between consecutive injections is an additional significant 
parameter in obtaining quality data. If the binding association is quick, the calorimeter 
will be able to equilibrate to baseline in a short time, and so only a few minutes would 
be sufficient to reach baseline again after injection. However, a slow binding process 
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will require much longer to reach equilibrium. When running an ITC experiment, it is 
imperative that the solutions of protein and ligand are pure and at exactly the same pH, 
buffer composition and salt concentration. To achieve this, the protein and ligand are 
usually dissolved in the same buffer or dialysed prior to the experiment. This ensures 
the prevention of spurious heat effects which result from the mixing of different buffer 
components. Additionally, air bubble formation is to be avoided, and so samples are 
degassed prior to the experiment. Air bubbles in the sample cell can lead to false signals 
since they can interfere with the thermal contact of solution and cell wall. Lastly, the 
heat effect of the first injection is usually too small as a result of diffusion during 
equilibration of the system. Thus it is common practice to make a small first injection 
and then subsequently delete the first data point prior to analysis (Bundle and 
Sigurskjold, 1994). 
ITC measures the total heat released or absorbed during a binding interaction which 
includes the heat contributions from dilution of ligand in the buffer, heat of mixing and 
possible mixing of buffers of slightly different composition. Before analysing the data 
for a specific reaction, these effects (particularly the heat of dilution) need to be 
accounted for by performing control experiments of the injecting ligand into buffer. An 
alternative option is to ensure that the experiment reaches complete saturation by the 
end of the titration so that the nonspecific heat effects can be averaged from the final 
injections. The area under the signal against time curve which is evolved during an ITC 
experiment represents the total heat absorbed or released by an injection (Figure 2.3). 
From this raw data, the baseline and dilution heats are subtracted. The data are 
presented in integral mode as a hyperbolic saturation curve or in differential mode as a 
sigmoid plot (Sigurskjold et al., 1991; Bundle and Sigurskjold, 1994).  
To obtain quantitative information, the data is subjected to non-linear curve fitting. In 
the simplest case, each protein molecule contains only one type of binding site, all of 
which display the same intrinsic affinity for the ligand. More complex fitting methods 
are also used to attempt to describe more complex binding systems, where multiple 
independent sets of binding sites occur or where cooperative binding sites exist. Using 
statistical thermodynamic treatment makes it possible to deconvolute a binding isotherm 
of such complex systems (Perozzo et al., 2004). However, the quality and reliability of 
the experimental data dictate the success of fitting parameters.   
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Figure 2.3. (a) An ITC isotherm for EDTA (0.4 mM) titrated with Ca
2+
 (5 mM). The top panel is the raw 
data showing the heat generated for each injection of Ca
2+
. The bottom panel is an integration of the raw 
data peaks showing the energy per mole of reactant, and the non-linear fit can be used to quantify the 
interaction. In this case, the reaction was exothermic with N= 0.93 and Ka= 1.35  10
5
 M
-1
. The important 
paraeters are highlighted. (b) The thermodynamic equations relating the change in enthalpy (ΔH) and the 
dissociation constant (Kd) with Gibbs’ free energy (ΔG). R is the Gas constant, T is temperature and ΔS 
the change in entropy. 
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Chapter 3 
Structural characterisation of HRG 
This chapter details the structural investigations into histidine-rich glycoprotein (HRG). 
As discussed previously, HRG is known to modulate a variety of processes in plasma 
through its ability to bind to a range of ligands but little is known about how these 
binding interactions occur and how HRG folds into a 3-dimensional structure (Figure 
3.1).  
 
Figure 3.1. Domain structure of rabbit HRG, showing the N1 and N2 domains, the proline-rich regions 
(PRR1 and PRR2), the histidine-rich region (HRR) and the C-terminal domain (C). The putative 
glycosylation sites and the cleavage sites for plasmin are also shown. The disulphide bridging 
arrangement is highlighted by grey lines, with the disulfide bridge between the N2 domain and the 
HRR/PRR fragment highlighted in bold black (Kassaar et al., 2014). 
Although the HRG sequence and domains are well conserved across different species, 
minor variations amongst species exist. Alignment of rabbit HRG with human HRG 
shows a 64% identity, with 69% similarity (Figure 3.2). The greatest homology occurs 
at the N-terminal domains, where the respective N2 domains are 68% identical and 93% 
similar. However, the HRR and PRR regions exhibit a lower degree of homology due to 
substitution of histidine for proline along the sequence in the rabbit protein. The 
HRR/PRR region of rabbit HRG is also extended compared to the human protein; 
human HRG contains 12 tandem repeats of the sequence Gly-His-His-Pro-His, while 
the rabbit HRG contains 16 repeats (including repeats where a proline substitutes for 
histidine). The HRR is involved in the binding of metal ions, particularly Zn
2+
. The 
binding of Zn
2+
 can modulate the affinity of HRG for its other ligand molecules and 
thereby regulate the activity of HRG in several processes like coagulation or 
angiogenesis. 
N1 N2 PRR1 HRR PRR2 C
disulfide
bonds
Cys6 –Cys497
Cys60 –Cys71
Cys87 –Cys108
Cys185 – Cys407
Cys199 –Cys222
Cys264 –Cys294
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cleavage
(Arg298)
1 118 119 235 243 288 321 442 518
predicted
glycosylation
sites
Asn107
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Asn232
Asn302
Asn477
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Figure 3.2. Sequence alignment of human HRG (NCBI: P04196) and rabbit HRG (NCBI: Q28640). 
Domains are labelled and coloured, and the high homology in the N-domains and C-domains can be seen. 
Rabbit HRG has a longer histidine-rich region. 
As described by its etymology, HRG is heavily glycosylated with six putative N-linked 
glycosylation sites. While the histidine- and proline-rich regions are anticipated to be 
intrinsically disordered due to the peculiar sequence, the remaining N1, N2 and the C-
terminal domains are predicted to have ordered structures. In particular, both the N1 and 
N2 domains are derived from the cystatin superfamily of cysteine protease inhibitors 
with which they share high sequence homology (Koide and Odani, 1987). Type 1 
cystatins (stefins) are characterised by a lack of disulfide bridges, while type 2 cystatins 
have two conserved disulfide bridges (Barrett et al., 1986). These include cystatin B and 
cystatin C which are suggested to have roles in inhibiting tumour neovascularisation 
(Chang et al., 2009).
 
The homology between the HRG N1 and N2 domain sequences 
with cystatin proteins has led to the classification of HRG as a type 3 cystatin (in the 
same class as fetuins and kininogens) (Lee et al., 2009). Although HRG has been 
classified as a cystatin, it does not exhibit cysteine protease inhibitor activity since it is 
incapable of inhibiting cysteine peptidases of the papain (C1) family (Lee et al., 2009). 
The N-terminal domains of HRG also share a degree of sequence homology with the N-
terminal region of antithrombin. This is understandable when considering that the 
respective N-terminal domains of both HGR and antithrombin associate with heparin 
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(Koide et al., 1986).This taken together with the fact that both proteins are involved in 
the regulation of thrombin activity, by competing for heparin with one another 
(Kluszynski et al., 1997), suggests an evolutionary relationship between the two. The 
HRG N1 and N2 terminal domains are also involved in interactions with C1q, IgG 
(Gorgani et al., 1997) and FcγRI (Poon et al., 2010) to regulate immune function. 
HRG controls the formation of blood vessels through both positive and negative 
mechanisms. The angiogenic activity of HRG is rooted in its high affinity for the 
angiogenesis inhibitor, thrombospondin, via CLESH motifs within the HRG C-terminal 
domain (Simantov et al., 2001). A similar interaction, but with vasculostatin, is also 
thought to induce a positive angiogenic mechanism (Klenotic et al., 2010).
 
A negative 
angiogenic effect facilitated by HRG was determined to be due to the HRR in studies 
using truncated recombinant HRG proteins, peptides based on the HRR and proteolytic 
fragments (Juarez et al., 2002). Inhibition of the proliferation of endothelial cells both in 
vitro and in vivo has been observed with HRG after being subjected to partial 
proteolysis with the plasma protease, plasmin (Juarez et al., 2002). This proteolytic 
regulation by plasmin of HRG is known to be required for some of its physiological 
functions, where release of a fragment from the intact protein that includes the HRR is 
necessary. For example, the endotoxin-neutralising and anti-microbial properties of 
HRG are solely down to the release of the HRR portion and subsequent further 
degradation (Bosshart and Heinzelmann, 2003; Rydengard et al., 2007). Various 
truncations and fragments of recombinant HRG were examined using fibrosarcoma 
tumor model mice to investigate the anti-angiogenic properties of HRG (Olsson et al., 
2004). HRG proteins and fragments containing the HRR reduced vascularisation and 
tumour growth, while those without the HRR had no effect. This strongly suggests that 
the histidine rich region is a potent angiogenesis inhibitor. HRGP330 is a 35-amino acid 
peptide that is based upon a sequence within the HRR and has been described as the 
minimal sequence with active anti-angiogenic properties in vitro and in vivo (Dixelius et 
al., 2006; Lee et al., 2006).
 
HRGP330 works by disrupting focal adhesion kinase (FAK) 
and integrin-linked kinase functions, subsequently stopping endothelial cell motility 
(Bosshart and Heinzelmann, 2003). Taken together, these studies associate HRG in the 
regulation of angiogenesis through a proteolytically-controlled mechanism which 
releases the HRR (Borza et al., 1996; Poon et al., 2009). The precursor to plasmin 
(plasminogen) is in close association with HRG in circulation, and approximately 50% 
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of plasminogen is bound to HRG in plasma (Lijnen et al., 1980). However due to the 
presence of a particular conserved disulfide bridge within HRG, proteolysis by plasmin 
alone is not sufficient to release the HRR. Four intradomain and two interdomain 
disulfide bridges hold the structure of HRG together. One of the interdomain bonds 
links the N1 and C-terminal domains, as is observed in the other members of the type 3 
cystatin family. Uniquely to HRG, the second interdomain disulphide links the N2 
domain to a region in between the HRR and PRR2 domains (Figure 3.1) (Sørensen et 
al., 1993). A peptide corresponding to the HRR/PRR fragment has been identified in 
vivo through mass spectrometric analysis of human tissue samples. However, the 
mechanism by which the interdomain disulfide is reduced is not understood (Thulin et 
al., 2009). 
A key aim here was to structurally characterise HRG using X-ray crystallography, 
which may help to unravel the binding characteristics of HRG with its binding partners 
and also provide clues for the in vivo functioning of HRG.  
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Methods 
Purification  
HRG was purified directly from either rabbit serum (Sigma-Aldrich) or human plasma 
(TCS Biosciences, Buckingham, UK) using Immobilised Metal Affinity 
Chromatography (IMAC) by exploiting its intrinsic histidine abundance and subsequent 
affinity for nickel. Elution was achieved by increasing the imidazole content of the 
buffer to provide competition for binding sites as imidazole and histidine show 
structural similarities: both are diazole rings. All purifications were performed using the 
ÄKTApurifier FPLC system (GE Healthcare, UK). 
 
Serum or plasma was centrifuged (4 000 x g, 30 minutes) and filtered through a 0.45 
µm syringe filter (Sartorius, Epsom, UK) to remove any aggregates and large particles. 
The sample was treated with 5 mM imidazole in keeping with the equilibration buffer 
(10 mM Tris, 150 mM NaCl, 5 mM imidazole, pH 8). A 5 ml HisTrap nickel column 
(6% highly cross-linked agarose matrix; GE Healthcare Life Sciences, Little Chalfont, 
UK) was equilibrated with 5-10 column volumes of the equilibration buffer and sample 
(50 ml) loaded. The column was washed with equilibration buffer and then with 30% 
elution buffer (10 mM Tris, 150 mM NaCl, 400 mM imidazole, pH 8). HRG was eluted 
with a gradient of 60-80% elution buffer. The purified HRG sample was then dialysed 
to remove any bound metals in a buffer of choice for further experiments, or in 50 mM 
ammonium carbonate prior to lyophilisation. This protocol was also repeated but using 
one tablet of SIGMAFAST
TM
 (Sigma-Aldrich) protease inhibitor cocktail per 100 ml of 
serum or plasma.  
 
All protein samples were confirmed to contain no detectable levels of Zn
2+
, as assessed 
by the colorimetric Zinc Assay Kit (Sigma-Aldrich). 
 
Protein Concentration Determination 
 
Protein concentration was determined either by direct weighing of samples prior to 
reconstitution in buffer, or by measuring absorbance at 280 nm. An extinction 
coefficient of 32150 M
-1
 cm
-1
 was used for rabbit and 26900 M
-1
 cm
-1
 for human HRG. 
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Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Analysis of protein purifications was followed by SDS-PAGE under denatured 
conditions to determine purities of samples. Samples to be analysed were mixed with 
NuPAGE LDS Sample Buffer at a typical ratio of 3:1 and loaded onto 4-12% NuPAGE 
Bis-Tris gels. Electrophoresis was conducted in NuPAGE MES SDS Running Buffer 
for 45 minutes at 200 V. All electrophoresis materials were supplied from Invitrogen. 
After the desired separation had been achieved, the gels were either stained with 
Coomassie Blue. Gels were visualised by staining with Coomassie stain (0.025% 
Coomassie Brilliant Blue R250, 40% methanol, 10% acetic acid) for 10 minutes, 
followed by destaining in boiling water. If greater sensitivity was desired, the staining 
incubation time was increased. 
 
To determine the redox condition of plasma HRG and the effect of the protease action 
of plasmin, SDS-PAGE analysis followed by Coomassie staining was used to monitor 
the domain structure of HRG after being subjected to a range of conditions: native non-
reduced HRG, native reduced HRG and plasmin-treated reduced HRG. Reduction was 
achieved with 2.5 mM dithiothreitol (DTT). To further analyse HRR/PRR and achieve 
sequence information, a band of approximately 25 kDa, putatively thought to 
correspond to this fragment, was cut and submitted for MS/MS analysis. 
 
Crystallography 
Data collection, structure solution and refinement were performed by Dr. Stephen 
McMahon and Prof. Jim Naismith. 
 
Rabbit HRG was used for crystallisation trials since it is ten times more abundant 
compared to human HRG. Prior to setting up crystallisation trials, the HRG sample was 
furthered purified by size exclusion chromatography using an S-200 column (GE 
Healthcare, Life Sciences) in 10 mM Tris, 150 mM NaCl, pH 8. HRG eluted as a single 
peak at a molecular weight of ~140 kDa. The sample was subjected to a Pre-
Crystallisation Test (Hampton) to determine a suitable concentration for crystallisation 
screens. HRG was screened for crystallization using two commercial screens, JCSG+ 
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and PACT (Qiagen, Manchester, UK), at a concentration of 16 mg/ml, alongside in-
house stochastically designed screens, on an Art Robbins Gryphon crystallization robot 
by sitting-drop vapor diffusion. Crystals appeared after 4 weeks at room temperature as 
two visibly distinct crystal morphologies: cubic and rod-shaped. Crystals were grown 
from 22.5% PEG MME 5000, 100 mM MES and 73 mM potassium sodium tartrate at 
pH 6.5. The rod-shaped crystals diffracted best and subsequently both native and heavy 
atom soaked data sets were collected with this morphology of crystal. For phasing, a rod 
shaped crystal was harvested and soaked for 5 minutes in mother liquor supplemented 
with 50 mM K2PtCl4 before being back-soaked in cryoprotectant (mother liquor with 
25% glycerol) and then immediately frozen in liquid nitrogen.  Data were collected on 
Diamond beamline I02 as 1,000 non-overlapping images using a Pilatus 6M detector. 
Later, a high-resolution native data set was collected on Diamond beamline I04-1 from 
a different crystal. All data were processed with xia2 (Winter et al., 2013). The data 
obtained from these crystals were analysed using PHENIX. Using both anomalous and 
isomorphous difference, Autosol identified two Pt sites in spacegroup P3121 with a 
figure of merit of 0.18 at 3.1 Å. Density modification and extension to 2.9 Å using 
Autobuild gave a preliminary model of 107 residues and an R-factor of 30%. This 
model was rebuilt using COOT by manual inspection and with new data extended to 
1.93 Å. The final structure was deposited in the RCSB Protein Databank (PDB code: 
4CCV). 
 
Protein Deglycosylation  
It was anticipated that the extent of glycosylation on HRG would seriously hinder and 
even preclude the formation of crystals. For this reason, an endeavour to establish a 
viable protocol for deglycosylation was investigated. Sugar chains of the heavily 
glycosylated HRG were removed using a Protein Deglycosylation Mix (NEB). The 
mixture contained PNGase F (500 units/µl), O-glycosidase (40,000 units/µl), 
neuraminidase (50 units/µl), β1-4 galactosidase (8 units/µl) and β-N-
acetylglucosaminidase (4 units/µl). A range of conditions were attempted in order to 
optimise the deglycosylation, the extent of which was analysed using mass 
spectrometry. Essentially, the protein sample was incubated with the Deglycosylation 
Enzyme Mix at 37 °C. Various concentrations of sample and enzymes, for a range of 
incubation times and in a native or denatured state were tested. Samples were denatured 
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by boiling for 10 minutes in the presence of SDS. 
 
Mass spectrometry (MS)  
Mass spectrometry was performed by Dr Catherine Botting. 
  
To determine the intact mass of plasma/serum purified HRG, protein samples (20 µL, 1 
mg/mL) were desalted on-line through a MassPrep On-Line Desalting Cartridge 2.1 x 
10 mm (eluting at 50 µL/min) with an increasing acetonitrile concentration (98 % H2O, 
2 % acetonitrile, 1 % formic acid to 98 % acetonitrile, 2 % H2O, 1 % formic acid) and 
delivered to a Waters LCT electrospray ionisation mass spectrometer. The molecular 
mass of the protein was obtained from an envelope of multiply charged signals which 
were deconvoluted using MaxEnt1 software. The mass spectrometer had previously 
been calibrated using myoglobin. 
 
For sequence analysis, the protein sample was analysed by SDS-PAGE as described 
above and the gel band was excised and cut into 1 mm
3
 cubes. These were subjected to 
a ProGest Investigator in-gel digestion robot (Genomic Solutions, Ann Arbor, MI). The 
gel cubes were digested with trypsin at 37 °C or thermolysin at 55 °C after being 
destained by washing with acetonitrile and subjected to reduction and alkylation. The 
peptides were extracted with 10% formic acid and the solution (0.5 µl) applied to the 
Matrix-assisted laser desorption/ionisation (MALDI) target along with alpha-cyano-4-
hydroxycinnamic acid matrix (10 mg/ml in 50:50 0.1% TFA:acetonitrile, 0.5 µl) and 
allowed to dry. 
 
Trypsin was used as is standard in this type of peptide identification. However, since 
trypsin cleaves after arginine or lysine residues, thermolysin was used in instances 
where the identification of the HRR was required (because of the lack of arginine and 
lysine residues in the HRR domain). 
 
MALDI MS was acquired using a 4800 MALDI TOF/TOF Analyzer (AB Sciex, Foster 
City, CA) equipped with a 355 nm Nd:YAG laser and calibrated using a peptide 
mixture. In positive MS mode, the spot was initially analysed between 800 and 4000 
m/z, by averaging 1000 laser spots. Up to 15 of the most intense peptides were selected 
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for MS/MS analysis and acquired to a maximum of 3000 laser shots or until the 
accumulated spectrum reached a S/N ratio of 35.  All MS/MS data were acquired using 
a collision energy of 1 keV. ProteinPilot 4.1 Paragon algorithm (AB Sciex) was used to 
analyse the MS/MS data, searching against an internal database to which the HRG 
sequence had been added, with no enzyme digestion parameters selected and 
modification of cysteines by carbamidomethyl selected. 
 
Free thiol concentration determination using Ellman’s reagent 
The rabbit plasma or serum samples were diluted 1:50, while the HRG from plasma or 
serum was reconstituted in PBS to 1 mg/ml, pH 7.2, and thiol determination was carried 
out using 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB). 5 µl of a 20 mM DTNB solution 
was added to 100 µl of sample. Absorbance was recorded at 405 nm and a thiol 
concentration calculated using a coefficient of 17 780 M
-1
 cm
-1
 (Ellman, 1958).  
 
Plasmin Digest 
Digests of 1 mg/ml samples of HRG with 1 unit of plasmin were performed for 30 
minutes at 37 °C in 20 mM potassium phosphate, 150 mM sodium chloride at pH 7.5. 
Samples were reduced with the addition of 2 mM dithiothreitol (DTT). 
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Results and Discussion 
Characterisation of HRG 
HRG was purified directly from serum or plasma with a simple one-step protocol, 
taking advantage of its natural abundance of histidine by using a nickel column This 
resulted in high yields (> 80%) and high purity of protein (> 95%) as assessed by SDS-
PAGE. Figure 3.3 shows an SDS-PAGE gel following purification of HRG. As judged 
by comparison with the molecular weight markers (Bioline) the mass of rabbit HRG is 
approximately 75 kDa. The band lanes 1 and 2 at approximately 140 kDa and is a HRG 
dimer.    
 
Figure 3.3. SDS-PAGE analysis (following Coomassie stain) of rabbit HRG following nickel affinity and 
gel filtration purification steps. HRG can be seen in lanes 1 to 8. The sample pooled from lanes 3-7 was 
used for crystallisation trials.   
The relative purity of the sample preparations was assessed using the gel imaging 
software (ImageLab) by comparing the relative intensities of visible bands. Typical 
working samples were > 95% HRG.  To confirm the protein identity, gel bands were 
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excised and submitted for sequence analysis. The mass spectrometry results for 
sequence analysis are shown in Figure 3.4. The rabbit HRG sample achieved coverage 
of 41.2% with 45 significant peptides while the human HRG was covered to 25.5% with 
12 significant peptides.   
 
Figure 3.4. Sequence analysis for identification of (a) rabbit HRG and (b) human HRG. Significant 
peptide fragments are highlighted in green. 
To show that there is no difference in HRG purified from serum or plasma and to 
determine whether the process of plasma developing to serum may have redox 
influences on activity at Cys185, free thiol concentrations were measured to represent 
the redox state in plasma and serum from rabbits. The free thiol concentration of plasma 
was determined to be 250 µM, significantly greater than that of serum, 208 µM (Figure 
3.5A). Additionally, HRG samples prepared from either serum or plasma were 
characterised and compared. Both preparations, serum and plasma HRG, had the same 
free thiol content (0.7 mol thiol/mol HRG; Figure 3.5B). The samples were also 
subjected to analysis by mass spectrometry and showed the same molecular mass 
profile (Figure 3.5C) and thus molecular composition. This provides definitive proof 
that preparing HRG from serum did not affect the redox state of the protein and the 
VSPTDCSAVEPEAEKALDLINKRRRDGYLFQLLRIADAHLDRVENTTVYYLVLD
VQESDCSVLSRKYWNDCEPPDSRRPSEIVIGQCKVIATRHSHESQDLRVIDFNC
TTSSVSSALANTKDSPVLIDFFEDTERYRKQANKALEKYKEENDDFASFRVDRI
ERVARVRGGEGTGYFVDFSVRNCPRHHFPRHPNVFGFCRADLFYDVEALDLESP
KNLVINCEVFDPQEHENINGVPPHLGHPFHWGGHERSSTTKPPFKPHGSRDHHH
PHKPHEHGPPPPPDERDHSHGPPLPQGPPPLLPMSCSSCQHATFGTNGAQRHSH
NNNSSDLHPHKHHSHEQHPHGHHPHAHHPHEHDTHRQHPHGHHPHGHHPHGHHP
HGHHPHGHHPHCHDFQDYGPCDPPPHNQGHCCHGHGPPPGHLRRRGPGKGPRPF
HCRQIGSVYRLPPLRKGEVLPLPEANFPSFPLPHHKHPLKPDNQPFPQSVSESC
PGKFKSGFPQVSMFFTHTFPK
LTPTDCKTTKPLAEKALDLINKWRRDGYLFQLLRVADAHLDGAESATVYYLVLD
VKETDCSVLSRKHWEDCDPDLTKRPSLDVIGQCKVIATRYSDEYQTLRLNDFNC
TTSSVSSALANTKDSPVLFDFIEDTEPFRKSADKALEVYKSESEAYASFRVDRV
ERVTRVKGGERTNYYVDFSVRNCSRSHFHRHPNAFGFCRADLSFDVEASNLENP
EDVIISCEVFNFEEHGNISGFRPHLGKTPLGTDGSRDHHHPHKPHKFGCPPPQE
GEDFSEGPPSQGGTPPLSPPSGPRCRHRPFGTNETHRFPHHRNFSEHHPHGPPP
HGHHPHGPPPHGHHPHGPPPHGHPPHGPPPHGHPPHGPPPHGHPPHGPPPHGHP
PHGPPPHGHPPHGPPPHGHPPHGPPPHGHPPHGHGFHDHGPCDPPSHKEGPQDL
HQHGHGPPPKHPGKRGPGKGHFPFHWRRIGSVYQLPPLQKGEVLPLPEANFPSF
SLRNHTHPLKPEIQPFPQVASERCPEEFNGEFAQLSKFFPSTFPK
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glutathione related conclusions that can be drawn from structural data are also 
applicable to plasma HRG. The predicted mass of rabbit HRG based on sequence is 58 
015.9 kDa, which is significantly lower than the mass of 72 179.9 kDa observed in ESI-
mass spectrometry. This discrepancy is explained by the heavy glycosyation of the 
HRG molecule, account for the 14 kDa difference in mass.  
 
Figure 3.5. Free thiol measurements of rabbit plasma, serum and HRG samples and mass spectrometric 
analysis of HRG purified from either rabbit serum or plasma. (A) The free thiol concentrations in rabbit 
plasma and serum were found to be different and were calculated to be 250 µM and 208 µM, 
respectively. (B) The free thiol contents of HRG preparations from both rabbit plasma and serum were 
very similar at ~0.7 mol/mol, with this likely to correspond to the reduced form of Cys407. Error bars 
indicate standard deviation. Statistical analyses were performed using a T-test (** indicates p<0.01; n=3). 
(C) ESI mass spectra of rabbit HRG purified from plasma and serum showing the samples to be almost 
identical in composition. One major form of HRG can be observed, which in each sample has essentially 
the same molecular mass (72 179 Da). A minor form can also be observed (72 835 Da), which likely 
corresponds to alternative glycosylation of the protein. 
Crystallography and Structure of HRG 
Prior to setting up crystallisation trials, the HRG sample was subjected to further 
purification by gel filtration to ensure maximum sample homogeneity. HRG eluted from 
the gel filtration column in line with a 140 kDa standard, which would suggest that it 
exists as a dimer, at least in the buffer solution. The precipitation rate of the pre-
crystallisation tests indicated a HRG concentration of 16 mg/ml as a starting point. 
Crystallisation screens set up at room temperature showed several incidents of salt 
precipitation and a few of protein precipitation, indicating promising conditions. After 4 
weeks, rod-shaped crystals appeared and later cubic crystals formed independently in 
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22.5% PEG MME 5000, 100 mM MES and 73 mM potassium sodium tartrate at pH 
6.5.   
The rod-shaped crystals diffracted best and were prioritised. The rod-shaped crystals 
grew from 21.3% PEG MME 5000, 30 mM potassium sodium tartrate, 100 mM MES at 
pH 6.5, which is from a stochastically designed in house crystal screen. Reproducible 
highly diffracting rod-shaped crystals were yielded from expanded trials of this 
condition after four weeks. Crystals with a cubic morphology were also identified 
(Appendix A1.5-A1.8), but only diffracted to 5.2 Å with an average unit cell (a,b,c) of 
87.8,   87.8 and   87.8 Å with angles () of 90,  90 and 90° (space group: F23). The 
rod-shaped crystals diffracted to 1.93 Å with an average unit cell (a,b,c) of 77.1, 77.1 
and 69.2 Å with angles () of 90,  90 and 120° (space group: P 31 2 1).  
The heavy glycosylation and intrinsic disorder of HRG have limited structural studies to 
date. The first step towards 3D characterisation of HRG at the molecular level is given 
here. In this study, crystallisation was attempted using purified intact HRG, producing 
crystals of the N2 domain which required 4 weeks to appear. This suggests that the 
relatively long crystallisation period may be due to the slow degradation process of 
whole HRG to release the N2 domain over this period of time and to allow the domain 
to arrange into a crystal. Flexible linker regions between the distinct domains of HRG 
would be very susceptible to cleavage either in vivo before purification, or even by co-
purified contaminating proteases from serum. Further evidence for a co-purified 
protease causing the cleavage of the HRG molecules was observed during 
crystallisation protocols which included protease inhibitors. These experiments failed to 
yield crystals, despite all other conditions remaining the same.  
It was revealed that these crystals were formed by the HRG N2 domain and thus the 
structure of the N2 domain of rabbit HRG was solved to a resolution of 1.93 Å (Kassaar 
et al., 2014). One complete N2 domain was contained in the structure of 115 amino 
acids from Ser123 to Arg237. Although the asymmetric unit contains a single due to the 
symmetry of the crystal, a dimeric arrangement of the domain exists within the unit cell 
(Figure 3.6). 
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Figure 3.6. Crystal structure of the HRG N2 domain. The structure obtained was in a dimeric 
arrangement of the N2 domain composed of 2 identical chains, A (cyan) and B (magenta). The sequence 
alignment of human and rabbit N2 domains is shown with secondary structure elements emphasised as 
follows: α-helix (cylinder) and the β-sheets (arrows). The N-glycosylated Asn184 residue is shown in 
blue and the conserved cysteine residues within the N2 domain are shown in red (Kassaar et al., 2014). 
Figure was drawn using PyMol by Prof. Jim Naismith. 
Since the rabbit and human HRG proteins share 64% sequence identity and 69% 
sequence similarity and the respective domain sequences of human and rabbit HRG N2 
are highly homologous (68% identity, 93% similarity), it can therefore be stated with 
confidence that these share the same folding pattern. The N2 domain sequence is also 
homologous with the cystatin family and HRG itself is classified as a type 3 cystatin. 
Conformation of this is provided by the structure showing the N2 domain possessing a 
cystatin-like fold consisting of a five-turn α-helix (Figure 3.7A) with a five-stranded 
anti-parallel β-sheet wrapped around it. The fold starts from a short β1 (Leu126 – 
Phe129) and follows through to an α-helix (Glu134 – Glu150) of five-turns with β2 
(Phe157 – Lys169), β3 (Thr174 – Asn184), β4 (Ala195 – Phe205) and β5 (Glu216 – 
Asn226) wrapping and twisting around the central α-helix. Interestingly, the electron 
Human  123-SPVLIDFFEDTERYRKQANKALEKYKEENDDFASFRVDRIERVARVRGGEGTGYFVDFSV-182
Rabbit 123-SPVLFDFIEDTEPFRKSADKALEVYKSESEAYASFRVDRVERVTRVKGGERTNYYVDFSV-182
****:**:**** :**.*:**** **.*.: :*******:***:**:*** *.*:*****
Human  183-RNCPRHHFPRHPNVFGFCRADLFYDVEALDLESPKNLVINCEVFDPQEHENINGV-234
Rabbit 183-RNCSRSHFHRHP-AFGFCRADLSFDVEASNLENPEDVIISCEVFNFEEHGNISGF-233
***.* ** *** .******** :**** :**.*::::*.****: :** **.*.
β1 β2 β3
β4 β5
α1
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density maps show the surprising presence of an S-glutathionyl adduct at Cys185 and 
also one site of glycosylation on the heavily glycosylated HRG at the conserved Asn184 
residue. Two N-acetyl glucosamine molecules (NAG1 and NAG2) and one α-D-
mannose molecule (MAN3) can be modelled at each N-linked glycan chain.  
 
 
Figure 3.7. The HRG N2 domain shown in closer detail, emphasising its cystatin-like fold. (A) Chain A 
(from Figure 2.5) is shown illustrating the 5 β-strands (β1- β5) twisting around the α-helix (α1). The 
internal disulfide bridge can be observed connecting β4 and β5 (yellow cylinders). The glycosylation at 
Asn184 and the S-glutathionyl adduct at Cys185 are also shown as labelled. (B) Fo-Fc electron density 
map showing the S-glutathionyl adduct (GSH1) bound to Cys185 as a mixed disulfide. (C) Fo-Fc electron 
density map for the first 3 sugars, NAG1, NAG2, and MAN3, of the carbohydrate chain linked to 
Asn184. The Fo-Fc maps (blue chicken wire contoured at 1s, carve radius 1.6 Å) were calculated from a 
model which has never contained NAG, MAN, or glutathione (GSH) (Kassaar et al., 2014). Figure was 
drawn using PyMol by Prof. Jim Naismith. (D) Chemical structure of glutathione.  
Both N1 and N2, the N-domains of HRG, based on their sequence homology to cystatin 
proteins are predicted to possess a cystatin-like fold (Lee et al., 2009). The N2 domain 
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crystal structure confirms that the N2 domain of rabbit HRG does indeed have a fold 
composed of an anti-parallel five-stranded β-sheet twisting around a five-turn α-helix 
that is characteristic of cystatin-like structures. Although the structure obtained here was 
that derived from rabbit HRG, the findings are also valid to the human protein due to 
the high degree of homology between human and rabbit HRG sequences (Figure 3.2). In 
addition to this structure being the first of HRG, it is also the first of a type 3 cystatin 
protein, even though several structures of other cystatin proteins have been solved. As 
mentioned previously, despite being part of the cystatin family, HRG does not exhibit 
any protease inhibitory activity (Lee et al., 2009). The crystal structures of pig cystatin 
A (Jenko et al., 2003), chicken egg white cystatin (Bode et al., 1988) and human 
cystatin B complexed with the protease papain (Stubbs et al., 1990) reveal the cystatin 
N-terminus and two loops called L1 (between β2 and β3) and L2 (between β3 and β4) to 
be important for their protease inhibitory activity. This wedge shaped segment docks 
into the active site opening of cysteine proteases.
 
By looking at the structure of HRG, in 
the N2 domain the corresponding L2 loop is extended by six amino acids, which would 
preclude binding to papain-like proteases. This would provide an explanation for the 
lack of inhibitory activity of HRG. 
The two N-terminal domains of HRG also share sequence homology with the 
antithrombin III heparin binding region (Jones et al., 2004; Koide et al., 1986). The α-
helix of the cystatin-like fold in the HRG N2 domain could mimic the antithrombin 
heparin binding site which is composed of positively charged helical regions. A heparin 
molecule has been observed binding by hydrogen bonds using its carboxylates and 
sulfates to the D-helix (residues Arg129 and Lys125), to the A-helix (residues Arg46 
and Arg47), to the P-helix (residues Lys114 and Glu113) and to Lys11 and Arg13 at the 
antithrombin III N-terminal (Jin et al., 1997).
 
Helical regions are also found in other 
proteins that bind to heparin, for example the protease nexin-1. The structure of nexin-1 
shows two monomers that bind heparin in between two helical segments with each 
monomer providing one helix (corresponding to helix D in each), and binding to 
heparin through lysine residues (Li and Huntington, 2012).
 
HRG could potentially 
reflect this binding mechanism, where a heparin-binding site could form between the 
helix of the two cystatin-like domains, N1 and N2, which also contain lysine residues.  
The HRG N2 structure provides evidence that the N2 domains of HRG are likely to 
contribute to the formation of HRG dimers in vivo. Although it must be acknowledged 
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that the protein concentration necessary for crystallisation was much greater than 
plasma levels. This could force domains to crystallise in unnatural conformations. It is 
also possible that other domains in solution could disturb the arrangement of the N2 
domains observed in the crystal. However, if the N2 domain does in fact contribute to 
HRG dimerization, it would be a significant advance in our understanding of the protein 
molecule. The PISA server (www.ebi.ac.uk) was used to assess the biological relevance 
of the dimer arrangement which predicts, by analysing the inter-chain interactions, if 
these are likely to be stable in solution. The arrangement was identified as stable by the 
analysis (maximum probability, significance = 1) and this arrangement buries 1,659 Å
2
. 
This suggests that the observed relative conformation of the N2 domains in the crystal 
structure is highly likely to be representative of their structure in the solution phase. 
Additionally, the purification protocol provided evidence for HRG existing as a dimer 
in solution since it eluted at 140 kDa from the gel filtration column. This dimerisation 
of HRG might be a necessary requirement for the protein to form binding sites for some 
of its ligands. In this arrangement the cysteine-glutathionyl adducts are on the same face 
of the dimer which could allow interdomain disulfides to cross over between molecules. 
However, other domain combinations forming a heparin site (or sites) are possible, 
especially as the protein exists as a dimer under native conditions. 
Glycosylation of HRG 
HRG is heavily glycosylated with around 13 kDa of its monomeric 72 kDa total mass 
corresponding to glycan chains and the structure given here confirms Asn184 as one of 
the N-linked glycosylation sites (Figure 3.7A and C). Although the structure only shows 
the beginning of the chain with three sugars, crystals subjected to deglycosylation with 
a mixture of deglycosylation enzymes (PNGase F, O-glycosidase, neuraminidase, β1-4 
galactosidase and β-N-acetylglucosaminidase) were analysed by SDS-PAGE, 
confirming that the electron density maps only show a small extent of the complete 
glycosylation state of the N2 (Figure 3.8A). Asn232 is annotated in the UniProt 
database (UniProt code: Q28640) as another potential glycosylation within this domain. 
However, there was no detectable glycosylation observed at this site in the structure.  
In anticipation of difficulty with crystallography due to the inherent characteristics of 
HRG, prior to obtaining HRG crystals, experiments to investigate deglycosylation of the 
protein were conducted using a mix of N- and O-glycosidases. Heavily glycosylated 
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proteins are notoriously difficult to crystallise due to the heterogeneity and flexibility of 
the glycan chains. The deglycosylation of rabbit HRG with the enzyme mix over four 
hours is shown in Figure 3.8B.  
 
Figure 3.8. SDS-PAGE analysis of (A) N2 domain crystals and (B) HRG having undergone 
deglycosylation. (A1) N2 domain crystals without deglycosylation, highlighted with an arrow. (A2) N2 
domain crystals after deglycosylation, highlighted with an arrow. (A3) The enzyme mix used to achieve 
deglycosylation. (B1) The untreated control HRG sample. (B2) Deglycosylation of HRG under native 
conditions. (B3) Deglycosylation of HRG under denatured conditions. Molecular weight markers are 
given in kDa. 
 The deglycosylation was conducted under native and denatured conditions. In theory, 
by denaturing the protein, the enzymes would have full access to the glycosylation sites 
thereby removing the full quotient of carbohydrate. This would cause degradation of the 
protein and loss of structure and function for subsequent experiments. Native conditions 
are gentler to the protein but could obstruct access to glycosylation sites. To determine a 
more accurate mass, samples were submitted for mass spectrometry analysis (Figure 
3.9).  
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Figure 3.9. ESI mass spectrum of (a) native, untreated rabbit HRG with (b) its calculated mass and (c) 
deglycosylated rabbit HRG with (d) its calculated mass. Insets show data processed to 0.1 Da for the main 
peaks. This was a reaction of 1 mg of HRG with 2 μl of enzyme mix for 4 hours.          
Comparison of the native HRG mass spectrum with the deglycosylated HRG mass 
spectrum (Figure 3.9 a and c) reveals that the native HRG protein had a lower charge 
state distribution. The deglycosylated sample was protonated to a greater extent. This 
could potentially be explained by the presence of the carbohydrate chains in the 
glycosylated sample providing a structural barrier towards protonation. It could also be 
due to their influence on the conformation of HRG. It would be interesting to compare 
the structural dynamics of native and deglycosylated HRG to investigate whether the 
carbohydrate chains are able to induce allosteric modulation of the tertiary structure of 
the protein. The calculated mass of native rabbit HRG (Figure 3.9b) was 72.18 kDa 
which compares with the observed mass on SDS-PAGE (ca. 75 kDa). The 
deglycosylated mass was 61.71 kDa, meaning that 10.47 kDa worth of carbohydrate had 
been removed. The peptide sequence mass of rabbit HRG is 58.5 kDa which means that 
3.21 kDa of carbohydrate remained attached. It also appears that the deglycosylation 
process infracts the homogeneity of the native sample. Figure 3.9b shows one clear 
central peak of a tentative purity of 70-80%, and also shows two smaller peaks which 
might be due to different glycosylation states of the native protein.  The deglycosylated 
sample (Figure 3.9d) shows a distinct decrease in homogeneity, most likely indicative 
of varying extents of deglycosylation. The nature of mass spectrometry does not lend 
(a) (b)
(c) (d)
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itself to quantitative analysis, but a comparison of peak intensity can allow for a relative 
estimation to be made.  
Attempts were made to completely deglycosylate rabbit HRG, 100 μg of HRG was 
incubated with 5 μl of the enzyme mix at 37 °C for 14 hours. Figure 3.10 shows the 
mass spectra for this reaction.  
 
Figure 3.10. ESI mass spectrum of (a) deglycosylated rabbit HRG and (b) its calculated mass. The inset 
shows data processed to 0.1 Da for the main peaks. This was a reaction of 100 μg of HRG with 5 μl of 
enzyme mix for 14 hours.          
By using less HRG and a higher enzyme concentration, a more optimal deglycosylation 
procedure was achieved and resulted in a mass of 61.16 kDa. As before, three discrete 
peaks were observed centred on a mass that was 550 Da less than the previous 
experiment. The homogeneity of this deglycosylation was slightly greater relative to the 
previous experiment, but the considerable increase in ratio of enzymes to HRG did not 
yield a parallel increase in the extent of deglycosylation. These experiments showed 
that, although complete deglycosylation of HRG is not possible using these simple 
procedures, a substantial portion of the glycan chains can be removed by the 
deglycosylation enzymes and provides an important future avenue to explore for the 
possible crystallization and structure resolution of full-length HRG. Table 3.1 
summarises the mass spectrometry data. 
Table 3.1. Summary of mass spectrometry, comparing the predicted mass of rHRG with native and 
deglycosylated rHRG samples.  
 
(a) (b)
Sample Predicted HRG Native HRG Deglycosylated HRG
Mass (kDa) 58 015.9 72 180.0 61 710.0 - 61 160.0
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S-glutathionyl adduct at Cys185 of HRG 
Significantly at Cys185, a S-glutathionyl adduct is observed, providing direct in vivo 
evidence of a redox-regulated mechanism for the release of the anti-angiogenic 
HRR/PRR region (Figure 3.7B). This suggests that the Cys185-Cys407 disulfide bridge 
is reduced by glutathione (GSH) in plasma at its Cys185 end leading to the mixed 
disulfide observed. This reaction would free the HRR domain from the N2 domain, 
which are otherwise connected by the conserved cysteine residues which form the 
interdomain disulfide bridge. 
In an effort to identify the HRR/PRR fragment, purified rabbit HRG was left untreated, 
reduced with DTT or reduced and exposed to the enzyme plasmin. The samples were 
then assessed by SDS-PAGE (Figure 3.11A). The resulting pattern on the gel shows 
interesting features when comparing the appearance of the protein across the range of 
experimental conditions. The native protein appears essentially as a single band under 
non-reducing conditions, as would be expected from a sample not exposed to exogenous 
plasmin. Although a fraction of the protein is subject to cleavage by plasmin in 
circulation, the disulfide bridges hold the protein together (particularly the Cys185-
Cys407 bond). When the HRG sample is reduced by DTT, the bulk of the protein 
sample appears unchanged, but a band of ~25 kDa can be seen to be released. To 
identify this band, it was excised from the gel, and reduced, alkylated and digested with 
thermolysin. The digested peptides were analysed by MALDI MS and MS/MS (Figure 
3.11B). Peptide fragments were identified, confirming the identity of the band as the 
HRR/PRR fragment. A peptide containing Cys407 was amongst the identified 
fragments. Cys407 forms a disulfide bridge with Cys185 in the N2 domain of the non-
reduced protein. The HRR/PRR release following treatment of purified HRG with DTT 
can be explained by in vivo plasmin activity occurring prior to purification. When HRG 
was treated with both plasmin and reducing agent, the protein was cleaved into several 
constituent parts as indicated by the band pattern on the gel, which included an intense 
band corresponding to the HRR/PRR fragment.  
GSH is known to be implicated in angiogenesis through post-translational modification 
of proteins. For example, tyrosine phosphatase provides a negative regulation of 
angiogenesis upon its S-glutathionylation via inhibition of vascular endothelial growth 
factor (VEGF)-regulated focal adhesion kinase activation (Abdelsaid and El-Remessy, 
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2012).
 
GSH is involved in regulating the induction of hypoxia inducible factor 1 (HIF-
1), which controls the expression of angiogenic genes, including VEGF (Forsythe et al., 
1996).
 
In squamous cell carcinoma cells, GSH has been found to reduce HIF-1 binding 
and HIF-1-dependent promoter activity in a dose-dependent manner.
 
Also, it has been 
shown that by quenching reactive oxygen species, GSH can prohibit ischemia-induced 
lung angiogenesis (Tajima et al., 2009).
  
 
Figure 3.11. HRR/PRR fragment release in rabbit HRG. (A) SDS-PAGE investigation of rabbit HRG 
under conditions with or without plasmin and the reducing agent dithiothreitol, as assigned by positive 
and negative symbols. The box highlights the HRR/PRR band and is only observed under reducing 
conditions. (B) MS/MS analysis of the excised HRR/PRR gel band. Peptide sequences giving a 
confidence of 99% are in red, and those with a 74% confidence in italics. NCBI accession 
number:XP_002716393 (Kassaar et al., 2014). 
For the GSH-mediated activation of HRG to affect angiogenesis by releasing the anti-
angiogenic HRR/PRR fragment, plasmin facilitated cleavage of the HRG backbone is 
also required. The fact that appropriate quantities of GSH reduced HRG were present in 
the protein sample to allow N2 domain crystals to form, may suggest that reduction 
occurs first and not proteolysis, however this offers not an absolute answer but only a 
clue. Further evidence that a fraction of the protein is first cleaved by plasmin in plasma 
was the detection of the HRR/PRR fragment in HRG samples in the presence of a 
reducing agent during SDS-PAGE analysis (i.e. the HRG had already been subjected to 
plasmin proteolysis in vivo, but required the reduction of the Cys185-Cys409 bond to 
accomplish the release of the HRR/PRR; Figure 3.12). Addition of plasmin to the 
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DAHLDGAESATVYYLVLDVKETDCSVLSRKHWEDCD
PDLTKRPSLDVIGQCKVIATRYSDEYQTLRLNDFNC
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PPSGPRCRHRPFGTNETHRFPHHRNFSEHHPHGPPP
HGHHPHGPPPHGHHPHGPPPHGHPPHGPPPHGHPPH
GPPPHGHPPHGPPPHGHPPHGPPPHGHPPHGPPPHG
HPPHGPPPHGHPPHGHGFHDHGPCDPPSHKEGPQDL
HQHGHGPPPKHPGKRGPGKGHFPFHWRRIGSVYQLP
PLQKGEVLPLPEANFPSFSLRNHTHPLKPEIQPFPQ
VASERCPEEFNGEFAQLSKFFPSTFPK
A B
80
50
40
25
marker (kDa)
reduced
plasmin-treated
+
+
- +
--
71 
 
sample increased the quantity of the HRR/PRR fragment by further degrading the 
protein.   
 
Figure 3.12. Schematic diagram representing the mechanism of release of the HRR/PRR fragment 
following both plasmin cleavage and reduction of the Cys185-Cys407 bond of HRG by GSH. The second 
interdomain disulfide bond between Cys6-Cys497 stays intact, holding the remainder of the protein 
together (Kassaar et al., 2014). 
HRG shares a close relationship with plasminogen (the precursor to plasmin) in the 
circulation, and it has been established that HRG can assist activation of plasminogen to 
plasmin by forming a complex between glycosoaminoglycans (GAGs) and plasminogen 
at cell surfaces (Jones et al., 2004b). Cleavage of HRG by plasmin has been revealed to 
decrease its capacity to bind heparan sulfate on cell surfaces (Poon et al., 2009). One 
idea suggests that a negative feedback loop exists, where plasmin-mediated cleavage of 
HRG could limit additional activation of plasminogen by decreasing the quantity of 
intact HRG that can proficiently bind plasminogen to cell associated GAGs (Poon et al., 
2009).
 
Release of the HRR/PRR fragment from HRG could consequently act to disrupt 
the angiogenic affects attributed to activated plasminogen through the anti-angiogenic 
action of the HRR (Oh et al., 2003).
 
Plasminogen promotes vascular remodelling in a 
genetic study in knock-out mice, via mechanisms that are both dependent and 
independent on fibrinogen (Drew et al., 2000).
 
Reducing levels of intact HRG could 
conceivably hinder its ability to promote angiogenesis through its binding of 
thrombospondin, since there would be less whole HRG available for this interaction. 
Hence, it is possible that the plasmin regulated degradation of HRG along with the 
release of the HRR/PRR region would simultaneously regulate angiogenesis negatively 
through the actions of independent mechanisms. 
To conclude this chapter on the structural studies of HRG, the crystal structure solved 
here provides the first insight to the molecular arrangement of HRG. The N2 domain is 
folded in a cystatin-like manner and is N-glycosylated at Asn184. In addition, the S-
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glutathionyl adduct observed at Cys185 gives potential in vivo evidence that the anti-
angiogenic HRR/PRR fragment release is controlled in part by a redox mechanism, 
representing a new role for GSH in regulation of angiogenesis. 
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Chapter 4 
Investigations into Zn
2+
 and heparin binding to HRG and 
implications for thrombin activation. 
This chapter aims to investigate the mechanisms by which histidine-rich glycoprotein 
(HRG) is activated by zinc and its subsequent processes in the blood, such as 
coagulation. HRG is a 65 kDa single chain plasma protein, synthesized in the liver and 
present in the circulation of mammals and birds (Hulett and Parish, 2000; Jones et al., 
2005). The protein is moderately abundant in the blood, circulating at a concentration of 
1.5–2.0 μM (Corrigan et al., 1990). HRG interacts with numerous molecules and is 
involved in the formation of multi-protein complexes that regulate coagulation, immune 
complex clearance, cell proliferation, cell adhesion and angiogenesis (Jones et al., 
2005). It has also been suggested that HRG can bind to receptors on the surface of a 
variety of cell types, including immune cells (Saigo et al., 1989). In clinical practice, 
high HRG levels are associated with thrombotic disorders such as thrombophilia and 
blood vessel occlusion (Engesser et al., 1987; Castaman et al., 1993; Kuhli et al., 2003). 
A part for HRG in blood clotting may include cell-cell interactions involving 
macrophages and platelets (Leung, 1986). Structurally, HRG contains two cystatin-like 
N-terminal domains (Kassaar et al., 2014), a histidine-rich region (HRR), two proline-
rich regions (PRR1 and PRR2) and a C-terminal domain (Koide et al., 1986).  
Uniquely, the HRR comprises of  sequential pentapeptide repeat sequences of Gly-His-
His-Pro-His and has the ability to bind to ten Zn
2+
 ions (Kd = 1–4 μM) through 
coordination to the imidazole nitrogen atoms of the many histidine residues (Morgan, 
1978). This coordination of zinc ions is integral to the working of HRG by regulating its 
affinity for the various ligands it binds to, such as directly increasing its affinity for 
heparin (Borza and Morgan, 1998; Mori et al., 2003; Jones et al., 2004a), IgG (Gorgani 
et al., 1999) and tropomyosin (Guan et al., 2004), while inhibiting the interaction 
between HRG and the complement protein C1q (Gorgani et al., 1997). Additionally, 
HRG is able to interact independently of Zn
2+
-binding with other functional partners. 
These include thrombospondin (Walz et al., 1987) and plasminogen (Jones et al., 
2004b), through interactions with the N- and C-terminal domains of HRG. Importantly, 
this Zn
2+
-binding increases the affinity of HRG towards the natural anticoagulants 
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heparin and heparan sulfate, which in turn neutralises these anticoagulants’ inhibition of 
antithrombin III activity (Mori et al., 2003; Jones et al., 2004a). Thus Zn
2+
-binding to 
HRG provides a potential means of regulating haemostatic function. Despite this, the 
Zn
2+
-binding properties of HRG and how exactly Zn
2+
 influences HRG-heparin 
interactions remain to be fully understood.  
Exchangeable zinc in plasma is regulated by albumin and can be affected by fatty 
acids 
Normally, the majority of the 20 μM Zn2+ in the blood is bound to human serum 
albumin (HSA) (Sarkar, 1989) and not HRG (Guthans and Morgan, 1982). HSA is a 
66 kDa plasma protein which is composed of three homologous domains (domains I–
III) (Sugio et al., 1999). HSA binds Zn
2+
 with greater affinity than HRG and is much 
more abundant in circulation (Masuoka et al 1993). Despite this, it is possible that 
certain conditions exist where the free Zn
2+
 plasma concentration can reach levels 
required for HRG-complexes that are Zn
2+
-dependent to form, for example, the release 
of Zn
2+
 from platelet-derived α-granules (Gorgani et al., 1999; Jones et al., 2004a), 
especially since HRG is also released by platelets. However,  this would only raise the 
local Zn
2+
 concentration (e.g. at the surface of platelets), and may not be significant to 
cause a systemic shift where the levels of Zn
2+
 released would be adequate to activate 
HRG in the presence of HSA. 
One of the main roles of HSA in circulation is to handle Zn
2+
 and other metals ions in 
order to protect blood cells and the endothelial cells from conditions that would 
otherwise be toxic. Hence, HSA acts as a chelating agent, tightly regulating the levels of 
free metal ions to sustain a viable level. Studies on rat WRL-68 cells have shown this 
protective property in vitro, where HSA reduced the toxicity of Zn
2+
 (Blindauer et al., 
2009). Additionally, an increase in HSA binding to Zn
2+
 is a cause of familial 
hyperzincemia (Failla et al., 1982). HSA is also involved in the transport of Zn
2+
 to cells 
and tissues. HSA is involved in Zn
2+
 uptake by endothelial cells (Rowe and Bobilya, 
2000) and erythrocytes (Gálvez et al., 2001) and has been observed to transport freshly 
absorbed Zn
2+
 in portal blood direct from the intestine to the liver (Smith et al., 1979). 
Recently, the major Zn
2+
 binding site of HSA was discovered using 
111
Cd-NMR in 
combination with site-directed mutagenesis (Stewart et al., 2003; Lu et al., 2008). This 
site (site A) is localised at the interface of domains I and II, and is composed of N-
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donating His67 and His247 residues, O-donating Asn99 and Asp249 residues and a 
water molecule or Cl
-
 as a final coordinating ligand. These residues are highly 
conserved across all mammalian albumin sequences. Previous NMR data supported 
these findings since it was expected that that the major Zn
2+
 site on HSA consisted 
mainly of N- and O-ligands (Goumakos et al., 1991; Sadler and Viles, 1996). 
HSA is the primary fatty acid transport protein in the circulation and binds fatty acids of 
various chain-lengths at 5 high-affinity sites (termed FA1-5) and several lower affinity 
sites. An investigation into zinc and cadmium binding to sheep serum albumin 
surprisingly appeared to show no detectable metal binding to this protein, despite the 
sheep sequence containing all four of the residues required. Interestingly, it was 
remarked that the sample preparation was purified directly from sheep plasma and had 
not been subjected to a defatting protocol. Hence, it was suggested that the observed 
lack of metal binding in these experiments may have been due to an allosteric effect 
caused by fatty acid binding to the albumin. Subsequent removal of fatty acids from the 
sheep albumin samples resulted in a restored metal binding profile at this site (Sadler 
and Viles, 1996). 
X-ray crystal structure comparisons of free and fatty acid-bound HSA (He and Carter, 
1992; Curry et al., 1998; Sugio et al., 1999; Bhattacharya et al., 2000a; Bhattacharya et 
al., 2000b; Petitpas et al., 2001) showed that the Zn
2+
 site is disrupted by fatty acids, 
which disengage the domain II residues (His247 and Asp249) with respect to the 
domain I residues (His67 and Asn99) as shown in Figure 4.1. This structural change is 
arbitrated by association of the fatty acid molecule to the FA2 binding site which lays in 
between domains I and II of HSA. Normal physiological conditions allow for HSA to 
carry 1-2 molecules of fatty acid at other separate fatty acid binding sites. However, 
when fatty acid concentrations increase above base levels, they are able to coordinate 
with this site, thereby reducing the affinity of HSA for Zn
2+
. Significant disruption of 
the Zn
2+
 site (and so Zn
2+ 
binding to HSA) necessitates the binding of 3-5 molecules of 
fatty acid per molecule of HSA. A recent study examining the binding of myristic acid 
(C14) to bovine albumin by isothermal titration calorimetry revealed that even the 
presence of 1 molar equivalent of myristic acid was able to slightly disturb the regular 
ability of albumin to bind Zn
2+
 and 4 to 5 molar equivalents were able to completely 
suppress Zn
2+
 binding at this site (Lu et al., 2008). 
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Figure 4.1. The fatty-acid/Zn
2+
 switch on serum albumin. (a) Overlay of crystal structures of human 
serum albumin with (grey; PDB: 1BK5) and without myristic acid bound (green; PDB: 1AO6) showing 
the location of the major Zn
2+
-binding site. (b) Close-up showing the movement of Zn
2+
-co-ordinating 
residues His247 and Asp249 relative to His67 and Asn99 between the two structures. Figure drawn using 
PyMol by Dr. Claudia Blindauer. 
Fatty acids could switch zinc speciation and activate HRG 
Fatty acids are absorbed into the blood stream through different mechanisms based on 
the carbon chain length. Medium and short chain fatty acids are directly absorbed into 
circulation after dietary intake (Jørgensen et al., 2001) and are transported through the 
circulatory system by HSA, to their intended target site, while long chain fatty acids are 
released into circulation from lipoproteins and adipocytes. Under normal physiological 
conditions the basal plasma concentration of free fatty acid is between 250-500 µM at 
rest (<1 molar equivalent, compared to HSA). However, free fatty acid levels are 
dynamic and rise following meals and during periods of exercise, but the majority 
remain bound to HSA, since the albumin molecule has a large number of fatty acid 
binding sites; HSA is able to bind up to 10 fatty acid molecules in vitro (Bhattacharya et 
al., 2000a). The most abundant serum fatty acids associated with HSA are palmitic acid 
(C16), stearic acid (C18) and oleic acid (C18) (Jørgensen et al., 2001). Chronically 
raised free fatty acid levels are associated with various conditions such as obesity 
(Björntorp et al., 1969; Koutsari and Jensen, 2006), diabetes (Reaven et al., 1988), fatty 
liver disease (Donnelly et al., 2005), cancer (Charles et al., 2001) and are observed as a 
symptom of plasma HSA deficiency (analbuminemia) (Bartter et al., 1961). In obese 
(a) (b)
N99
H67
H247
D249
Myr2
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individuals, plasma concentrations of free fatty acids at rest are often 2-3 times higher 
(Koutsari and Jensen, 2006), and in some cancer patients are 4-6 times higher than 
controls (Kleinfeld and Okada, 2005). These conditions are also associated with an 
increased risk of thrombotic complications (Connolly and Khorana, 2009; Previtali et 
al., 2011). For example, thromboembolism (caused by obstructive blood clots) is the 
second leading cause of death associated with malignancy (Connolly and Khorana, 
2009). 
From current understanding of the Zn
2+
 binding properties of HSA and HRG, it is clear 
that either continuous or temporary enhanced plasma fatty acid concentrations could 
prospectively increase the fraction of plasma Zn
2+ 
associated with HRG. The reduced 
Zn
2+ 
binding competition from HSA could allow an adequate proportion of Zn
2+
 to 
switch from its usual speciation (being bound to HSA) to being coordinated to HRG. 
This could then lead to activation of HRG with respect to some of its binding partners, 
triggering its actions (such as coagulation). It is likely that HRG and fat-loaded HSA 
would have comparable affinities for Zn
2+
, so under these conditions, HRG could bind 
as much as 5% of plasma Zn
2+
. This is just speculation, and the percentage would 
perhaps be even higher (at the surface of platelets following granule release, for 
example) but would also be contingent on the concentrations of Zn
2+
-binding proteins 
and molecules (such as histidine). These observations led us to hypothesize that under 
conditions where free fatty acid levels are elevated, Zn
2+
 displaced from HSA could 
bind to HRG, enhancing its interaction with heparin/heparan sulfate and induce a pro-
coagulatory effect (Stewart et al., 2009). If so, this would constitute a novel targetable 
mechanism by which thrombotic complications arise in high-risk individuals. 
High HRG levels have clinically been associated with thrombotic disorders including 
blood vessel occlusion (Kuhli et al., 2003), and thrombophilia (Engesser et al., 1987).
 
This is significant when taking the possible switch of Zn
2+ 
speciation into consideration. 
If fatty acid binding to HSA can increase the Zn
2+
 concentration associated with HRG, 
this increase in Zn
2+
 activated HRG could consequently cause thrombotic disorders, or 
at least enhance the possibility of thrombosis occurring. The key mechanism under 
investigation here is the regulation of the coagulation protease, thrombin, which forms 
an inactive ternary complex with its binding partners: antithrombin and heparin.   
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The coagulation cascade and thrombin  
The coagulation mechanism which acts to help prevent infection and the loss of blood 
in mammals and other higher organisms following injury is often described by two 
pathways, known as the contact activation (intrinsic) pathway and tissue factor 
(extrinsic) pathway. These mechanisms converge at the final common pathway (Figure 
4.2).  
 
Figure 4.2. Schematic diagram of the coagulation cascade showing the contact activation, tissue factor 
and common pathways. Factors are shown as their Roman numerals; TFPI is tissue factor pathway 
inhibitor. The blue arrows show the additional functions of thrombin behind its primary function of 
fibrinogen conversion to fibrin, highlighting the central role it plays in the process. It can be seen how 
thrombin is involved in both pro- and anti-coagulant roles and is involved in self-regulation. The red 
arrows show points of inhibition.  
Before these cascades come in to play, platelets become activated and adhere to the 
injury site. These platelets will then aggregate and form a plug to reduce or stop the loss 
of blood temporarily. Activation of platelets releases several proteins that increase and 
accelerate platelet plug formation, and also begin the tissue repair process. The agent, 
von Willebrand factor, forms a bridge between the subendothelium layer and the 
activated platelets, thus playing an important role in platelet adhesion (Ruggeri and 
Zimmerman, 1987). Similarly, fibrinogen forms a bridge between adjacent activated 
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platelets (Savage and Ruggeri, 1991), leading to aggregation and plug formation. These 
reactions make negatively charged phospholipids available on the surface of the 
damaged cell membranes or activated platelets, thereby setting the scene for the 
coagulation cascade and its terminal insoluble fibrin clot formation which strengthens 
the platelet plug.  
In the intrinsic pathway, fibrin formation is a consequence of a series of stepwise 
reactions involving plasma proteins circulating in an inactive or precursor form. These 
zymogens are activated by proteolysis and converted to serine proteases. Many of these 
calcium dependent reactions occur at activated platelets, which provide the 
phospholipids. The intrinsic pathway has an important role in regulating the growth and 
maintenance of fibrin formation, but the extrinsic pathway is the primary and critical 
mechanism in the formation of a fibrin clot. 
The extrinsic pathway is also known as the tissue factor pathway since it requires tissue 
factor, located in the tissue adventitia, which only comes in contact with blood after 
vascular injury (Maynard et al., 1975, Maynard et al 1977; Wilcox et al., 1989). Tissue 
factor apoprotein is a membrane glycoprotein that is tightly associated with 
phospholipids (Broze et al., 1985; Guha et al., 1986) and has a high affinity for factor 
VII (Broze, 1982; Bach et al., 1986; Sakai et al., 1989). At the point of injury, a 
complex between the two proteins is formed in the presence of calcium which facilitates 
the conversion of factor VII to the active factor VIIa by proteolysis (Rao and Rapaport, 
1988; Sakai et al., 1989) by trace levels of a plasma protease in circulation (such as 
thrombin) (Masys et al., 1982; Wildgoose and Kisiel, 1989; Pedersen et al., 1989). The 
tissue factor-factor VIIa complex then activates factor X to factor Xa. This generated 
factor Xa forms a complex with factor Va in the presence of calcium and phospholipids 
(Tracy et al., 1981). This complex converts prothrombin to thrombin, which is the final 
and most critical protease generated in the coagulation cascade since it is the only factor 
capable of cleaving ﬁbrinogen to create a ﬁbrin clot. Fibrin is formed by the proteolysis 
of a peptide bond in each of the fibrinogen chains. This releases four fibrino-peptide 
monomers, which then polymerise to form the insoluble fibrin clot (Laudano and 
Doolittle, 1980). 
Thrombin is the integral enzyme in blood coagulation because of its exclusive ability to 
cleave ﬁbrinogen to ﬁbrin; it contributes to the “thrombin burst” feedback mechanisms 
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and stabilises clots. Any deviation from regular functioning can cause grave effects. 
Without adequate thrombin generation, haemorrhage can occur since stable blood clots 
cannot form. Equally, unregulated thrombin activity can lead to thrombosis in instances 
where clots disseminate away from the site of tissue damage. 
Thrombin is a serine protease and is a member of the chymotrypsin family. It has a 
structure and catalytic function like the prototypic protease chymotrypsin, and works in 
a similar manner to trypsin. The multiple functions of thrombin are balanced by its 
specificity for the particular substrate. Since thrombin has lost the Gla and kringle 
domains of its zymogen prothrombin, all substrate recognition occurs at the catalytic 
domain. Thrombin is composed of two polypeptide chains (A and B) which are linked 
covalently by a disulfide bridge. The A chain is only 36 amino acid residues long and 
has no documented functional roles. The B chain is 259 amino acid residues, and 
composes the entrance to the active site (Bode et al., 1992). The active site cleft is a 
canyon at the centre of the protein. Because of the homology between thrombin and 
trypsin, thrombin also cleaves preferentially at Arg residues of the substrate, but 
selectively at specific Arg sites using auxiliary interactions from two exosites at distinct 
locations from the active site.  
Exosite I contains hydrophobic regions and several charged residues on its surface, 
providing electrostatic navigation and positioning to fibrinogen during its approach to 
the thrombin active site. This epitope extends from exosite I to the active site (Mosesson 
et al., 2001). Similar epitopes are employed by thrombin to interact with the natural 
inhibitor hirudin (Rydel et al., 1991), fibrin (Ayala et al., 2001) and thrombomodulin 
(Pineda et al. 2002). Exosite II is positioned opposite to exosite I and features numerous 
charged residues, but no hydrophobic regions. The charged residues enable interactions 
with anionic heparin and other glycosaminoglycans (GAGs) (Sheehan and Sadler, 
1994). GAGs are highly sulfated polysaccharide molecules of various chain lengths that 
festoon the proteoglycans in vascular and extravascular spaces. Heparin is a highly 
sulfated GAG produced by mast cells and is a potent anticoagulant used in clinical 
practice. The thrombin binding site for heparin is localised at exosite II (Sheehan and 
Sadler, 1994; Gan et al., 1994; Ye et al., 1994; Tsiang et al., 1997), and a high-
resolution crystal structure shows thrombin binding a heparin octa-saccharide (Carter et 
al., 2005) via a non-specific electrostatic interaction (Olson et al., 1991). GAGs are 
used by thrombin to regulate its interactions with other proteins, including antithrombin, 
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which is the basis for heparin’s role as an anticoagulant. Antithrombin is a serpin which 
forms a ternary complex with heparin and thrombin, irreversibly inhibiting thrombin 
activity (Olson and Chuang, 2002). Antithrombin is one of only two specific thrombin 
inhibitors in circulation (with heparin cofactor II being the other, which also requires the 
presence of GAGs), and its important inhibition effects are demonstrated in cases of 
antithrombin deficiency where patients have an increased incidence of thrombosis (van 
Boven and Lane, 1997), and in knockout mouse models where embryonic mortality was 
observed (Ishiguro et al., 2000). Antithrombin recognises a unique pentasaccharide 
sequence of heparin (which has a random distribution along the polysaccharide chains) 
with high affinity that causes a global conformational change through a hinge motion. 
This conformational change has been shown to be important in the action of 
antithrombin on factor Xa, but is not the mechanism behind its thrombin inactivation. 
For this, the heparin chain provides a template on which inhibitor and protease interact, 
where the high-affinity sites of the heparin chain are occupied by antithrombin while 
thrombin translates along the chain until encountering the inhibitor (Li et al., 2004). 
Both unfractionated heparin, which is a mixture of polysaccharide chains ranging from 
3 to 30 kDa, and for low molecular weight heparins (less than 8 kDa) can bind to 
antithrombin. However, for heparin to catalyse antithrombin inhibition of thrombin, a 
specific ternary complex between the three parties needs to form which requires the 
pentasaccharide containing heparin chains to be at least 18 saccharide units long. This 
complex inactivates thrombin activity by factor of greater than 1000. Thrombin binds 
heparin through an interaction at its exosite II, stabilising the thrombin-antithrombin 
complex by sharing the same heparin chain (Stone SR and Le Bonniec, 1997). In 
addition to this, a crystal structure of the ternary complex (Li et al., 2004) revealed a 
close direct contact interface between the thrombin and antithrombin molecules.  
Taking all this information together, we hypothesise that HRG activated by Zn
2+
, the 
dynamics of which have been affected by increased fatty acid binding to HSA, could 
allow for HRG to effectively compete for heparin against antithrombin and reduce 
thrombin inhibition leading to enhanced thrombosis (Figure 4.3). Since clinical 
conditions which are associated with high levels of plasma fatty acids also are known to 
show an increased incidence of thrombosis, this novel molecular mechanism could 
provide an explanation for this observation and also potentially improve the efficacy of 
heparin anticoagulation treatments. To help prove this hypothesis, studies on HRG 
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binding to zinc, heparin and both zinc and heparin were conducted using isothermal 
titration calorimetry and enzyme-linked immunosorbent assays. Similar isothermal 
titration calorimetry studies on HSA binding to zinc under a range of fatty acid 
conditions were also performed and an in vitro thrombin activity assay was developed 
to assess the veracity of the proposed mechanism.  
 
Figure 4.3. A schematic representation of the hypothesis proposed in text. Allosteric modulation of 
albumin (HSA) can switch the Zn
2+
 dynamics towards histidine-rich glycoprotein (HRG). This activation 
of HRG makes it more effective in competition for heparin against antithrombin (AT), thereby breaking 
or preventing the inhibitory ternary complex between AT, heparin and thrombin. This process would free 
the thrombin to proceed in coagulation.    
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Methods 
Purification  
Purification was performed as described earlier (see Chapter 3). 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed as described earlier (see Chapter 3). 
Protein Concentration Determination 
Protein concentration was determined as before (see Chapter 3). 
Isothermal titration Calorimetry (ITC) 
ITC experiments were carried out using a VP-ITC instrument (MicroCal) in 50 mM tris, 
140 mM NaCl, pH 7.4, at 25 °C. Titration reagents (zinc, heparin) were added to the 
reaction buffer and the pH adjusted to 7.4 to match the buffer. Solutions were degassed 
at 22 ºC for 15 minutes prior to running the experiment. Typical titrations performed 
were one 2 μl injection over 4 s followed by up to 55 injections of 5 μl over 10 s with an 
adequate interval of 240 s between injections to allow complete equilibration. The 
stirring speed was 307 rpm. Heats of dilution were accounted for with blank titrations 
performed by injecting ligand solution into reaction buffer and subtracting the averaged 
heat of dilution from the main experiment. Alternatively, in cases of saturated binding 
blank titrations were omitted where the averaged residual signal of the last injections 
was used to determine the heat of dilution. Raw data were processed using MicroCal 
Origin software and data fitted using the same software. Protein concentrations were 
determined either by using absorbance at 280 nm or by weighing out lyophilised 
sample. Specific experimental reaction conditions are given in each figure legend.  
ITC experiments with low molecular weight heparin were performed on an iTC200 (GE 
Healthcare Life Sciences, Little Chalfont, UK) and were typically of 19 injections of 2 
µl with 120 s intervals. Stirring speed was 750 rpm. Consecutive data sets were 
combined using ConCat32 software. 
Raw data for the ITC experiments presented here can be found in Appendix 2. 
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Enzyme-linked immunosorbent assay (ELISA) 
An ELISA experimental set-up was devised to investigate the interaction between HRG 
and heparin compounds. Undefined heparin (Acros Organics) or low-molecular weight 
heparin (Iduron, Manchester, UK) were coated overnight at room temperature onto a 
heparin-binding plate (Iduron) at a concentration of 25 μg/ml in 50 mM HEPES, 150 
mM NaCl, 0.2% Tween 20 at pH 7.4 with or without ZnCl2. The wells were washed 
using the same buffer, and then blocked with the same buffer supplemented with 0.2% 
gelatin from fish skin (Sigma-Aldrich) for 1 hour at 37°C. Human HRG was incubated 
for 2 hours over a range of concentrations (0–3 μM) at 37°C. Binding was detected with 
primary rabbit anti-HRG (Sigma-Aldrich) followed by alkaline phosphatase linked anti-
rabbit antibody (Sigma-Aldrich) and observed with a pNPP substrate (Sigma-Aldrich) 
at 405 nm. 
Thrombin assay 
To investigate the proposed mechanism of thrombin activation via Zn
2+
-dependent 
modulation of HRG functioning by plasma fatty acids, an in vitro assay system was 
established containing all constituents of the proposed pathway at physiological 
concentrations. Serum albumin (600 μM, purchased from Sigma-Aldrich) was pre-
loaded with fatty acid by incubating with lauric acid (0, 1.5 or 3 mM) for 1 hour at 37 
°C in 50 mM HEPES, 150 mM NaCl at pH 7.4 and ZnCl2 (20 μM). HRG (1.5 μM), 
heparin (0.5 U/ml), antithrombin (2 μM) and thrombin (0.5 nM) were mixed with the 
albumin sample and allowed to equilibrate for 1 hour at 37 °C. S-2238 (100 μM), the 
thrombin substrate, was then added to the reaction which was detected after 20 minutes 
at 380 nm using a Fluostar Optima. Final concentrations are shown in parenthesis; 
experiments were performed in triplicate. 
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Results and discussion 
Purification of HRG 
HRG samples were purified from human plasma or rabbit serum. Rabbit HRG was used 
in initial experiments since a greater yield of protein was afforded and rabbit serum was 
more readily available. The purification protocol involved one step on a nickel affinity 
matrix and resulted in yields of > 80% and high purity (> 95%) as assessed by SDS-
PAGE (Figure 4.4). Protein identity was confirmed by mass spectrometry.  
 
Figure 4.4. SDS-PAGE analysis of the one step nickel affinity purification of human HRG from plasma, 
stained with coomassie. Molecular weight markers are shown in kDa. HRGcan be seen in lanes 4 to 6. 
The purity of all samples was assessed to be at least greater than 95%, and samples of this quality were 
used in experiments. Rabbit HRG was purified as before (Chapter 3, Figure 2.4). 
The mass spectrometry analysis was shown earlier (Chapter 3, Figure 3.4), as was the 
sequence homology between human and rabbit HRG (Chapter 3, Figure 3.2). Although 
the proteins share a high sequence homology, the greatest variance between their 
respective sequences is observed in the HRR and PRR2 domains. This region of HRG is 
involved in Zn
2+
 and heparin binding, so any difference observed between human and 
rabbit HRG with these interactions could be accounted for by keeping the sequence 
variance in mind.  
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Zinc binding studies with HRG 
The Zn
2+
-binding properties of hHRG (human) and rHRG (rabbit) were studied using 
ITC. Both hHRG and rHRG exhibited almost identical binding profiles, revealing an 
exothermic binding process between HRG and Zn
2+
 (Figure 4.5).  
Figure 4.5. ITC data for Zn
2+
 binding to (a) human HRG and (b) rabbit HRG. 55 injections of 5 μl of 150 
μM ZnCl2 were delivered to HRG (10 μM in buffer containing 50 mM Tris, 140 mM NaCl at pH 7.4) 
over 10 s with an adequate interval (240 s) between injections to allow complete equilibration. Raw data 
can be found in appendix A2.1 and A2.3. 
Previous studies on the metal binding properties of HRG have utilised rHRG since 
rabbit plasma contains almost ten times more of the protein. Thus the hHRG Zn
2+
-
binding characteristics provided here are the first attempts to quantitatively and 
qualitatively interpret this binding. The ITC data determined that hHRG is capable of 
binding 10 molar equivalents (N=10.3) of Zn
2+
, with an average Ka of 8.1  10
4 
(± 4.0  
10
3
) M
-1
 (Figure 4.5a). The rHRG ITC data show that the rabbit protein is also able to 
bind 10 molar equivalents (N=10.4) of Zn
2+
, in keeping with previously reported data 
(Morgan, 1981), but had a lower affinity with an average Ka of 4.4  10
4
 (± 3.3  103) 
M
-1
 (Figure 4.5b). The lower affinity of rHRG for Zn
2+
 when compared with hHRG 
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could potentially help explain why the former is more abundant in rabbit plasma, than 
the latter is in human plasma. In addition to this, although both proteins share a high 
homology, the greatest difference in their sequence comes at the respective HRR and 
PRR2 domains where the rabbit sequence is elongated (Chapter 3, Figure 3.2).  
 
Figure 4.6. ITC data for Zn
2+
 binding to human HRG in physiological ionic strength (PI) and low ionic 
strength (low I) buffers. 55 injections of 5 μl of 150 μM ZnCl2 were delivered to samples of 10 μM HRG 
in buffer containing 50 mM Tris, 140 mM NaCl at pH 7.4 (white squares) or  50 mM Tris, 50 mM NaCl 
at pH 7.4 (Black squares) over 10 s with an adequate interval (240 s) between injections to allow 
complete equilibration. Raw data can be found in appendix A2.2.  
Interestingly, when the ITC experiment was performed under conditions of lower ionic 
strength (the previous experiments were conducted at physiological ionic strength), 
hHRG was shown to bind only 5 molar equivalents of Zn
2+
, with a Ka of 3.6  10
4
 (± 2.4 
 103) M-1 (Figure 4.6). This suggests that salt ions are involved in the binding of Zn2+ 
either as a direct ligand for the Zn
2+ 
ion or by playing a role in forming binding sites 
through salt bridges. Intriguingly, EXAFS studies on HRG led the researchers to 
postulate a Zn
2+
 binding site to be composed of three histidine ligands and one heavier 
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ligand which was proposed to be a cysteine sulfur atom (Mangani et al., 2003).  
However, they admitted that the EXAFS analysis did not allow for the differentiation 
between a sulfur or chloride ion. The data presented here conducted at different ionic 
strengths would support the latter, since at the lower ionic strength (i.e. lower Cl
-
 levels) 
significantly attenuated the ability of hHRG to bind Zn
2+
. If a cysteine sulfur was indeed 
involved in the Zn
2+
 binding, it would have appeared as a distinct region on the ITC 
isotherm. The ITC data shows all 10 sites are identical, but since most cysteine residues 
of HRG are involved in disulphide bridging, it would not be possible for all 10 sites to 
contain a cysteine residue. Although Cl
-
 is a weak Zn
2+
 binding ligand, there is evidence 
that it can form part of a Zn
2+
 binding site (Smith et al., 1996; Hymowitz et al., 1999).       
Heparin binding studies on HRG 
A similar approach using ITC was used to examine the effect of Zn
2+
 on the heparin 
binding properties of hHRG. Unfractionated heparin (molecular weight range 3-30 kDa) 
was injected into samples of hHRG at different concentrations of ZnCl2 (Figure 4.7).  
The presence of ZnCl2 had a marked effect upon the mechanism by which human HRG 
bound heparin. In the absence of Zn
2+
 the interaction between heparin and HRG is 
endothermic. Upon the presence of 1 µM Zn
2+
, an exothermic mode of binding appears 
observable at the start of the isotherm, which becomes more pronounced at 5 µM. This 
suggests that heparin binds HRG via different modes, whereby the exothermic mode 
occurs before the endothermic mode and is enhanced by Zn
2+
 binding to HRG. These 
modes could arise from heparin binding to different regions of the HRG molecule. HRG 
is known to have N-terminal sequence homology with the antithrombin heparin binding 
site which could provide one binding mode, and the HRR (which would become 
positively charged upon binding Zn
2+
, thereby enhancing any effect) could provide 
another region of binding for the negatively charged heparin. It was possible to fit 
curves to the endothermic data collected in the absence and presence of 1 µM ZnCl2, 
but not to the most complex isotherm observed at 5 µM. The resultant curves suggested 
that the endothermic mode most probably corresponds to a single heparin site. The 
calculated Ka for this mode was 3.27  10
6
 (± 2.5  105) M-1 with no ZnCl2 and 3.95  
10
6
 (± 5.2  105) M-1 in the presence of 1 µM ZnCl2. However, the “real” affinities are 
likely to be higher as this analysis does not take into account binding via the exothermic 
mode. 
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Figure 4.7. Effect of Zn
2+
 on heparin binding to human HRG. Here 45 injections of 5 μl of 50 μM 
heparin (average mol. wt. assumed to be 15 kDa) was delivered to samples of HRG (10 μM in buffer 
containing 50 mM Tris, 50 mM NaCl and 0, 1 and 5 µM ZnCl2 at pH 7.4) over 10 s with an adequate 
interval (240 s) between injections. Zn
2+
 was included in the buffer at concentrations of 0, 1 and 5 μM. 
Raw data can be found in appendix A2.4-2.6. 
It was also observed that there is a difference in the stoichiometry of heparin binding to 
HRG in the presence of 1 µM Zn
2+
 (as illustrated by a shift in the curve to the left) 
compared with the data without Zn
2+
 or with 5 µM Zn
2+
. This correlates with a previous 
study which revealed that complexes of 1 heparin:1 HRG and of 1 heparin:2 HRG can 
form with formation of the 1:2 complex enhanced by the presence of Zn
2+ 
(Burch et al., 
1997). Since we used unfractionated heparin in this instance, it was not possible to 
assign an accurate molecular mass to the titrant solution (an average mass of 15 kDa 
was used), and so the x-axis on Figure 4.7 is to a large degree arbitrary. But, if we use 
the molar ratio of 0.4 observed in these experiments to represent the 1:1 complex 
(which is the calculated N value for both the without Zn
2+
 and 5 µM Zn
2+
 data sets), 
then the molar ratio of 0.2 (which is the calculated N value for the 1 µM Zn
2+
 data set) 
can be taken to represent the 1:2 complex. The data here suggests that higher 
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concentrations of Zn
2+
 (5 µM)
 
preclude the formation of the 1:2 complex, which will 
enhance the proportion of heparin bound to HRG. However, this interaction is complex 
and becomes even more convoluted if experiments at higher Zn
2+
 levels are attempted 
(Appendix A2.7). The complexity is a corollary of the molecules involved, since HRG 
is likely able to bind heparin at different regions, and heparin molecules themselves are 
heterogeneous (existing in varying chain lengths) which interact differently with HRG 
depending on length. For example, heparin chains of 10 kDa do not form the 1 
heparin:2 HRG complex (Burch et al., 1997). It should be stated that the heparin ITC 
experiments were conducted at an ionic strength lower than physiological for qualitative 
and aesthetic reasons. Experiments performed at physiological ionic strength showed 
the same pattern and trends observed here (Appendix A2.8).   
Since quantitative information from the ITC data was problematic to obtain due to the 
mix of endothermic and exothermic interactions observed, and ELISA protocols were 
established to calculate the affinities involved in this interaction (Figure 4.8).  
 
Figure 4.8. (a) Schematic representation of the ELISA set up. (b) The substrate para-
Nitrophenylphosphate (pNPP) cleaved by alkaline phosphatase (AP), to produce a yellow coloured 
compound under basic conditions. 
pNPP
HRG HRG
Zn2+
AP AP
Heparin-binding plate
Heparin
Rabbit anti-HRG primary
Anti-rabbit secondary
Alkaline phosphatase
HRG (with or without zinc)
AP Base
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In addition, low molecular weight (LMW) heparin was included in these studies to 
provide further insights into the mechanistics of heparin binding to HRG under the 
influence of Zn
2+
. In these experiments plates were coated with unfractionated heparin 
(3-30 kDa) and human HRG solutions containing different concentrations of ZnCl2 
were added. After washing, binding was detected through the use of a specific rabbit 
anti-HRG antibody and an alkaline phosphatase-linked anti-rabbit secondary antibody. 
The alkaline phosphatase cleaves the substrate para-Nitrophenylphosphate (pNPP) to 
produce a yellow compound.  
In each case HRG bound heparin in a concentration-specific manner (Figure 4.9a). In 
the absence of Zn
2+
, the average Kd value was 32.9 nM (much stronger than the affinity 
calculated from the ITC data). However the affinity was significantly higher in the 
presence of Zn
2+
, with similar binding profiles observed at all concentrations 
investigated. In these cases the average Kd values were calculated to be 5.1 nM, 6.2 nM 
and 8.2 nM in the presence of 1 µM, 5 µM and 20 µM ZnCl2, respectively. The 
maximum level of binding was similar in all cases suggesting that the independent 
binding modes observed in the ITC experiments are likely to be mutually exclusive (i.e. 
coordination of Zn
2+
 does not create additional heparin-binding sites). These data 
suggest that even relatively small changes in the speciation of plasma Zn
2+
 are likely to 
affect the heparin-binding properties of HRG and its haemostatic functions. 
Antithrombin has a high affinity for heparin with a Kd in the region of 10-36 nM (Olson 
et al., 1992), and also binds a fraction of heparin (termed low affinity heparin) with a Kd 
of 19 µM (Streusand et al., 1995). Taking these numbers into account with the data 
obtained here (showing that HRG binds heparin with a Kd of 32.9 nM in the absence of 
Zn
2+
 and 5.1-8.2 nM in the presence of Zn
2+
) it is apparent that HRG is an important 
competitor for heparin against antithrombin even under normal conditions; but is a more 
significant and stronger competitor in the presence of Zn
2+
.    
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Figure 4.9. Effect of Zn
2+
 on (a) unfractionated heparin (ranging from 3-30 kDa) and (b) low molecular 
weight heparin (6850 Da) binding to human HRG examined by ELISA. Heparin (25 μg/ml) was coated 
overnight onto a heparin-binding plate in 50 mM HEPES, 150 mM NaCl, 0.2% Tween 20 and 0, 1, 5 or 
20 µM ZnCl2 at pH 7.4 in triplicate. The reaction was washed using the same buffer, then blocked with 
the same buffer containing 0.2% gelatin. Human HRG was then added over a range of concentrations (0–
3 μM) and incubated for 2 hours. Detection was with primary rabbit anti-HRG followed by alkaline 
phosphatase linked anti-rabbit antibody and observed with a pNPP substrate at 405 nm. (c) ITC 
experiments performed using low molecular weight heparin (6850 Da). 2μl injections of 150μM low 
molecular weight heparin was delivered to samples of 10 μM HRG in 50 mM Tris, 50 mM NaCl at pH 
7.4. Buffers contained either 0 or 1 μM ZnCl2. Data from consecutive experiments were combined using 
ConCat32 software. Raw data can be found in appendix A2.9-2.10. 
The complementary LMW heparin ELISA experiments (Figure 4.9b) showed that Zn
2+ 
had no influence on the ability of HRG to bind to the LMW heparin chain, where the Kd 
values were ~30 nM for both without Zn
2+
 and with 1 µM Zn
2+
 (Figure 4.9b). To 
supplement the ELISA data, ITC experiments using the same LMW heparin were 
conducted (Figure 4.9c) and confirmed that Zn
2+
 has no effect on the affinity or 
stoichiometry of the HRG interaction with LMW heparin.    
By taking the data presented here and by combining it with what is already known about 
the HRG-heparin interaction, such as both the N1N2 domain and the HRR can 
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independently bind heparin (Jones et al., 2004a; Vanwildemeersch et al., 2006), a 
schematic representing the sophisticated interaction can be developed (Figure 4.10). 
HRG can initially bind heparin via its N1N2 domain which is then enhanced upon the 
chelation of Zn
2+
 by the HRR. At higher concentrations of Zn
2+
, repulsion effects 
between the dimers force them apart and into the 1:1 complex. This could explain why 
increasing the Zn
2+
 levels in the ELISA experiments did not show a parallel in 
increasing the HRG affinity for heparin. It could also explain why HRG binding to 
LMW heparin is not enhanced by Zn
2+
, since there is not enough template surface (i.e. 
heparin chain length) for this augmentation effect to work.  
 
Figure 4.10. Schematic showing a possible mechanism behind the interaction between HRG and heparin 
and the effect of Zn
2+
. (a) First, a heparin molecule tethers to HRG at either its N1N2 or HRR domains. 
The binding of Zn
2+
 by HRG pulls the longer chain heparin into position (perhaps overlapping both 
regions involved in heparin binding) and facilitates the formation of the 1:2 heparin:HRG complex. As 
the Zn
2+
 levels increase, repulsion between the HRG molecules cause the return to the 1:1 complex. (b) 
Low molecular weight heparin is able to bind in the same initial manner. However, due to its shorter 
length, is unable to provide the template required to feel the effects of Zn
2+
 activated HRG.  
However, this is stated with caution since the data here still does not fully decipher the 
binding mechanism. To do this, a further project would need to be undertaken which 
used isolated N1N2 and HRR domains (either recombinant or otherwise) to conduct 
heparin binding ITC studies. This would allow the binding mechanism to be broken 
down to respective exothermic and endothermic constituents and show how Zn
2+
 
activates the HRR in this specific case, leading to the subsequent building up of the 
mechanism from the bottom up. 
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These data are significant since heparin is used in clinical practice as an anticoagulant, 
although there are some complications with its use (particularly for unfractionated 
heparin). Unfractionated heparin is plagued by a narrow therapeutic window and an 
unpredictable dose-response profile as well as other problems including the inability to 
promote inhibition of fibrin-bound thrombin and platelet-bound factor Xa and the 
potential to trigger heparin-induced thrombocytopenia. LMW heparins have a more 
predictable dose-response profile, but are still unable to inhibit fibrin-bound thrombin 
and platelet-bound factor Xa (Weitz, 1997; Hirsh et al., 2001). The fact that HRG is 
enhanced in its affinity for unfractionated heparin and not LMW heparin (by the 
influence of Zn
2+
) could help explain the poor clinical predictability of the former 
compared to the latter. In cases where individuals have altered Zn
2+
 dynamics from 
normal (e.g. higher plasma fatty acids), a patient receiving unfractionated heparin 
treatment would show a dose-response profile differing from the expected due to the 
fact that HRG is able to compete and bind for the heparin molecules against the 
intended target, antithrombin.    
Thrombin activation by HRG following fatty acid induced Zn
2+
 release 
Previous studies have demonstrated that fatty acid binding to bovine serum albumin 
triggers changes in its ability to bind Zn
2+
 to alter the speciation of this metal in plasma 
(Lu et al., 2012). Here, similar experiments were conducted, but used human albumin in 
place of bovine albumin to examine whether the same process occurs with the human 
protein. ITC experiments were performed with HSA (50 µM), loaded with increasing 
molar equivalents of myristic acid (0-250 µM myristic acid, corresponding to 0-5 molar 
equivalents respectively) being titrated with ZnCl2 (1.5 mM). Myristic acid was used 
since it balances solubility issues with still being able to bind HSA in a manner which 
closely matches that of the more physiologically relevant stearic acid and palmitic acid 
(Curry et al., 1998) albeit slightly weaker (Spector, 1975). Figure 4.11 shows the 
resulting isotherms, where a trend in decreasing stoichiometry and a likely lowering of 
the affinity of HSA for Zn
2+
 are observed when myristic acid concentration increases. 
These salient features of the data confirm that as the level of fat associated with HSA 
progressively increases, its high affinity Zn
2+
 site is destructed as was observed in the 
BSA experiments. 
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Figure 4.11. ITC experiments showing the interaction between HSA and Zn
2+
 under a range of myristic 
acid concentrations (0-5 molar equivalents). 50 µM HSA was loaded with the desired amount of myristic 
acid for 2 hours at 37 °C. The HSA sample was then titrated with 5 µl injections of a 1.5 mM ZnCl2 
solution for 55 injections. Experiments were conducted in buffer containing 50 mM Tris, 140 mM NaCl at pH 
7.4. Raw data can be found in appendix A2.11-2.16. 
The ITC data highlights the complexity of this system where two or three binding sites 
for one ligand and up to ten binding sites for another exist, making complete fitting of 
the curves difficult. However, tentative and simplified fitting approaches were taken in 
an attempt to relatively quantify the process.  A sequential binding site model was used 
to fit two sites to obtain reliable quantitative data for the main Zn
2+
 site (Ka= 1.35  10
5 
± 2.5  104 M-1, ΔH= -8166 kJmole-1). These values were then used to fit a two site 
model to obtain a stoichiometry for the interaction as it progresses through increasing 
myristic acid levels. The stoichiometry data showed the main Zn
2+
 site disappear as 
observed in Figure 4.10. N decreased from N=0.95, 0.74, 0.55, 0.37, 0.35 to 0.09 as the 
myristic acid level increased. From these data, it is clear that the high affinity Zn
2+
 site 
disappears by 5 molar equivalent of myristic acid but it is uncertain what happens to the 
other sites. This level of fatty acid (which would equate to around 3 mM in vivo) is 
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observed in the clinical conditions described earlier. Also, it is likely that longer chain 
fatty acids, which would be more abundant in vivo, would induce this allosteric effect 
on HSA at concentrations lower than observed for myristic acid in these studies. A 
summary of the ITC data is presented in Table 4.1. 
Table 4.1. Summary of the ITC data for selected interactions, showing the Kd where appropriate and the 
stoichiometry (N). IS is ionic strength; mol. eq. is molar equivalent.  
 
Having clearly established that the fatty acid induced allosteric modulation of HSA 
severely hinders its native ability to bind Zn
2+
, an approach was established to 
determine whether this would be likely to impact upon HRG function. An in vitro assay 
was developed based upon HRG’s ability to neutralise heparin and inhibit thrombin (Fu 
and Horn, 2003). This system uses a colorimetric thrombin substrate (S2238), together 
Interaction Kd (µM) N
hHRG-Zn2+ 12.4 10.3 (± 0.1)
rHRG-Zn2+ 22.8 10.4 (± 0.1)
hHRG-Zn2+ at low IS 27.8 4.9 (± 0.01)
HSA-Zn2+ (Site A) 7.4 0.95 (± 0.01)
HSA-Zn2+ (Site A) + 1 mol. 
eq. Myr
- 0.74 (± 0.01)
HSA-Zn2+ (Site A) + 2 mol. 
eq. Myr
- 0.55 (± 0.01)
HSA-Zn2+ (Site A) + 3 mol. 
eq. Myr
- 0.37 (± 0.02)
HSA-Zn2+ (Site A) + 4 mol. 
eq. Myr
- 0.35 (± 0.02)
HSA-Zn2+ (Site A) + 5 mol. 
eq. Myr
- 0.09 (± 0.01)
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with thrombin, antithrombin III, heparin, human HRG, HSA, Zn
2+
 and different 
concentrations of lauric acid (C12). The reaction scheme is shown in Figure 4.3. The 
assay conditions were optimised to be as close to physiological as possible 
(concentrations of Zn
2+
, serum albumin, HRG, antithrombin and thrombin were all 
within the normal physiological range). Due to complications arising from attempting to 
dissolve fatty acids at millimolar levels in aqueous buffers, lauric acid was chosen 
because of its more favourable solubility, but with the stipulation that any effects 
observed are likely to be increased in conditions where longer chain fats are present 
(e.g. in vivo), since they bind stronger to HSA and would disrupt the Zn
2+
 easier due to 
their increased chain length (Curry et al., 1998). 
In this assay system, increasing concentrations of lauric were found to augment 
thrombin activity, with the highest activity observed in the presence of 3 mM lauric 
acid, which equates to 5 molar equivalents relative to HSA (Figure 4.12).  
 
Figure 4.12. Examination of the fatty acid/Zn
2+
 switch and modulation of HRG functioning in the context 
of thrombin activation. Experiments were performed in triplicate. Data are representative of multiple 
experiments. Error bars presented are S.E.M. Statistical analysis performed was a two-tailed T-test. 
Serum albumin (600 μM) was pre-loaded with fatty acid by incubating with lauric acid (0, 1.5 or 3 mM) 
for 1 hour at 37 °C in 50 mM HEPES, 150 mM NaCl at pH 7.4 with ZnCl2 (20 μM). HRG (1.5 μM), 
heparin (0.2 U/ml), antithrombin III (2 μM) and thrombin (0.5 nM) were mixed with the albumin sample 
and allowed to equilibriate for 1 hour at 37 °C. The thrombin substrate S-2238 was then added to the 
reaction and the reaction was detected after 20 minutes at 380 nm. Final concentrations are shown in 
parenthesis.  
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In this case the increase in activity was statistically significant (p=0.0376). The 
prothrombotic effect of the fatty acid was reversed by the including 0.1 mM EDTA to 
the system, confidently suggesting that Zn
2+
 is central to this phenomenon.  
The concentrations of fatty acid used in this experiment reflect free fatty acid levels 
observed in certain pathological conditions (such as obesity, diabetes and cancer). It is 
important to note that other Zn
2+
-binding molecules are present in the circulation (and 
absent from this simplified experimental system) that could bind at least some of the 
Zn
2+
 displaced from serum albumin. The relative abundance of HRG in plasma (low 
micromolar levels) and its affinity toward Zn
2+
 would suggest that it would be likely to 
bind a significant proportion of this. Furthermore, it is clear from our experiments that 
only a small proportion of the Zn
2+
 bound to serum albumin would need to be displaced 
(and bind HRG) to have a pronounced effect upon the affinity of HRG toward heparin. 
HRG has been shown to neutralise heparin at Zn
2+
 concentrations as low as 1.25 µM 
(Kluszynski et al., 1997), which is consistent with the enhanced binding between HRG 
and heparin observed in the study here. Conversely, it should also be noted that other 
factors (such as factor X) are absent from this system, which would usually also be 
under inhibition by antithrombin. That is to say, in this assay antithrombin solely 
inhibits thrombin since its other targets are unavailable, thereby effectively increasing 
the proportion of antithrombin associated with thrombin than would normally occur in 
vivo. It is also conceivable that some of the HRG, having been activated by Zn
2+
 in this 
manner, would modulate the other processes in which it is known to be involved 
through enhanced binding to its partners and so not all of it would be involved in the 
process described here. Despite the limitations that are obviously intrinsic to such a 
simplified system, the assay proved that activation of HRG by Zn
2+
 can occur under 
conditions of elevated fatty acid levels. The HRG in this system was then enhanced in 
its ability to compete for heparin against antithrombin, which led to increased thrombin 
activity.   
Thus, the data presented here support the hypothesis that elevations in plasma fatty acid 
levels will negatively influence haemostatic function through changes in Zn
2+
 speciation 
and contribute to thrombotic pathologies in some individuals. Interestingly, recent 
clinical trials examining whether the chelation agent, EDTA, offered therapeutic benefit 
to patients with a history of heart disease found that a subgroup of patients who also had 
diabetes (and presumably elevated plasma fatty acid levels) benefited from the 
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treatment (Lamas et al., 2013; Escolar et al., 2014). The molecular basis for this effect 
remains unknown, but it is likely that the EDTA would chelate plasma Zn
2+
, prevent its 
binding to HRG and return thrombin activity to normal levels. 
The results of this study are compelling and provide further evidence to suggest that 
Zn
2+
-dependent activation of HRG (following fatty acid binding to HSA) may play a 
role in the development of haemostatic complications in some individuals. Given that 
this mechanism would likely be targetable with existing therapeutics (such as chelation 
agents and heparins), it requires further investigation. 
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Chapter 5 
Identification of novel metal binding sites on albumin 
This chapter aims to look closer at the metal binding properties of human serum 
albumin (HSA), by attempting to locate the secondary Zn
2+
 binding site. Typically, 
HSA will complex approximately 80% of all plasma zinc (Foote and Delves, 1984), 
making it the major zinc binding protein in plasma (Cousins, 1986). HSA has been 
shown to modulate zinc uptake into cells endothelial cells (Pattison and Cousins, 1986; 
Gálvez et al., 2001), via a receptor-mediated endocytosis pathway (Rowe and Bobilya, 
2000). Additionally, cases of familial hyperzincaemia seem to be a consequence of 
increased zinc binding to HSA (Failla et al., 1982). 
In addition to Zn
2+
, HSA has been shown to bind an assortment of essential and toxic 
metal ions, including Ca
2+
, Cd
2+
, Co
2+
, Cu
2+ 
and Ni
2+
 (Giroux and Schoun, 1981; 
Martins and Drakenberg, 1982; Goumakos et al., 1991; Vidal et al., 1992; Masuoka et 
al., 1993; Masuoka and Saltman, 1994; Sadler and Viles, 1996; Ohyoshi et al., 1999; 
Zhang and Wilcox, 2002). Despite a lack of detailed structural information regarding 
metal coordination to HSA, seven different sites have been described: the N-terminal 
copper and nickel-binding (ATCUN) motif at the N-terminus which is the primary site 
for Cu
2+
 and Ni
2+
 (Harford and Sarkar, 1997); site A, the primary Zn
2+
-binding site that 
also binds other divalent metal ions (Bal et al., 1998); site B, the unknown site which 
displays a high affinity towards Cd
2+
, but is likely to be a secondary Zn
2+
 site (Giroux 
and Schoun, 1981; Goumakos et al., 1991; Sadler and Viles, 1996); and the free thiol 
group at Cys34 which binds heavier soft ions such as Au
2+
 (Christodoulou et al., 1994) 
and Pt
2+
 (Esposito and Najjar, 2002). Lastly, Ca
2+
 is known to be transported by HSA in 
the plasma (Kragh-Hansen and Vorum, 1993), and a recent crystal structure of bovine 
albumin co-crystallised with Ca
2+
 revealed the presence of three binding sites (Majorek 
et al., 2012). 
N-terminal copper and nickel-binding (ATCUN) motif 
The ATCUN motif is characterised by a histidine residue at position three of an amino 
acid chain, as observed for most serum albumins and other metal binding proteins 
(Harford and Sarkar, 1997). This binding site is especially suitable for metal ions that 
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have a desire for square-planar or tetragonal coordination spheres, and provides four 
coordinating nitrogen ligands, including the imidazole nitrogen of His3, the N-terminal 
amino group and two deprotonated backbone amide nitrogens. The ATCUN motif has  
been shown to have a very high affinity for Cu
2+
, with a dissociation constant in the 
picomolar region (Rózga et al., 2007), and a low micromolar dissociation constant for 
Ni
2+ 
(Sokołowska et al., 2002). This high affinity for Cu2+ makes HSA one of the 
largest pools of Cu
2+
 in plasma after ceruloplasmin, even though only 2% of the 
ATCUN site is populated with Cu
2+
 (Linder and Hazegh-Azam, 1996). Theoretically, 
because of the residues involved in forming the ATCUN site, it could also bind other 
metals such as Zn
2+
, Cd
2+
 and Co
2+
 but this has not been observed experimentally. The 
Co
2+
 binding is a current controversial topic (Bar-Or et al., 2001, 2008; Mothes and 
Faller, 2007), as was discussed in Chapter 1.  
Site A  
The term “site A” originates from 111/113Cd2+ NMR experiments where the addition of 
111/113
Cd
2+
 to HSA resulted in two peaks in the NMR spectra; one with a chemical shift 
of around 130 ppm (site A) and the other with a chemical shift of around 30 ppm (site 
B) (Martins and Drakenberg, 1982; Goumakos et al., 1991; Sadler and Viles, 1996). 
111/113
Cd
2+
 NMR provides details regarding the binding environment of the metal ion 
(Oz et al., 1998), and in this case showed two nitrogen donors and two oxygen donors 
were likely to be involved in the binding site. Inspecting the published X-ray crystal 
structures of HSA showed that two histidine ligands in close proximity to potential 
oxygen donors are only found in the region involving His67 and His247. Site directed 
mutagenesis of His67 to alanine had a major effect on site A, strongly suggesting that 
His67 may indeed be involved in metal binding to this site (Stewart et al., 2003). Site A 
is located at the domains I and II interface, where domain I provides His67 and Asn99 
from, and domain II provides His247 and Asp249. In all X-ray structures of fatty acid 
free HSA, this site appears essentially preformed. A fifth ligand has been suggested as a 
water molecule, which can be replaced by Cl
-
 at higher chloride concentrations (Stewart 
et al., 2003). Site A is the preferred site for Zn
2+
 and one of two for Cd
2+
 (Martins and 
Drakenberg, 1982; Goumakos et al., 1991; Blindauer et al., 2009), although binding of 
Cd
2+
 to this site in HSA is not likely to be relevant under normal physiological 
conditions. Other metals such as Cu
2+
 and Ni
2+
 have also been shown to bind to this site 
(Sadler and Viles, 1996; Bal et al., 1998). 
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 Site B 
The location of site B is as yet unidentified. In NMR studies it correspond to a 
111/113
Cd
2+
 peak with a chemical shift of about 30 ppm, indicating the involvement of 
not more than one nitrogen donor (Martins and Drakenberg, 1982; Goumakos et al., 
1991; Sadler and Viles, 1996; Oz et al., 1998). Mutant studies involving His39 showed 
no difference in the Cd
2+
 NMR spectrum (Stewart et al., 2003), meaning it is unlikely 
that this residue forms part of the site. Site B has a lower affinity for Zn
2+
 compared 
with site A, and could be the primary site for Mn
2+
 ions (Fanali et al., 2012).  
Cys34 
HSA in plasma exists as a heterogeneous mixture due to the existence of Cys34. HSA 
contains 35 cysteine residues, of which 34 are involved in the 17 disulfide bridges that 
interconnect α-helices and maintain the tertiary structure of the molecule (Peters, 1985). 
Cys34 in HSA contains the only free thiol group and this can undergo oxidation 
reactions in vivo. Thus, Cys34 is reactive towards glutathione or cysteine (Sogami et al., 
1986), is involved in disulphide dimerisation of HSA molecules and can be nitrosylated 
(Stamler et al., 1992). The HSA molecules which preserve the free thiol form of Cys34 
can bind metal ions at this position. It is most likely that this site is specific for metal 
ions that can bind to the protein effectively through a single bond such as the heavier 
Au
2+
 and Pt
2+
 ions (Isab and Shaw, 1990; Ivanov et al., 1998). 
Ca
2+
 binding sites 
Recently, a structure of bovine albumin was solved with Ca
2+
 bound to the molecule 
(Majorek et al., 2012). This was the first structure of bovine serum albumin and the first 
albumin structure with a metal ion bound. Although the interaction between albumin 
and Ca
2+
 is relatively weak with a dissociation constant in the high micromolar range 
(Kragh-Hansen and Vorum, 1993), around 45% of the 2.4 mM of Ca
2+
 circulating in 
plasma is coordinated to albumin (Peters, 1995). Additionally it has been suggested that 
albumin mirrors this binding with Mg
2+
. Approximately 45% of the 1.2 mM Mg
2+
 is 
also bound to albumin. This would suggest that there are three sites for these ions, as 
was observed in the Ca
2+
 bound crystal structure.   
All three Ca
2+
 binding sites are found in domain I (Figure 5.1). The first site involves 
residues Glu6, Glu243, Asp248 and Glu251. The second site involves residues Asp13, 
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Asp254 and Asp258. The third site includes Ser109 and Asp111. Water molecules 
provided additional ligands in all cases.  
 
Figure 5.1. Crystal structure of bovine serum albumin complexed with three Ca
2+
 ions (PDB code: 
3V03). Site one is highlighted with the residues in red (Glu6, Glu243, Asp248 and Glu251), site two is 
highlighted in blue (Asp13, Asp254 and Asp258) and site 3 in green (Ser109 and Asp111). Ca
2+ 
ions are 
coloured purple and water molecules are coloured cyan. The peptide backbone is highlighted grey. Figure 
drawn using Accelrys. 
Locating metal binding sites on HSA 
The study here aims to locate site B and any other metal binding sites on HSA by site 
directed mutagenesis and use of isothermal titration calorimetry to monitor binding 
energetics between HSA and metals. Figure 5.2 shows putative sites for metal binding 
based on identified clusters of nitrogen and oxygen donating amino acids within close 
proximity of each other.  
 
Figure 5.2. Putative novel metal binding sites on HSA (PDB file: 1AO6). Figure drawn using Accelrys. 
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To probe this experimentally, a eukaryotic recombinant system was developed using the 
yeast K. lactis to express and secrete the proteins of interest. HSA mutants H9A and 
H288A were constructed to determine additional putative Zn
2+
 binding sites, since they 
would require the presence of nitrogen donors (most probably histidine). E252, D255A 
and D256A mutants were constructed to probe Zn
2+
 binding to HSA (the numbering of 
residues differs by one between human and bovine albumin). The position of each of 
these residues in the HSA molecule is shown in Figure 5.3.  
 
Figure 5.3. Crystal structure of human serum albumin (PDB code: 1AO6), showing the positions of the 
amino acid residues which were mutated to alanine in this study. The peptide backbone is highlighted 
grey. Figure drawn using Accelrys. 
α-Fetoprotein (AFP) 
AFP is the main protein of foetal plasma (Bergstrand and Czar, 1956; Ruoslahti and 
Seppälä, 1972) and shares 39.4% sequence identity with HSA. AFP is produced by the 
liver and exists at concentrations ranging between 1–10 mg/ml in the foetus, but it 
decreases sharply down to trace amounts after birth and is replaced by HSA as the 
major component of plasma (Bergstrand and Czar, 1956; Ruoslahti and Seppälä, 1972; 
Deutsch, 1991). It has been observed that the changes in serum AFP levels during 
pregnancy can lead to the development of several embryonic disorders including 
Down’s syndrome and spina bifida (Seppälä and Ruoslahti, 1973; Brock et al., 1975; 
H9
D256
D255
E252
H67
H288
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Seppälä, 1975; Ruoslahti, 1979; Deutsch, 1991) and an increase in AFP level in adult 
plasma correlates with the occurrence of pathological conditions such as hepatocellular 
carcinoma and several others (Abelev, 1971; Okuda et al., 1975; Yoshiki et al., 1976). 
This correlation allows the clinician to use AFP as a diagnostic marker in these cases. 
The assumed function of AFP is that of a transporter molecule, essentially mimicking 
the role of HSA (in adult serum) during foetal development. It has been observed that 
AFP interacts with fatty acids (Parmelee et al., 1978; Hsia  et al., 1980), where each 
molecule of AFP can contain two or three molecules of polyunsaturated fatty acids, 
having a high affinity for arachidonic (C20:4) and docosahexaenic (C22:6) acids 
(Parmelee et al., 1978; Nagai et al., 1982). AFP also binds Cu
2+
 and Ni
2+
 ions (Aoyagi 
et al., 1978) and has a high affinity for bilirubin (Ruoslahti et al., 1979). However, there 
is a significant functional divergence between AFP and HSA. HSA is known to bind 
many more ligands, but it usually shows a dissociation constant for these in the low 
micromolar range, whereas AFP shows stronger binding to its ligands (with dissociation 
constants in the nanomolar range) (Deutsch, 1991). Additionally, unlike HSA, for which 
the transport and storage of ligands represents the major function, AFP participates in 
other physiological processes, such as immune suppression (Yachnin, 1983). AFP has 
also been stated to play a role in the sexual differentiation of the foetal brain, based on 
its ability to bind estrogens (Soloff et al., 1972; Uriel et al., 1972; Nishi et al., 1991), 
thereby protecting the development from the masculinising effects of the hormone. 
However, only rat and mouse AFP have been shown to bind estradiol and the specific 
estradiol binding region on the rat and mouse variants is absent in human AFP (Nishi et 
al., 1991).   
The homology between AFP and HSA has led to the understanding that AFP will be 
similar in structure to that of the much studied HSA molecule, but detailed studies on 
AFP have yet to be conducted. Thus, AFP has been suggested to be composed of three 
domains and due to 15 disulfide bridges, also takes the ‘heart-shape’ formation as 
observed in albumins (Barker, 1988). However, the relationship between structure and 
function of AFP is thought to be more complex than that which has been characterised 
for HSA. HSA is known to go through strict structural changes in response to pH 
changes that are fully reversible and non-reliant on ligand binding (Peters, 1996). In the 
case of AFP, samples purified from the same source but by different methods show a 
heterogeneity which it has been proposed is due to the stripping of natural ligands 
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during preparation processes which can ultimately lead to irreversible denaturation of 
the protein (Uversky et al., 1997a; Tomashevski et al., 1998).      
Hence it is thought that ligands may play a role in maintaining the rigid spatial structure 
of AFP. It has been suggested that AFP represents a ‘molten globule’ conformation in 
its ligand-free form. This means that it will possess compact native secondary structure, 
but without a unique three-dimensional tertiary structure (Uversky et al., 1997b). This 
semi-rigid molten globule model preserves the main features of the native folding 
pattern, while allowing for much greater internal rotations, which could bestow the 
protein molecule with the ideal qualities necessary for living in a cell due to the range of 
conditions that are encountered. A rigid native protein molecule undergoing a structural 
transformation into a molten globule state is associated with a substantial increase in 
flexibility which could prove to be a functional mechanism (i.e. for the release of 
hydrophobic ligands) (Narizhneva and Uversky, 1997). This molten globule state (or 
ligand-free) AFP has been postulated to be a functional form of AFP, with regards to its 
immunomodulating effects. 
The immunosuppressive ability of AFP observed in vitro is known to be susceptible to 
variations (Lester et al., 1977) and depends on the origin and purification procedure 
(Lester et al., 1977; Yachnin and Lester, 1977; Goeken and Thompson, 1977). Also, it 
has been observed that AFP purified from serum is capable of immunosuppression, but 
the source serum (containing the same AFP levels) does not possess the same capability 
(Yachnin, 1983). Also, the immune-suppression strength of AFP preparations is higher 
when cord serum is subjected to acidic conditions during ion-exchange protocols 
(Goeken and Thompson, 1977), which would provide conditions inducing protein 
denaturation (Uversky et al., 1995). 
The study here aims to develop a viable expression and purification system for 
recombinant AFP, which includes the proper conformation of AFP, to be used in 
fundamental binding studies and potential structural characterisation.  
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Methods 
Materials 
Image clones containing full length human serum albumin (HSA) and human α-
fetoprotein (AFP) coding sequences was purchased from Source Lifesciences. All 
primers used during cloning reactions were purchased from Eurofins MWG Operon and 
are described in Appendix A3.1. K. lactis Protein Expression Kit (New England 
Biolabs, USA) was used to engineer recombinant proteins.  
Expression using Kluyveromyces lactis and the pKLAC2 plasmid  
Recombinant protein expression of wild type-HSA (wtHSA) and the albumin mutants 
H9A, H67A, E252A, D255A, D256A and H288A, as well as AFP, was attempted using 
the K. lactis Protein Expression Kit (NEB, E1000) which included the K. lactis strain 
GG799 and the plasmid pKLAC2. The pKLAC2 plasmid contains a LAC4 promoter, 
LAC4 transcription terminator and encodes β-lactamase (ApR) as well as the pMB1 
origin (ori) to allow for propagation in E. coli. The plasmid also contains the K. lactis α-
mating factor secretion leader sequence (α-MF) which can be used if desired to allow 
the protein to be secreted into the growth media. To provide a means of selection, the 
yeast ADH1 promoter drives expression of an acetamidase marker gene, which allows 
selection to be performed on a carbon based medium where the only nitrogen source is 
acetamide. The plasmid can be digested with SacII or BstXI to create a linear DNA 
fragment capable of integrating into the native LAC4 promoter region of the K. lactis 
genome.    
Construction of expression vectors 
HSA coding sequences were amplified using the Expand Long Template PCR kit with 
buffer system 1 (Roche) and cloned into pKLAC2 (Figure 5.4) using XhoI/NotI 
restriction sites. The primers used in this, and all following experiments, are shown in 
Appendix A3.1. Vector and insert DNA (1 µg) were digested with NotI (20 units) and 
XhoI (20 units) at 37 °C for 2 hours. The reaction also contained BSA (100 µg/ml), 
NEBuffer 3 and was made up to 50 µl with ddH2O. Cloning reactions were completed 
by ligation of the inserts in to the restriction enzyme treated plasmid at a ratio of 
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approximately 2.5:1, using T4 DNA ligase (6 units) in reaction buffer (5 µl) at 16 °C 
overnight. 
 
Figure 5.4. The K. lactis integrative expression vector pKLAC2. The multiple cloning site (MCS) is the 
location of gene insertion, which is within the same translational reading frame as the α-mating factor (α-
MF) native K. lactis leader sequence. K. lactis expression is initiated by the PLAC4-PBI promoter. The 
promoter ADH1 drives the expression of an acetamidase gene (amdS), allowing for the selection of 
colonies on acetamide medium. ORI is the origin of replication. 
Site Directed Mutagenesis of Albumin 
Point mutations within the coding sequence of human albumin (corresponding to 
putative metal sites in the expressed protein) were generated via a PCR-based method 
using the Quikchange kit (Stratgene), however VELOCITY DNA Polymerase enzyme 
(Bioline) was used instead of the Pfu Turbo enzyme (which is usually used as part of 
the kit).  Reactions were set up using the primers shown in Appendix A3.1 (125 ng 
each), 2 mM dNTP mix, HSA-pKLAC2 template DNA (25 ng), reaction buffer, Quick 
Solution and polymerase enzyme (2.5 units). The final volume of each reaction was 
made up to 50 µl with ddH20. The DNA was sequenced commercially to confirm 
integration of correct mutations and to show no additional de novo mutations occurred 
(DNA Sequencing & Services, Dundee) using the primers shown in Appendix A3.1.  
Media 
Liquid cultures of the yeast strain were grown in YPGal medium (1% yeast extract, 2% 
Bacto™ Peptone, 2% galactose) or YPGlu (1% yeast extract, 2% Bacto™ Peptone, 2% 
glucose). Solid yeast carbon-based media (YCB) with 5 mM acetamide (New England 
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Biolabs, B9017S) was used to grow colonies under selective conditions. K. lactis cells 
were grown to an OD600 > 30 (typically 4-5 days) in YPGal unless otherwise stated.  
Transformation of K. lactis GG799 cells 
Linearisation of pKLAC2 must precede the integrative transformation of K. lactis 
GG799 cells. This is required to allow integration of the desired gene into the K. lactis 
genome at the LAC4 locus. Plasmid DNA (pKLAC2) containing the coding sequences 
of HSA (wildtype or mutants) or AFP (2 µg) were digested with SacII (20 units) in 1X 
NEBuffer 4 (50 µl) at 37 °C for 2 hours. This gives rise to two fragements, one 
containing the expression cassette and the other containing the remainder of the 
pKLAC2 plasmid. It was not necessary to purify the digested fragment as only the 
expression cassette has the ability to integrate within the K. lactis genome. However, 
agarose gel electrophoresis was conducted to confirm the digestion, yielding the 
expression fragment at >10 kb and the remaining pKLAC2 DNA at 2.8 kb. Following 
this, the DNA was desalted using SOPE resin (EdgeBio).  
Chemical transformation of K. lactis GG799 cells was achieved by incubating the 
linearised DNA (up to 1 µg in less than 15 µl) with the chemically competent K. lactis 
GG799 cells mixed with NEB Yeast Transformation reagent (620 µl) at 30 °C for 30 
minutes. After incubation, the cell mixture was heat shocked at 37 °C for 1 hour. The 
cells were washed and resuspended in YPGlu (1 ml), transferred to a sterile culture tube 
and incubated with shaking at 30 °C for 4 hours. The cell mixture was resuspended in 
sterile PBS (1 ml). A dilution of the transformed cells (10 µl in 50 µl sterile H2O) were 
spread onto YCB agar plates containing acetamide (5 mM) for selection of correctly 
integrated colonies. Colonies were picked and spotted onto fresh plates for further use.  
Identification of integrated cells  
Colonies containing the integrated albumin sequence were confirmed by PCR 
amplification of the yeast genomic DNA with integration primers 1 and 2 (singly 
integrated copies) or integration primers 2 and 3 (multiple integrated copies). Reactions 
were composed of the required primers (5 µl each), dNTP mix (0.2 mM), Green Go 
Taq
®
 Flexi buffer (10 µl), MgCl2 (2 mM), the yeast DNA (up to 1 µg) and Go Taq
®
 
DNA Polymerase (1.25 units). The volume was made up to 50 µl with ddH2O.  
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The PCR reaction followed from isolating the yeast genomic DNA using a Yeast DNA 
Extraction Kit (Thermo) from single colonies grown on YCB agar plates containing 
acetamide (5 mM). A 1 mm
2
 fraction of the colony was suspended in Y-PER (20 µl) to 
form a homogeneous mixture and incubated at 65 °C for 10 minutes. The cells were 
centrifuged (13 000 x g, 5 minutes) and resuspended in DNA Releasing Reagent A (16 
µl) and DNA Releasing Reagent B (16 µl).  The homogeneous mixture was then 
incubated at 65 °C for 10 minutes. Protein Removal Reagent (8 µl) was added into the 
mixture and inverted several times. The mixture was centrifuged (13 000  g for 5 
minutes) and the supernatant transferred to a new tube. Isopropyl alcohol (24 µl) and 
glycogen (1 µl) were added to precipitate the genomic DNA and to make the pellet 
visible; the mixture was inverted and then centrifuged (13 000  g for 10 minutes). The 
supernatant was removed and the DNA pellet washed with 70% ethanol, before 
resuspension in sterile ddH2O (5 µl). 
Fermentation of yeast  
Yeast colonies containing the desired insert were grown overnight in YPGlu medium at 
30 °C, with shaking at 200 rpm, prior to fermentation. The starter culture was used to 
inoculate 3 L of YPGal media in a Fermac 231 fermenter (Electrolab, UK), which had 
been saturated with O2. The fermenter culture was left to grow for 3 days within a pH 
range of 4.5 to 5.5, with stirring at 350 rpm. Cells were removed from the culture by 
centrifugation at 8,000 rpm for 45 minutes. The 3 L supernatant was concentrated using 
a PES membrane filter with a molecular weight cut-off of 30 kDa (Sartorius, UK).  
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed as described before (see Chapter 3). 
After the desired separation had been achieved, the gels were stained either stained with 
coomassie, or were immediately transferred for Western Analysis. In the case of 
staining, gels were visualised by staining with coomassie solution (0.025% Coomassie 
Brilliant Blue R250, 40% methanol, 10% acetic acid) for 10 minutes, followed by 
destaining in boiling water.  
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Immunoblotting Western analysis 
All blot module components (Invitrogen) were immersed in NuPAGE Transfer Buffer 
(Invitrogen) with methanol (20%) before arranging the apparatus. The PVDF membrane 
was soaked in methanol for 5 minutes, followed by water for 5 minutes. The module 
was arranged from the anode with: sponge pads/filter paper/gel/membrane/filter 
paper/sponge pads. The blot module was filled with transfer buffer and the transfer was 
conducted for 1 hour at 30 V.  
Upon completion of the transfer, the blot module was disassembled and the membrane 
washed with methanol, then water. The membrane was blocked overnight at 4 °C in 
Tris-buffered saline (TBS) with 5% skimmed milk. The membrane was quickly rinsed 
and the incubation with the primary antibody was started. Recombinant albumin and its 
mutants were detected using an anti-HSA antibody raised in rabbit (Sigma, A0433), at 
1:1000 dilutions in TBS + 1% skimmed milk and 0.5% Tween 20 for 1.5 hours at room 
temperature. The primary antibody was washed off with three washes of TBS 
containing 0.2% Tween 20 of 15 minutes each.  
The membrane was incubated with alkaline phosphatase conjugated anti-rabbit 
secondary antibody (Sigma, A9919) at a dilution of 1:10,000 in TBS containing 5% 
skimmed milk and 0.5% Tween 20 for 1.5 hours at room temperature. After this time, 
the membrane was washed three times with TBS containing 0.2% Tween as before, 
followed by one wash with TBS then one wash with ultrapure water. Protein bands on 
the membrane were visualised using Western Blue reagent (Promega).   
Purification 
Recombinant HSA was purified using a HiTrap Blue HP column (GE Healthcare, UK), 
followed by size exclusion chromatography using a HiLoad Superdex-75 column (GE 
Healthcare, UK). All preparations were performed on an AKTA Purifier (GE 
Healthcare, UK). The HSA sample was equilibrated to 20 mM potassium phosphate at 
pH 7 and bound to the HiTrap Blue HP column, which had previously been equilibrated 
in the same buffer. After washing with this buffer, elution was achieved by applying 20 
mM potassium phosphate, 1.5 M KCl at pH 7 over a gradient. Fractions containing 
recombinant HSA were pooled and further purified on a HiLoad Superdex-75 column, 
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which had been equilibrated in a desired buffer (typically 50 mM Tris, 140 mM NaCl at 
pH 7.4). 
Recombinant AFP was purified using a HiTrap chelating column (GE Healthcare, UK) 
which was charged with copper sulfate. Binding of AFP was achieved using 20 mM 
sodium phosphate, 1 M NaCl at pH 7.2. After washing in the same buffer, elution was 
achieved by a one-step introduction of 20 mM sodium phosphate, 1 M NH4Cl at pH 7.2. 
The NH4Cl provides weak competitive binding to the column which is enough to 
displace AFP. Fractions containing recombinant AFP were pooled and further purified 
on a HiLoad Superdex-75 column, which had been equilibrated in the experimental 
buffer of choice.   
Protein Concentration Determination 
Protein concentration was determined as before (see Chapter 3). An extinction 
coefficient of 34445 M
-1
 cm
-1
 was used for HSA and 32830 M
-1
 cm
-1
 for AFP. 
Isothermal Titration Calorimetry (ITC) 
ITC experiments were carried out using either a VP-ITC instrument (MicroCal, USA) 
or iTC200 (GE Healthcare, UK) in 50 mM Tris, 140 mM NaCl, pH 7.4, at 25 °C. The 
titration ligand was added to the reaction buffer and the pH adjusted to 7.4 to match the 
buffer of the protein. Specific concentrations used in experiments are given in figure 
legends. The titration of estradiol into AFP included 1% DMSO in the buffer to 
facilitate estradiol dissolution. Solutions were degassed at 22 ºC for 15 minutes prior to 
running the experiment. Typical titrations on the VP-ITC performed were one 2 μl 
injection over 4 s followed by up to 55 injections of 5 μl over 10 s with an adequate 
interval of 240 s between injections to allow complete equilibration. The stirring speed 
was 307 rpm. Typical titrations on the iTC200 were an initial injection of 0.4 μl over 0.8 
s followed by 18 injections of 2 μl over 4 s with an interval of 120 s between injections. 
Heats of dilution were accounted for with blank titrations performed by injecting ligand 
solution into reaction buffer and subtracting the averaged heat of dilution from the main 
experiment. Alternatively, in cases of saturated binding, blank titrations were omitted 
where the averaged residual signal of the last injections was used to determine the heat 
of dilution. Raw data were processed using MicroCal Origin software and data were 
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fitted using the same software. Raw data for the ITC experiments presented here can be 
found in Appendix 3. Plasma HSA was obtained from Sigma-Aldrich.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
129 
 
Results and discussion 
Expression of recombinant albumin in K. lactis  
To understand the metal binding properties of albumin, mutant albumins were 
expressed in K. lactis and investigated using ITC. Expression of HSA mutants was 
detected by Western analysis. Figure 5.5a shows analysis of the H288A mutant as an 
example of expression. All recombinant albumins (wtHSA, H9A, H67A, E252A, 
D255A, D256A and H288A) were subjected to the same protocol. 
 
Figure 5.5. (a) Western analysis of the human albumin mutant H228A showing a major band at 65 kDa 
from 10 random K. lactis colonies. (b) Western analysis of the HSA mutant H288A from 3-7 days growth 
of K. lactis. 
Ten K. lactis colonies were grown in 10 ml liquid cultures to evaluate expression levels. 
All yeast colonies showed a distinct band at 65 kDa relating to HSA. Coinciding with 
the mature H288A band is a band at around 45 kDa which was postulated to represent a 
digested fragment. K. lactis are known to secrete proteases and have membrane bound 
proteases which could interact with any secreted protein in the growth medium. Sleep 
et. al. (1990) made a similar observation in their work comparing the expression of 
HSA from S. cerevisiae using different secretion leader sequences. They found that the 
α-MF (the secretion signal used in our work) produced a truncated fragment of HSA for 
secretion and ruled out any degradation possibilities, but were unable to determine an 
exact cellular cause for its appearance. This pattern was reproducible for all 
recombinant HSA constructs. Before transforming the competent K. lactis cells, the 
DNA was sequenced to confirm the presence of the mutation. The Western analysis 
confirms the expression of recombinant HSA, and no de novo mutations were present.  
 
65 kDa 
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In an effort to optimise HSA mutant secretion and purification, the H288A mutant 
expression was monitored over a period of 7 days in order to determine if there was a 
maximum level of expression over time (Figure 5.5b).  The main band at 65 kDa shows 
very little alteration from 3 to 7 days. The truncated fragment at around 45 kDa displays 
a steady increase in secretion during the growth period. It was concluded that no 
significant advantage could be had by growing the yeast strains longer than 4-5 days.  
With regards to recombinant AFP, since at the time we had no anti-AFP antibody, K. 
lactis colonies containing AFP were not subjected to Western analysis; instead they 
were subjected to purification and subsequent analysis by mass spectrometry.  
Purification of recombinant HSA and AFP 
Recombinant HSA was purified from culture medium using a HiTrap Blue column. 
This column contains the ligand Cibracon Blue F3G-A, which is known to bind albumin 
(Altintaş and Denizli, 2006). Following this, size exclusion chromatography was used to 
polish the sample (Figure 5.6). Typical protein yields were 1 mg/ml for shake flask 
cultures, and up to 20 mg for 3 L fermenter culture. The first step of the procedure 
provided a protein sample typically of 90% purity, which was then improved to >99% 
pure following the size exclusion step. All recombinant HSA constructs were isolated to 
this level of purity and used for experimental studies.   
 
Figure 5.6. Example preparation of the recombinant HSA mutant H288A from K. Lactis. (a) SDS-PAGE 
analysis following the first step of purification on a HiTrap Blue column. Lane 1: media sample, lane 2: 
flow through from column, lanes 3-10: eluted HSA protein (b) SDS-PAGE analysis following the final 
size exclusion step, to yield a protein sample of a suitable quality for experimental work. Gels were 
visualised using Coomassie blue stain.   
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Recombinant AFP was purified using a Cu
2+
-column, exploiting the natural affinity 
AFP has for Cu
2+
. This step afforded two bands that eluted under the same conditions, 
which were then separated by size exclusion chromatography to yield a 99% pure AFP 
sample (Figure 5.7).  The gel band was identified as AFP using mass spectrometry.  
 
Figure 5.7. Preparation of recombinant AFP from K. Lactis. SDS-PAGE analysis of an AFP sample 
(marked with an arrow) can be seen in lanes 4-7 following Cu
2+
 affinity and size exclusion 
chromatography. Lanes corresponding to AFP were pooled and used for experimental studies. Gel was 
visualised using coomassie stain.   
The structural integrity of AFP was determined by circular dichroism (CD), since there 
is a note of controversy regarding AFP preparations (Leong and Middelberg, 2006). 
Figure 5.8 shows the near-UV spectrum of AFP, which conforms to the shape 
previously reported indicating that the protein as expressed by K. Lactis is in at 
correctly folded conformation (Leong and Middelberg, 2006). 
 
Figure 5.8. Near-UV CD spectra of recombinant AFP. Peaks in this region confirm the protein is in a 
native folded conformation.  
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Zn
2+
 binding studies on recombinant HSA mutants 
The first step of these studies involved establishing that the properties of the 
recombinant HSA were comparable to that of native plasma-derived HSA, since 
although in theory they are the same protein, being derived from different sources could 
potentially affect binding abilities. To do this, both plasma HSA and recombinant 
wtHSA were subjected to identical ITC experiments with Zn
2+
 titrations (Figure 5.9).  
 
Figure 5.9. Comparison of the Zn
2+
 binding ability of recombinant and plasma derived HSA studied by 
ITC. 50 µM plasma HSA and 46 µM wtHSA were titrated with 1.5 mM ZnCl2. The binding pattern is 
very similar with only minor deviances, most notably with the energies of the first few injections. 
The ITC data prove that there is essentially no significant difference in the Zn
2+
 binding 
ability between wtHSA and plasma HSA, since they both show a similar binding 
profile. However, wtHSA shows lower exothermic energy released for the first 3-4 
injections which could be representative of minor differences between the two samples. 
The wtHSA is supposed to be a more homogeneous sample since each protein molecule 
is theoretically subjected to the same processes during expression. Plasma HSA on the 
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other hand will have been circulating through the plasma prior to purification and so 
would have been subject to various in vivo processes that would lead to heterogeneity 
(e.g. oxidation at Cys34 by different species).  
Having established that the recombinant expression system was able to express reliable 
HSA proteins, all mutants were included in ITC experiments with Zn
2+
 to determine 
qualitative Zn
2+
 binding profiles of the mutant HSAs (Figure 5.10).  
 
Figure 5.10. ITC data comparing the Zn
2+
 binding ability of the six HSA mutants against plasma HSA. 
As expected the H67A mutant shows the loss of the high affinity Zn
2+
 binding site (site A), as does the 
E252A mutant. H9A, D256A and H288A showed a variance in Zn
2+
 binding from plasma HSA which 
would suggest that these residues are involved in forming the weaker Zn
2+
 sites in some way. D255A had 
no effect on Zn
2+
 binding. All experiments were performed with 50 µM HSA samples and 1.5 mM ZnCl2, 
except for H288A which used 25 µM protein and 0.75 mM ZnCl2. Raw data can be found in appendix 
A3.2-3.7. 
The first feature of note is that the D255A mutant shows a virtually identical Zn
2+
 
binding profile to that of HSA, meaning that this residue is not involved in any Zn
2+
 
binding. Conversely, H67A, which is one residue from site A (Stewart et al., 2003), 
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shows significant disruption of the Zn
2+
 binding ability if HSA, as would be expected. 
E252A (violet) also shows a profile similar to that of H67A, suggesting that this residue 
is either involved in directly in Zn
2+
 binding, or allosteric effects caused by mutation of 
glutamic acid to alanine disrupt a metal binding site (likely to be site A, based on the 
comparable ITC data between H67A and E252A). This is understandable since the 
Glu252 residue is only 3.5 Å away from the site A residue Asp249. However, any 
proposals made regarding the E252A binding profile should be taken with caution as 
this was the only mutant HSA that was not reproduced due to time constraints. 
However, the binding profiles of each of the others were reproducible and so can be 
considered as reliable accounts of their respective Zn
2+
 binding abilities, but E252A 
would need to be reproduced before any reliable assessment is made. The remaining 
mutants: H9A, D256A and H288A all showed a significant degree of reduced Zn
2+
 
binding compared to HSA, suggesting that these residues are involved in the weaker 
Zn
2+
 binding sites and could be the location of site B.  
These observations can be understood in context with the crystal structure of HSA. His9 
would be in close proximity to metal binding residues His3 and Asp13 which could 
form part of the metal binding site in this position. His288 has nearby neighbours in 
Glu154 and His157 which would be able to bind metals and together form part of a 
binding site. In the case of D256A, it is difficult to determine any obvious partner 
residues that could form a site for Zn
2+
 binding, but looking at the structure of bovine 
albumin with Ca
2+
 (Figure 5.1), it can be seen that Asp256 is directly next to Ca
2+
 
binding residues. Hence, any mutation of this residue could produce allosteric effects 
which alter metal binding properties of the HSA molecule, which could explain the Zn
2+
 
binding profile of the D256A mutant.   
Although the ITC data alone does not allow for definitive determination of the weaker 
Zn
2+
 binding sites, it does indicate whether residues may be involved. The novel 
histidine mutants (H9A and H288A) showed decreased Zn
2+
 binding ability. Since 
histidine residues are expected in Zn
2+
 binding, and the fact that both His9 and His288 
are in close proximity to other histidine residues (His3 and His157 respectively), it is 
highly likely that these form the remaining two of the three Zn
2+
 sites that HSA is 
thought to have (Lu et al., 2008). As discussed previously in Chapter 3, the non-linear 
curve fitting for this interaction (HSA to Zn
2+
) is complex and proves difficult to 
achieve a complete quantitative picture of the process. This is compounded by the fact 
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that the different mutants show different binding profiles and so the same fitting 
protocol could not be used for each making quantitative comparisons even more 
problematic. For these reasons, the ITC data in this instance was used purely as a 
qualitative measure of observing the Zn
2+
 binding differences between the mutants 
expressed.  
Binding of Zn
2+
 and estradiol to AFP 
The Zn
2+
 binding ability of AFP was monitored by ITC (Figure 5.11). AFP was shown 
to have a similar Zn
2+
 binding profile to HSA as studied by ITC. That is, AFP has one 
high affinity Zn
2+
 site and one (or possibly two) lower Zn
2+
 binding regions. As with the 
HSA and Zn
2+
 titrations, non-linear curve fitting for AFP and Zn
2+
 was not conclusive, 
although a low to mid-micromolar dissociation constant was consistently calculated. 
The data here shows less Zn
2+
 binding to AFP, and at a lower affinity, than previous 
studies which were conducted using different methods (Wu et al., 1987; Permyakov et 
al., 2002).  
 
Figure 5.11. ITC data showing the binding of Zn
2+
 into AFP. 25 µM AFP was titrated with 0.75 mM 
ZnCl2. The shape of the curve is similar to that observed for HSA, albeit with slightly lower affinity and 
stoichiometry. Raw data can be found in appendix A3.8. 
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It should be noted that AFP and HSA are likely to display a cooperative binding ability 
towards Zn
2+
. So, if the initial binding of Zn
2+
 to the protein is able to induce further 
binding to the weaker sites within the molecule, the mixture of the sample in the ITC 
cell becomes heterogeneous (i.e. “protein-Zn2+” is a different species from “apo-
protein”). These two species will then compete for the additional Zn2+ titrations against 
each other, affecting the appearance of binding isotherm. This highlights the complexity 
of these systems and helps explain why simple fitting is not possible using these 
methods.  
Having established that the expressed AFP is able to bind Zn
2+
, a study on estradiol 
binding to AFP was conducted (Figure 5.12). The estrogen binding ability of AFP has 
received considerable attention due to its potential role in reproductive development. 
Female AFP knockout mice have been shown to be infertile as estradiol can masculinise 
the female foetus, if no protection is provided by AFP (Brock et al., 2012). However, 
only rat and mouse AFP have been observed binding estradiol, whereas human AFP is 
unable to, and so the role of AFP in reproductive development in humans is still 
uncertain. 
 
Figure 5.12. ITC data of AFP being titrated with estradiol. 25 µM AFP was titrated with 250 µM 
estradiol. The experiment showed no binding of estradiol to AFP, which is in line with literature 
observations. Raw data can be found in appendix A3.9. 
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The ITC data here confirmed that AFP lacks the ability to bind estradiol, in keeping 
with literature. These observations here support the fact that AFP expressed in K. Lactis 
is a viable means of preparing this protein for various studies, since the preliminary 
experiments done here are in line with literature data. It would be interesting in future 
studies to investigate the structure-function relationship of AFP, particularly with 
respect to its ligand binding. For example, AFP may need to be in a specific 
conformation (e.g. molten globule) for binding of estradiol to be observed. The study 
conducted here made no attempt to alter the structural state of AFP due to time 
constraints. However, if the molten globule form of AFP could represent a structural 
regulation of the molecule functions, there may be very different binding observations 
under this state. Additionally, native ligands (e.g. fatty acids) may first be required to 
bind to AFP, in order to induce cooperative binding of further ligands to the protein 
molecule. All these factors have to be taken into account and investigated, and could 
provide a reason for differences observed between studies.  
In conclusion, this project was able to develop a recombinant expression and 
purification system for both HSA and AFP, yielding natively folded proteins of a high 
purity. The mutants H9A and H288A were identified as being likely candidates for the 
additional unknown Zn
2+
 binding sites on HSA, while E252A and D256A were also 
shown to have alter the ability of HSA to bind Zn
2+
, although it is not known whether 
these are direct effects. The expressed AFP showed an ability to bind Zn
2+
, but did not 
bind estradiol, suggesting that this expression system is able to produce AFP which 
conforms to literature observations and thus is ready for use in further studies on the 
binding properties of AFP and also for structural characterisation by X-ray 
crystallography. 
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Chapter 6 
Conclusions 
This project started with ambitious aims and strong directives. HRG was to be 
structurally characterised and a functional link between plasma fatty acid levels and 
increased thrombosis through activation of HRG by Zn
2+
 was to be established. Until 
recently, structural information relating to HRG had come only from sequence analysis 
and spectroscopic studies. The study here published the X-ray crystal structure of the 
N2 domain of rabbit HRG. This structure showed the domain has a cystatin-like fold, is 
N-glycosylated at Asn184, S-glutathionylated at Cys185 and is likely to contribute to 
dimerisation (through interaction with another N2 domain). The observation of the 
glutathione adduct at Cys185 provided potential in vivo evidence that the release of the 
anti-angiogenic HRR/PRR fragment is controlled in part by a redox mechanism. 
The major transporter of Zn
2+
 and fatty acids in plasma is HSA. The Zn
2+
 binding site 
on HSA had previously been identified, which is also concurrent with one of the fatty 
acid binding sites. Using ITC experiments to examine the binding of Zn
2+
 to HSA under 
a range of fatty acid concetrations, this study has revealed that pathophysiological 
concentrations of free fatty acids (up to 5 molar equivalents) significantly perturb the 
ability of albumin to bind Zn
2+
, due to disruption of the main Zn
2+
-binding site.  
From what is currently known regarding the Zn
2+
 binding properties of HRG and HSA, 
it is clear that either transient or sustained elevation of plasma fatty acid levels would be 
likely to increase the proportion of plasma Zn
2+
 associated with HRG. Reduced 
competition from HSA due to the presence of fatty acids could allow a sufficient 
proportion of Zn
2+
 to bind HRG, activating HRG and triggering association to heparin. 
This led us to study the the Zn
2+
 binding properties of HRG and the ability of Zn
2+
 to 
influence HRG-heparin interactions by ITC and ELISA.  
The ITC experiments revealed human HRG has 10 Zn
2+ 
binding sites with an average 
Kd of 12.4 µM. The effect of Zn
2+
 on heparin binding by human HRG was also assessed 
using ITC. Heparins of molecular weight range 3-30 kDa were injected into samples of 
human HRG that contained different concentrations of Zn
2+
. Zn
2+
 had a marked effect 
upon the mechanism by which human HRG bound heparin. In the absence of Zn
2+
 the 
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interaction between the first few injections of heparin and HRG was exothermic. This 
initial exothermic form of heparin binding is more pronounced as the concentration of 
Zn
2+ 
is raised to 5 µM. This reveals that heparin binds HRG via different “modes”, 
whereby the exothermic mode of binding occurs with higher affinity than the 
endothermic mode and is enhanced by Zn
2+
. It was possible to fit curves to the 
endothermic data collected in the absence and presence of 1 µM Zn
2+
. These fits suggest 
that the endothermic mode most likely corresponds to a single heparin site. However, 
the “real” affinities are likely to be higher as this analysis does not take into account 
binding via the exothermic mode. Interestingly a difference in the stoichiometry of 
heparin binding to HRG in the presence of 1 µM compared with the data without Zn
2+
 
or with 5 µM was observed, suggesting that a mixture of 1:1 or 1:2 heparin:HRG 
complexes exist in solution. Our study suggests that higher concentrations of Zn
2+
 (5 
µM) inhibit formation of the 1:2 complex, which will enhance the proportion of heparin 
bound to HRG.  
The effect of Zn
2+
 on human HRG-heparin interactions was further explored through the 
use of an ELISA-based assay. In each case HRG bound heparin in a concentration-
dependent manner. In the absence of Zn
2+
, HRG bound with an average Kd= 32.9 nM. 
However the affinity was higher in the presence of 1 µM Zn
2+
 (ca. Kd= 5.1 nM). The 
ELISA assay was repeated using a low molecular weight heparin fraction, 6,850 Da in 
size. Zn
2+
 had no effect upon the ability of HRG to bind 6,850 Da heparin (in each case 
Kd was ~30 nM). The contrast between heparins of different mass ranges is interesting 
given that heparins of different sizes are used clinically as anti-thrombotic agents. 
An in vitro assay to study Zn
2+
-dependent effects upon of the coagulation pathway 
involving HRG, thrombin, antithrombin and apo- and fatty acid-loaded albumins was 
also developed. The assay conditions were optimised to be as close to physiological as 
possible (concentrations of Zn
2+
, serum albumin, HRG, antithrombin and thrombin were 
all within the normal physiological range). Lauric acid was chosen as a medium/long-
chain fatty acid with a relatively high solubility in aqueous solutions. In this assay 
system increasing concentrations of lauric acid were found to augment thrombin 
activity, with the highest activity observed in the presence of 3 mM lauric acid. The 
prothrombotic effect of the fatty acid was reversed by the introduction of 0.1 mM 
EDTA to the system, suggesting that Zn
2+
 is involved. If a role for free fatt acids in 
increasing the risk of thrombotic complications (via modulation of free/exchangeable 
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Zn
2+
 levels) is confirmed, then chelation therapy could be seen as a viable preventative 
treatment in certain individuals. 
To drive this research onwards from the fundamental studies conducted so far, several 
salient aims appear appropriate. The only 3D-structural information that currently exists 
for HRG is the N2 domain structure that was presented here. In order to gain structural 
insight into the organisation of individual domains, interactions with other molecules 
(including heparins) and the molecular basis for Zn
2+
-binding to the HRR, full length 
and individual domains of human HRG (including HRR, N1/N2 together and C2 
domains) should be subjected to crystallisation trials. Full length HRG could be purified 
from human plasma. Where applicable, co-cystallisation could be attempted with Zn
2+
 
and other binding partners. These include homogenous preparations of different 
heparins. 
With the anticipated difficulty in growing suitable crystals of a large protein such as 
HRG, some complementary approaches should also be adopted. Trials to crystallise the 
full length protein following a partial protease (trypsin) step may be carried out. 
Proteases preferentially process proteins at disordered regions, removing these regions 
can greatly increase the potential to form ordered crystals suitable for diffraction 
studies. Enzymatic removal of polysaccharide chains using commercially available 
enzymes may aid formation suitable crystals as can chemical modification (reductive 
methylation).  Any future work should also attempt to establish a recombinant system 
for the expression of full length and truncated versions of HRG.  
To further understand how HRG and heparins interact and the influence of Zn
2+
 in this 
process, the established approaches of ITC and ELISA can be used to examine binding 
of heparins of different chain lengths to full length plasma-purified human HRG and 
recombinant domains (particularly N1/N2 and the HRR, which are known interaction 
sites) in the presence and absence of Zn
2+
. This will not only confirm that these domains 
are responsible for heparin-binding but give clues as to how the Zn
2+
 enhances the high 
affinity mode of binding. More specifically, it will tell us whether the domains act 
independently or in concert (following Zn
2+
-binding) to elicit the high-affinity mode of 
binding.  
Functional assays designed to ascertain the ability of human HRG to neutralise different 
heparins and the role of Zn
2+
 in this process, could be developed. A thrombin assay 
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(utilising physiological levels of albumin HRG, antithrombin, heparin, thrombin and the 
chromogenic thrombin specific substrate S2238) as an in vivo platform to examine the 
effect of Zn
2+
 displacement from serum albumin by free fatty acids has already been 
developed. Using pathophysiological concentrations of free fatty acids and heparins of 
different sizes the influence free fatty acid mediated changes in free/exchangeable Zn
2+
 
has on the ability of HRG to neutralise heparins of different molecular weights could be 
examined. The complexity of this assay could be increased by developing a system to 
detect the thrombin activity in plasma samples. These samples could be spiked with 
increasing fatty acids, and any detectable increase in thrombin activity could be related 
to the mechanism detailed. 
As a side project, to investigate the metal binding properties of HSA, recombinant 
mutants were made in an attempt to identify binding sites. H9A, H67A, E252A, D255A, 
D256A and H288A mutants were engineered. Based on ITC binding profiles between 
Zn
2+
 and the respective mutants, H9 and H288 were identified as being possible 
residues involved in the unknown Zn
2+
 binding sites on HSA. E252 and D256 appear to 
effect the ability of HSA to bind Zn
2+
, although these effects could be through indirect 
means. Recombinant AFP was also expressed and purified during this project, and 
preliminary studies on its Zn
2+
 and estradiol binding abilities suggest that the K. lactis 
expression system used is able to produce viable, fully-folded AFP.  
With regards to identifying new metal binding sites on HSA, towards the end of the 
project our collaborators were able to co-crystallise HSA with Zn
2+
. The functional data 
presented here will compliment the solution of the HSA-Zn
2+
 structure. The future 
direction of the project on AFP could follow the same trajectory as used for the studies 
on HRG and HSA here. The binding properties of AFP could be studied with ITC using 
a variety of ligands including metals, fatty acids or hormones. Since there is no structure 
of AFP currently available, any project involving AFP should make crystallisation trials 
with the ultimate aim of structure solution a main priority. 
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Appendix 1 
The supporting material provided in this section relates to Chapter 2, the structural 
characterisation of HRG. This includes images of the crystals, diffraction patterns and 
X-ray crystallography data tables.  
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A1.1. Photograph of a drop containing HRG N2 domain crystals. 3 crystals are shown 
with arrows.  
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A1.2. Photograph of the HRG crystal used to collect data. 
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A1.3. Diffraction pattern obtained from the rod-shaped crystal. 
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Data Collection K2PtCl4-soaked Native 
Beamline Diamond I02 Diamond I04-1 
Wavelength (Å) 0.97 0.92 
Space group P 31 2 1 P 31 2 1 
Cell dimensions (c), (°) 
 
77.6, 77.6, 69.2 
90, 90, 120 
77.1, 77.1, 69.2 
90, 90, 120 
Resolution (Å) 
(high resolution) 
69.2 – 2.91 
(2.99 – 2.91) 
34.7 – 1.93 
(2.00 – 1.93) 
Rmerge 10.0 (92.3) 5.1 (33.0) 
I / σ (I) 29.2 (5.2) 11.3 (2.1) 
Completeness (%) 99.5 (99.2) 93.7 (69.2) 
Average redundancy 26.9 (28.6) 4.1 (2.7) 
Vm (Å
3
 / Da) 4.3 4.2 
Solvent (%) 71.4 70.9 
Refinement   
Unique reflections  17163 
Rwork / Rfree  0.18 / 0.22 
Geometric  deviations   
Bonds (Å
3
) / Angles (°)  0.017 / 2.02 
No. atoms  1104 
Protein 
Water 
Sugar 
Glutathione 
Glycerol 
 952 
75 
39 
20 
18 
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A1.4. Crystallographic data collection and structure refinement statistics for the rod-
shaped crystal. 
 
 
 
 
B factors (Å)   
Protein  41 
Water  51.8 
Sugar  69.6 
Glutathione  63.6 
Glycerol  74.3 
Ramachandran 
Allowed / disallowed (%) 
  
100 / 0 
Molprobity score / centile  3.52 / 100 
PDB code  4CCV 
* Values in parenthesis refer to the highest resolution shell 
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A1.5. Photograph of a cubic HRG crystal used to collect data. 
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A1.6. Diffraction pattern obtained from diffraction of a cubic HRG crystal. 
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Data Collection HRG – cube 
Beamline Diamond I24 
Wavelength (Å) 0.99 
Space group F 2 3 
Cell dimensions (c), (°) 
172.6 172.6, 172.6 
90, 90, 90 
Resolution (Å) 52.0 – 5.05 
(high resolution) (5.53 – 5.05) 
Rmerge 11.2 (26.5) 
I / σ (I) 2.9 (2.2) 
Completeness (%) 66.2 (66.2) 
Average redundancy 1.4 (1.4) 
 
A1.7. Crystallography data for a cubic HRG crystal. 
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A.1.8. SDS-PAGE analysis of cubic crystals. (a) HRG sample from solution, visualised 
with coomassie stain. (b) Cubic crystals, after washing in mother liquor, visualised with 
silver stain. It appears that this morphology of crystal could contain a significant 
proportion of the protein, as indicated by the arrow.  
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Appendix 2 
The supporting material provided in this section relates to Chapter 3, the investigations 
into Zn
2+
 and heparin binding to HRG and implications for thrombin activation. This 
includes raw data of all of the ITC experiments performed, as well as additional 
experiments as described in the main text (unless otherwise stated). 
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A2.1. ITC data for human HRG titrated with Zn
2+
. 
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A2.2. ITC data for human HRG titrated with Zn
2+
 in a low ionic strength buffer. 
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A2.3. ITC data for rabbit HRG titrated with Zn
2+
.  
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A2.4. ITC data for human HRG titrated with heparin.  
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A2.5. ITC data for human HRG titrated with heparin in the presence of 1 µM Zn
2+
. 
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A2.6. ITC data for human HRG titrated with heparin in the presence of 5 µM Zn
2+
. 
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A2.7. ITC data for rabbit HRG (20 µM) titrated with unfractionated heparin (100 µM, 
average mass of 15 kDa), at increasing concentrations of Zn
2+
. 
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A2.8. ITC data for human HRG titrated with unfractionated heparin at increasing 
concentrations of Zn
2+
. The experiment was conducted in 50 mM tris, 140 mM NaCl at 
pH 7.4. 
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A2.9. ITC data for human HRG titrated with low molecular weight heparin. 
Consecutive experiments were combined using ConCat32. 
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A2.10. ITC data for human HRG titrated with low molecular weight heparin in the 
presence of 1 µM Zn
2+
. Consecutive experiments were combined using ConCat32. 
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A2.11. ITC data for HSA titrated with Zn
2+
.  
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A2.12. ITC data for HSA loaded with 1 molar equivalent of myristic acid, titrated with 
Zn
2+
. 
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A2.13. ITC data for HSA loaded with 2 molar equivalent of myristic acid, titrated with 
Zn
2+
. 
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A2.14. ITC data for HSA loaded with 3 molar equivalent of myristic acid, titrated with 
Zn
2+
. 
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A2.15. ITC data for HSA loaded with 4 molar equivalent of myristic acid, titrated with 
Zn
2+
. 
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A2.16. ITC data for HSA loaded with 5 molar equivalent of myristic acid, titrated with 
Zn
2+
. 
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A2.17. ITC data for heparin (50 µM) titrated with Zn
2+
 (750 µM), using the standard 
conditions described in text. 
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Appendix 3 
The supporting material provided in this section relates to Chapter 4, the identification 
of novel metal binding sites on albumin. This includes raw data of the ITC experiments 
performed (as described in the main text, unless otherwise stated) and tabulates primers 
used during the cloning of albumin.  
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A3.1. Primers used during the expression of albumin in K. Lactis. 
Primer name Sequence
Expression Primers
HSAexp Fwd1 5'-gcatctcgagaaaagagatgcacaagagtgaggttgc-3'
HSAexp Rev1
5'-cccgcggccgcttacttctcgaattgtgggtggctccataagcctaaggcagcttgacttgc-
3'
HRGexp Fwd1 5'-gcatctcgagaaaagagtgagtcccactgactgcag-3'
HRGexp Rev1
5'-
cccgcggccgcttacttctcgaattgtgggtggctccattttggaaatgtatgtgtaaaaaacatg
gaaacttg-3'
Mutation Primers
H9A fwd2 5'-gatgcacacaagagtgaggttgctgctcggtttaaagatttgggagaag-3'
H9A rev2 5'-cttctcccaaatctttaaaccgagcagcaacctcactcttgtgtgcatc-3'
D256A Fwd1 5'-gatctgcttgaatgtgctgatgccagggcggaccttgccaagta-3'
D256A Rev1 5'-tacttggcaaggtccgccctggcatcagcacattcaagcagatc-3'
H288A Fwd1 5'-gaaaaacctctgttggaaaaatccgcctgcattgccgaagtggaaaatg-3'
H288A Rev1 5'-cattttccacttcggcaatgcaggcggatttttccaacagaggtttttc-3'
Sequence Primers
pKLAC2 seq fwd 5'-gaagaagccttgattgga-3'
pKLAC2 seq rev 5'-tcggcactaataaccgttt-3'
HSA seq1 5'-gaggttgatgtgatgtgc-3'
HSA seq2 5'-cctctgttggaaaaatcc-3'
HSA seq3 5'-gttatgtgtgttgcatgag-3'
HRG seq1 5'-cttgagaagtacaaagaggag-3'
HRG seq2 5'-cctgctcaagttgtcaac-3'
K. Lactis Integration 
Primers
Integration Primer 
1 5'-acacacgtaaacgcgctcggt-3'
Intergation Primer 
2 5'-atcatccttgtcagcgaaagc-3'
Integration Primer 
3 5'-acctgaagatagagcttctaa-3'
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A3.2. ITC data forH9A titrated with Zn
2+
. 
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A3.3. ITC data for H67A titrated with Zn
2+
.  
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A3.4. ITC data for E252A titrated with Zn
2+
. 
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A3.5. ITC data for D255A titrated with Zn
2+
.  
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A3.6. ITC data for D256A titrated with Zn
2+
. 
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A3.7. ITC data for H288A titrated with Zn
2+
. 
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A3.8. ITC data for AFP titrated with Zn
2+
. 
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A3.9. ITC data for AFP titrated with estradiol.  
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Appendix 4 
This section provides sample chromatograms for all protiens purified during this 
project.  
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A4.1. Purification chromatogram for human HRG following nickel affinity column.  
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A4.2. Purification chromatogram for human HRG following size exclusion column. 
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A4.3. Purification chromatogram for rabbit HRG following nickel affinity column. 
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A4.4. Purification chromatogram for rabbit HRG following size exclusion column. 
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A4.5. Purification chromatogram for recombinant HSA following Blue Sepharose 
column. 
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A4.6. Purification chromatogram for recombinant HSA following size exclusion 
column. 
 
HSA
HSA Dimer
m
A
U
ml
194 
 
 
A4.7. Purification chromatogram for recombinant AFP following copper affinity 
column. 
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